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Over the last years ultrasound has become an important tool in the assessment of 
rheumatic diseases, as it accurately detects many essential lesions including joint 
effusion, synovial hypertrophy, enthesopathy, bursitis and bone erosions. This 
introduction will start with a short background in ultrasound physics. This is followed 
by current perspectives of ultrasound in early recognition, diagnosis and monitoring 
in rheumatology and the challenges that are faced. The introduction will end with the 
aims and outline of this thesis.
Basic ultrasound physics 
Ultrasound B-mode 1, 2
Sounds with a frequency above 20,000Hz are called ultrasonic, since these frequencies 
are above the range of the human hearing (20-20,000Hz) [Figure 1]. The frequencies 
used for ultrasound imaging vary significantly dependent on the application, for 
diagnostic ultrasound frequency ranges from 5MHz to 20MHz. 
Figure 1. Range of sound frequencies with the audible range (20Hz-20kHz) and the ultrasonic 
range (>20kHz).
When sound is emitted at short bursts, ultrasound waves are generated and machines 
receive the reflected echoes. Soundwaves are emitted from piezoelectric crystals from 
the ultrasound transducer. These crystals are fabricated from material that changes 
electrical signals to mechanical vibrations and vice versa. This property is called the 
piezoelectric effect. Ultrasound pulses are formed by applying electrical waveforms 
to the piezoelectric element, causing it to vibrate and emit mechanical ultrasound 
waves. Mechanical waves must travel through physical medium like air, water or tissue. 
As ultrasound waves pass through various body tissues, they are reflected back to 
the transducer where the vibrations are converted by the piezoelectric material into 
electrical signals, creating an image on the screen as a brightness-mode (B-mode; 
grayscale) image [Figure 2]. Ultrasound transducers consist of arrays of many narrow 
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piezoelectric elements. In linear-array transducers, the ultrasound beam is created by 
electrically exciting only a subset of these elements. Successive beams are obtained 
by shifting the subset of excited elements across the array, shifting the beam laterally. 
Ultrasound images result from the interaction of the incident ultrasound pulse with 
structures in the tissue. When an incident ultrasound pulse encounters an interface 
between two types of tissue with different acoustic impedance a partially reflected echo 
will travel back to the transducer and a partially transmitted pulse will travel deeper 
into the patient. Acoustic impedance is defined as the resistance for propagation of 
ultrasound waves. The acoustic impedance varies according to the density of the tissue. 
The intensity of the reflected echo increases with increasing impedance difference 
between two tissues. If two tissues have identical impedance, no echo results. As 
ultrasound pulses and echoes travel through tissue, their intensity is reduced. This 
is called attenuation. Attenuation is due to reflection and scattering, which remove 
intensity from the pulse. These losses result from the induced oscillatory tissue motion 
produced by the pulse, which causes conversion of energy from the original mechanical 
wave into heat.  This is referred to as absorption and is the most important component 
of ultrasound attenuation. Longer path lengths (depths) and higher frequencies result 
in greater attenuation. The frequency dependence of attenuation suggests that to 
image structures deep in the body, lower ultrasound frequencies are needed to ensure 
that adequate echo intensity is detected by the transducer. 
Figure 2. B-mode (grayscale) ultrasound image of an MCP2 joint. The white line on the right hand side of the 
image is the proximal phalanx; from the middle to the left is the caput of the metacarpal bone. 
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Figure 3. The Doppler effect is experienced when a vehicle approaches, passes and moves away from an observer. 
The received frequency is higher during approach and lower during the recession. 
Ultrasound Doppler mode 3
The Doppler effect has been used in medicine for over 50 years. Advances in equipment 
and data processing have made it possible to use the Doppler effect to visualise flow. 
The Doppler effect is commonly experienced when a vehicle sounding a siren or horn 
approaches, passes and moves away from an observer [Figure 3]. Compared to the 
emitted frequency, the received frequency is higher during the approach, identical 
at the instant of passing by, and lower during the recession. The shift in frequency is 
related to the contraction or expansion of wavelengths ahead of or behind the sound-
emitting moving vehicle. In ultrasound there is a Doppler effect with the sound 
arriving at the moving object (red blood cells) and a Doppler effect as the sound is 
reflected from that object back toward the ultrasound transducer. From the frequency 
shift estimates of blood flow velocity can be produced by ultrasound machines, which 
is valuable clinical information. However, there are a number of complicating aspects 
of which some are related to the geometry of the blood vessel and the ultrasound 
beam; others are related to varying blood flow velocities across the vessel lumen 
and variation of velocity with the cardiac cycle. There are various manners to process 
Doppler ultrasound, like continuous-wave Doppler ultrasound, pulsed-wave Doppler 
ultrasound, colour Doppler ultrasound and power Doppler ultrasound. Power Doppler 
ultrasound is most commonly used in rheumatological clinical practice to detect blood 
flow, which would indicate ongoing inflammation. Power Doppler imaging adds all 
of the Doppler shift frequencies and presents on the display a pixel intensity based 
on that summed value. In power Doppler mode only the intensity of the Doppler shift 
is shown, the velocity information and directional information are not preserved. 
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The advantages of power Doppler ultrasound in comparison with other Doppler 
imaging modes is that slow flows and small vessels are more readily depicted due to 
the fact that all phase shifts are summed up. 
Current perspectives on ultrasound in rheumatology
The importance of early diagnosis and accurate monitoring of inflammation in 
rheumatic diseases has contributed to the increasing interest in ultrasound.4 
Minimising disease activity through strict monitoring and aggressive treatment (tight-
control) improves long-term outcomes for patients with rheumatoid arthritis (RA), 
including radiographic progression and increased remission rates.5 Since ultrasound is 
more sensitive than physical examination in the detection of synovitis, it is increasingly 
used in daily clinical practice.6, 7 Yet, its added value to the already existing diagnostic 
and monitoring tools needs to be established. Ultrasound synovitis is based on 
grayscale (GS; B-mode) ultrasound images combined with the power Doppler mode.8 
Inflammatory arthralgia
Up till now it has been fairly difficult to identify those arthralgia patients who would benefit 
from early initiation of treatment. Although ACPA positivity is a good predictor for those 
patients who will develop inflammatory arthritis (IA) within a year, it is still difficult to 
distinguish at patient level. Recent developments in ultrasound suggest that earlier detection 
of inflammation should be possible before clinical manifestation. Therefore, the prognostic 
value of ultrasound in patients with inflammatory arthralgia has been investigated. In auto-
antibody positive arthralgia patients, patients with ultrasound synovitis had an increased 
risk for developing IA.9, 10 In the seronegative patients the prediction of IA is even more 
difficult and the added value of ultrasound needs to be addressed more extensively. 
Rheumatoid arthritis 
A European League Against Rheumatism (EULAR) task force developed 
recommendations for the use of imaging of joints in the clinical management of RA.11 
One of their recommendations was, when there is diagnostic doubt, ultrasound can 
be used to improve the certainty of a diagnosis of RA above clinical criteria alone.12, 13 
The value of ultrasound in classifying patients as having RA, has also been recognised 
in the 2010 ACR/EULAR classification criteria for RA, which includes imaging evidence 
of synovitis in joint involvement.14 In addition, in RA patients who were clinically 
in remission ongoing active ultrasound synovitis has been found in 48-73% of the 
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patients.6, 15-18 In these RA patients, ultrasound synovitis (power Doppler positive) 
predicts short-term relapse and radiographic progression.16, 19-22 This means ultrasound 
could be used as a tool to monitor RA patients to identify patients who can taper their 
medication or to recognise those patients who might need more intensive treatment. 
Psoriatic arthritis
Psoriatic arthritis (PsA) is a progressive inflammatory disease, that can lead to serious 
joint damage over time.23 It can manifest with peripheral arthritis, mostly in an 
asymmetrical distribution, but also with entheseal or spinal involvement. Since the 
introduction of the CASPAR classification criteria for PsA in 2006, psoriasis patients can 
classify as PsA with only enthesitis as inflammatory articular involvement.24 However, 
there are difficulties regarding clinical assessment of the entheses such as overuse 
and anatomical location, which could lead to clinically false-positive patients.25-27 
Assessment of the entheses could be improved by using ultrasound, especially the 
power Doppler mode.28, 29 In addition, it is possible to differentiate patients with PsA 
from healthy controls with ultrasound.30, 31 Since it is important to diagnose PsA at an 
early stage, the prevalence of PsA in primary care psoriasis patients was studied by 
Karreman et al.32 The frequency of PsA in psoriasis patients was estimated to be 3.1% 
for arthritis and axial disease, increasing to 4.6% when enthesitis would be included. To 
differentiate between active inflammation and other manifestations of enthesopathy 
ultrasound could be a tool to diagnose enthesitis. 
Challenges regarding ultrasound in rheumatology
At this moment several clinical questions regarding ultrasound in rheumatic diseases 
are addressed. However, there is still a large amount of research required to determine 
the added value of ultrasound and to optimise the use of ultrasound in current clinical 
practice. Technological developments in ultrasound machines could also improve 
early detection of inflammation. Developments in 3D ultrasound, plane wave imaging 
and contrast imaging are very promising.33-36 
Plane wave ultrasound imaging
Clinical application of ultrasonic plane wave imaging was made possible by advances in the 
electronic hardware of ultrasound machines. With the use of plane wave imaging ultrafast 
frame rates can be achieved, since the entire field of view is imaged with a single transmission 
[Figure 4B].37 Backscattered echoes are simultaneously recorded form the entire scan plane, 
47571 Myrthe van der Ven NIEUW.indd   13 09-12-17   09:48
Chapter 1
14
and all imaging lines are simultaneously computed using parallel beamforming processes. 
The increase in frame rate comes at the expense of image contrast and spatial resolution. 
To improve image quality,  a set of plane waves can be sent at different angles at an ultrafast 
frame rate, which is called compounding [Figure 4C, 4D]. 
High-frame rate ensures high temporal correlation between frames, which facilitates 
good separation between relatively slow tissuemotion, and blood flow. Therefore, this 
technique allows detection of slow flow in very small vessels.34, 37, 38 The high temporal 
correlation between frames also allows for using spatial correlation to further 
discriminate blood flow in small localised vessels from global motion of soft tissue 
and bone.39, 40 Since high-frame rate Doppler ultrasound imaging is more sensitive to 
low flow than conventional ultrasound, it might provide accurate detection of active 
inflammation in joints of RA patients. This could enable earlier diagnosis of RA and 
better treatment monitoring. 
 A B C D
Figure 4. Conventional focused and ultrafast ultrasound imaging sequences (4-cm deep region of interest): (a) 
conventional focused imaging, (b) plane-wave imaging, (c) plane-wave compounding with 17 angles, and (d) 
plane-wave compounding with 40 angles. [Adapted from Tanter et al.34]
Aims and outline of this thesis
The aims of this thesis were:
1.  to evaluate the added value of ultrasound in clinical decision making in:
 a. Patients with arthralgia
 b. Patients with psoriasis
 c. Monitoring RA patients
2.  to increase sensitivity of power Doppler ultrasound for MCP joints.
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Early diagnosis of RA and thereby facilitating early initiation of effective disease-
modifying drugs can slow down disease progression and diminish joint damage.41 
With the introduction of the 2010 ACR/EULAR classification criteria for RA we are able 
to classify patients as having RA at an earlier stage.14 Chapter 2 will describe which cut 
point of the 2010 criteria would enable us to earlier identify RA patients among recent 
onset inflammatory arthritis patients. 
Part one – Ultrasound in clinical practice 
Since physical examination reached its maximum to identify synovitis, the first chapters 
of this thesis focus on the added value of ultrasound in daily clinical practice. The 
association of ultrasound inflammation and the development of inflammatory arthritis 
in an early arthralgia cohort is described in chapter 3. In chapter 4 the frequency of 
ultrasound enthesitis in primary care psoriasis patients with musculoskeletal complaints 
is explored. The course of ultrasound inflammation and clinical findings in the feet in 
newly diagnosed RA patients is investigated in chapter 5. The association of the presence 
of ultrasound synovitis and health status in RA patients who are in clinical remission 
is studied in chapter 6. The focus of chapter 7 is to evaluate if ultrasound synovitis is a 
biomarker for clinical flare in RA patients who are tapering their medication. 
Part two – Experimental technical research 
The performance of the power Doppler modality of several ultrasound machines is 
compared by a flow phantom and this study is described in chapter 8. The same flow 
phantom was used to compare conventional ultrasound with high-frame rate Doppler 
ultrasound, which is explored in chapter 9. This chapter also gives the results of high-
frame rate Doppler ultrasound imaging in RA patients to evaluate whether it is possible 
to detect higher levels of vascularisation than with conventional ultrasound. 
In chapter 10 the conclusions of this thesis are discussed in light of current practice and 
implications for future research. Finally, in the addendum a summary of the complete 
thesis is given. 
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Abstract
Objectives: In part of the patients who do not fulfil the 2010 ACR/EULAR classification 
criteria at first consultation (<6 points) arthritis persists. To be able to identify more 
patients with rheumatoid arthritis, we evaluated the effect of lowering the cut point 
of the 2010 criteria.
Methods: We included early arthritis patients from the Rotterdam Early Arthritis 
Cohort (REACH) with at least one joint with clinical synovitis and symptoms less 
than 1 year with no other explanation for their symptoms. Demographic and clinical 
characteristics of each patient were recorded at baseline. Patients were classified as 
case or non-case at 1 year follow-up by the definition used in the development of the 
2010 criteria (methotrexate initiation). To assess diagnostic performance of the 2010 
criteria sensitivity and specificity at each cut point was determined.
Results: We included 557 patients in our analysis. After 1 year follow-up 253 patients 
(45%) were classified as case (methotrexate use). In the group of patients who scored 
0-5 points (n=328) 98 patients (30%) were classified as case (methotrexate use). 
Sensitivity and specificity of the 2010 criteria using the cut point of 6 were 61% and 76% 
respectively. With the cut point of 5, sensitivity would increase to 76% and specificity 
would decrease to 68%.
Conclusions: By lowering the cut point of the 2010 criteria from 6 to 5 points, we were 
able to identify 15% more rheumatoid arthritis patients at the cost of 8% more false-
positive patients. 
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Introduction
Recently, the 2010 American College of Rheumatology (ACR)/European League 
Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) were 
developed to facilitate research in earlier stages of the disease. The 2010 criteria also 
facilitate optimal use of the window of opportunity by starting disease modifying drugs 
at an earlier time point.1 The 2010 criteria assign the risk or probability of developing 
RA on a continuous score (from 0 to 10). A score of ≥6/10 is needed to classify a patient 
as having definite RA. 
Some of the patients in whom arthritis persists over time do not fulfil the 2010 criteria 
(<6/10 points) at first consultation.2 In unselected early arthritis cohorts, the proportion 
of missed persistent arthritis patients can increase to almost 40%, which is likely to 
reflect the case-load of daily practice.3 As Krabben et al. showed neither ACPA nor the 
Leiden prediction rule are able to identify which individual patients will be missed by 
the 2010 criteria.4 Therefore, we need another way to identify patients whose arthritis 
will persist. 
The developers of the 2010 criteria suggest that there is scope for using other cut points 
for different purposes.1 In this study we evaluated which cut point of the 2010 criteria 
would enable us to identify more early rheumatoid arthritis patients among early 
inflammatory arthritis patients at first consultation. 
Methods
Patients
For the present study we used clinical data from early arthritis patients from the 
Rotterdam Early Arthritis Cohort (REACH). These patients had at least one joint with 
clinical synovitis and had symptoms for less than 1 year with no other explanation 
for their symptoms. Patients were recruited via their general practitioner, or via the 
outpatient rheumatology clinic. Patients were included in REACH in case of one or 
more swollen joints. Patients were excluded if their symptoms resulted from trauma 
or overuse, if their symptoms were present for over 12 months, or if they were younger 
than 16 years. For a detailed description of REACH, see Alves et al.5 
Each patient was assigned a score from 0 to 10 points using the four domains of the 
2010 criteria: i) joint involvement; ii) serology; iii) acute-phase reactants; iv) symptom 
duration.1 If results were not available for a domain, results were regarded as normal or 
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negative following the guidelines of the developers of the 2010 criteria.6 Demographic 
and clinical characteristics of each patient were recorded at baseline, 6 months and 
12 months. Data collection included a detailed medical examination (swollen joint 
count, tender joint count), laboratory variables (ACPA, RF, ESR), diagnosis and 
medication used.
Written informed consent was obtained from the participants according to the 
declaration of Helsinki. The REACH study was approved by the local medical ethic 
committee of Erasmus MC, University Medical Center Rotterdam, the Netherlands. 
This secondary analysis was covered by this ethical approval. 
Case definition
Patients were classified as case (true-positive patients) or non-case after 1 year follow-
up by the definition used in the development of the 2010 criteria.1 This definition 
includes the use of methotrexate (MTX) after one year. If a patient had to stop MTX 
due to side-effects, and was assigned another DMARD, it was also considered a case. If 
no MTX was used and no other classifiable disease was present after one year follow-
up the patient was regarded a non-case.
Statistical analysis
Discriminative performance of the 2010 criteria in relation to the case definition was 
determined by calculating the receiver operating characteristic (ROC) curve. Sensitivity 
and specificity were calculated for each cut point (0-10 points). To obtain information 
on potential other clinical characteristics that could help improve the diagnostic 
performance we tested differences between cases and non-cases among the patients 
with <6/10 points using the independent T-test or Wilcoxon-Mann-Whitney test 
depending on the distribution of the data. Frequencies were compared using a Chi-
square test. Analyses were done using STATA 12.0. 
Results
In REACH we identified 726 early arthritis patients. At baseline we excluded 169 
patients with another classifiable disease, such as gout, psoriatic arthritis and systemic 
diseases. Consequently, in 557 patients the 2010 criteria could be applied  of which 328 
patients (69%) obtained a score from 0 to 5.
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Sensitivity and specificity 2010 criteria
The ROC curve was calculated for the 2010 criteria in relation to MTX use in the total 
study population (0-10 points; n=557) [Figure 1]. The area under the ROC curve (AUC) 
was 0.79 (SE 0.02). From this curve sensitivity and specificity for each score were 
determined.
Sensitivity and specificity of the 2010 criteria using the cut point of 6 were 61% and 
76% respectively. With the cut point of 5, sensitivity increased to 76% and specificity 
decreased to 68%. Among patients with 5 points (n=59) 22 patients (37%) would be 
false-positively classified as RA. After one year follow-up the diagnosis of these false-
positive patients was osteoarthritis (n=2) or remitting oligoarthritis/polyarthritis 
(n=20) .
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1 100 2
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3 98 21
4 92 46
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10 10 98
Figure 1. The receiver operator characteristic curve, and sensitivity (Sens) and specificity (Spec) for the 2010 criteria 
and MTX use (n = 557)
Patients with 0-5 points
In the patients with 0-5 points (n=328) 98 patients (30%) used MTX (case) after 1 year 
follow-up. The distribution of cases and non-cases over the 2010 score can be described 
that patients with a higher score on the 2010 criteria showed a higher frequency of 
MTX use after one year.
Characteristics of patients with MTX (case; n=98) were compared with patients who 
did not use MTX (non-case; n=230) [Table 1]. Patients who used MTX tended to have 
more tender and swollen joints and higher ESR values, but showed no differences on 
the other characteristics such as rheumatoid factor and ACPA positivity. 
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Table 1 Baseline characteristics of patients with 0-5 points who used MTX  after 1 year follow-up (case) and of 
those patients who did not use MTX (non-case)
Case (MTX use)
(n=98)
Non-case
(n=230)
p-value*
Women, % 69 67 0.667
Age, mean (s.d.), years 54 (16) 50 (16) 0.051
SJC, median (IQR) 5 (3-7) 2 (1-4) <0.001
TJC, median (IQR) 9 (4-12) 5 (2-10) <0.001
RF positive, % 7 5 0.494
ACCP positive, % 2 5 0.370
ESR, median (IQR) 24 (12-39) 13 (6-25) <0.001
CRP, median (IQR) 6 (3-35) 5 (2-16) mv=50 0.032
Morning stiffness, median (IQR), min 60 (30-140) mv=20 45 (30-90) mv=78 0.034
DAS44 score, mean (s.d.) 4.6 (1.0) 3.8 (1.1) <0.001
Symptom duration, median (IQR), months 3 (2-6) 3 (1-5) 0.029
MCP symmetry, % 62 40 <0.001
PIP symmetry, % 46 36 0.077
Wrist symmetry, % 39 19 <0.001
MTP symmetry, % 12 7 0.164
s.d. = standard deviation, IQR = interquartile range, mv = missing values,  *depending on distribution of the data 
we used independent T-test or Wilcoxon-Mann-Whitney test, frequencies were compared using a Chi-square test
Discussion
By lowering the cut point of the 2010 criteria from 6 to 5 points, we were able to identify 
15% more rheumatoid arthritis patients at a cost of 8% more false-positive patients. 
If these reclassified patients had started DMARD therapy after first consultation, 2/3 
of the patients would have received optimal treatment earlier, while the other 1/3 
of the patients might not have needed this treatment, as their symptoms were not 
related to the presence of RA. Each rheumatologist has to weigh the benefit of early 
treatment in true-positive rheumatoid arthritis patients against the harm of treatment 
in oligoarthritis/polyarthritis and osteoarthritis patients, i.e. the false-positive patients. 
Balancing the benefit and harm of treatment depends on the safety profile of the 
DMARDs and the quality of life lost if true-positive patients are left untreated.7 In 
general, the safety profile of the different DMARDs is regarded as acceptable in the 
treatment of RA8, but it is not clear whether this also holds for arthritis patients who 
score 5 points. Treatment in arthritis patients with 5 points seems beneficial9, but none 
of these studies have evaluated the potentially negative effect of treatment in the 
false-positive patients. In terms of quality of life, Geuskens et al found no difference in 
health-related quality of life between RA patients and non-RA patients10, which might 
47571 Myrthe van der Ven NIEUW.indd   24 09-12-17   09:48
Lowering the cut point of the 2010 criteria
25
2
imply that treatment in arthritis patients with 5 points will improve their quality of life. 
Data is lacking on the presence of off-days mentioned by patients, which affects worker 
productivity due to the side-effects of medication.  
The characteristics of the  patients with 0-5 points (n=328) differed little between those 
with and those without MTX. Although swollen and tender joint counts differed, the 
differences were not strong enough to be used as an additional diagnostic criterion 
[data not shown]. This is in accordance with findings of Krabben et al.4 To reduce over-
treatment in false-positive patients and to be more certain which patients could start 
early DMARD treatment, it might be beneficial to add other (imaging) biomarkers that 
distinguish true positive patients from false-positive patients at an earlier stage.11-13 
Nevertheless, lowering the cut point from 6 to 5 points would be a more feasible way 
to identify more persistent arthritis patients. This study showed that 2/3 of the patients 
with 5 points were already treated with MTX after one year follow-up, which could 
indicate that our results reflected daily clinical practice. 
Our study has certain strengths and limitations. The REACH dataset was one of the 
early arthritis cohorts included in the pooled analysis to develop the new criteria for 
RA.1, 14 The cut point of 6 was chosen using the AUC of three cohorts, including REACH. 
When we removed those patients (n=184) from our analysis, the results were similar 
[data not shown]. However, external validation of our results in another early arthritis 
cohort is recommended. Especially larger cohorts could advance our work and could 
give more insight in other variables. The strength of our study includes the selection of 
patients, which was not biased towards RA. In REACH, no limits were set regarding the 
minimal number of swollen joints required, and the sample represents patients in an 
early phase of their disease (median duration of symptoms of 3 months). 
In conclusion, by lowering the cut point of the 2010 criteria, we identified more 
rheumatoid arthritis patients in whom early treatment could have been initiated. This 
could have led to better patient outcomes.
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Ultrasound in clinical practice 
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Abstract
Background: To decrease burden of disease of rheumatoid arthritis (RA) we need to 
identify patients at risk for RA as early as possible, preferably as no clinical apparent 
synovitis could be detected yet. Up to now it has been fairly difficult to identify those 
arthralgia patients who develop inflammatory arthritis (IA), but recent studies in 
ultrasound suggest that earlier detection is possible. We aim to identify arthralgia 
patients developing IA within a year using ultrasound to detect subclinical synovitis 
at first consultation. 
Methods: In a multi-centre cohort study we followed arthralgia patients with ≥2 
painful joints of hands, feet or shoulders without clinical synovitis over one year. 
Symptom duration was <1 year and symptoms were not explained by other conditions. 
At baseline, 6 and 12 months data were collected on physical examination, laboratory 
values and diagnosis. At baseline we examined 26 joints ultrasonographically (bilateral 
MCP2-5,PIP2-5,wrist,MTP2-5). Images were scored semi-quantitatively on grayscale 
(GS;0-3) and power Doppler (PD;0-3). Ultrasound synovitis was defined as GS≥2 and/
or PD≥1. IA was defined as clinical soft tissue swelling. Sensitivity and specificity were 
used to assess the diagnostic value of ultrasound for the development of IA. Univariate 
logistic regression was used to analyse the association between independent variables 
and the incidence of IA. For multivariate logistic regression strongest variables 
(p<0.157) were selected. Missing values in independent variables were imputed. 
Results: 196 patients were included, 159 completed 12 months follow-up. Thirty-one 
(16%) patients developed IA of whom 59% showed ultrasound synovitis at baseline. 
Sensitivity and specificity of ultrasound synovitis were 59% and 68% respectively. 
If no joints were positive on ultrasound, negative predictive value was 89%. In the 
multivariate logistic regression age (OR1.1), the presence of morning stiffness >30 
minutes (OR3.3) and PD signal (OR3.4) were associated with incident IA. 
Conclusions: The presence of PD signal, morning stiffness >30 minutes and age at 
baseline were independently associated with the development of IA. Regarding the value 
of ultrasound in the diagnostic work up of early arthralgia patients at risk for IA, ultrasound 
did perform well in ruling out IA in patients who did not have ultrasound synovitis.
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Background
Rheumatoid arthritis is a debilitating chronic auto-immune disease. Early initiation of 
effective disease-modifying drugs can slow down disease progression and diminish 
joint damage.1, 2 It could be that starting DMARD therapy already in the arthralgia 
phase or even before that could provide better patient outcome.3, 4 Up till now it has 
been fairly difficult to identify those arthralgia patients who would benefit from such 
early initiation of DMARD therapy. Because only those that would have subsequently 
developed inflammatory arthritis (IA) related to a chronic inflammatory joint disease 
would benefit from such an early intervention. Recent technical developments in 
magnetic resonance imaging (MRI) and ultrasound suggest that earlier detection of 
inflammation should be possible before clinical manifestation.5
We know from previous research that 15% of arthralgia patients who present 
themselves without clinical signs of inflammation at baseline, will be diagnosed with 
IA one year later of whom half were ACPA positive.6 Although ACPA positivity is a very 
good predictor for those patients who will develop IA within a year, it is still difficult 
to identify the exact individual who will develop IA as any ACPA positive individual 
has a priori chance of 50%. In the seronegative patients the prediction of IA is even 
more difficult as only 5% develops IA in the subsequent year. Imaging techniques have 
shown to be able to detect synovitis before clinical appearance and could be of help 
to identify those that  are at risk of IA.5, 7 MRI and ultrasound are both available in the 
daily rheumatological clinic. MRI has the disadvantage of being time consuming and 
thereby constraining the number of joints which could be assessed. In addition, MRI is 
expensive and not accessible for everyone (e.g. joint replacement, pacemaker). When 
we focus on ultrasound, this modality is more operator dependable, due to probe 
position multiple examiners can have different observations. However, ultrasound is 
more flexible and easily applied in the clinic. 
In this study we aim to identify which arthralgia patients will develop clinically apparent 
IA within one year using ultrasound to detect subclinical synovitis at first consultation 
added to demographic and clinical variables. 
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Methods
This study was a multi-centre prospective cohort study in which we followed patients 
with inflammatory joint complaints for one year.
Patients
Patients with inflammatory joint complaints of hands, feet or shoulders without clinical 
apparent synovitis at any joint were recruited from the outpatient clinic. Patients had 
a symptom duration of less than one year which could not be explained by other 
conditions, such as IA, fibromyalgia, overuse or trauma. To distinguish inflammatory 
arthralgia from other forms of arthralgia, patients had to have at least two painful 
joints in hands, feet or shoulders and 2 of the following criteria adapted from REACH8: 
morning stiffness for more than 1h; unable to clench a fist in the morning; pain when 
shaking someone’s hand; pins and needles in the fingers; difficulties wearing rings 
or shoes; family history of RA; unexplained fatigue for less than 1 year. Patients had 
to be able to understand, speak and write in Dutch. Patients received treatment as 
the rheumatologists saw fit, but no disease modifying anti-rheumatic drugs were 
prescribed at first consultation. Written informed consent was obtained from the 
participants according to the declaration of Helsinki. The study was approved by the 
medical ethic committee of Erasmus MC, University Medical Centre Rotterdam, the 
Netherlands (MEC-2010-353) and was assessed for feasibility by the local ethical bodies 
of Maasstad Hospital and Vlietland Hospital.
Clinical examination
A trained research nurse collected data about articular symptoms, extra-articular 
symptoms, family history and previous medical history. Data collection at baseline, 
six months and twelve months follow-up included a detailed medical examination 
(swollen joint count in 44 joints, tender joint count in 44 joints), laboratory variables 
(ACPA, RF, ESR), diagnosis and medication used. Observed soft tissue swelling needed 
to be confirmed as an arthritis by the treating rheumatologist. As substantial lost 
to follow-up was expected at the start of the study due to the nature of recovering 
arthralgia for the majority of patients, a telephone interview was scheduled if patients 
did not want to return to the clinic for their 6 and 12 months evaluation. Patients 
were asked about their clinical symptoms. If the interviewer doubted about potential 
presence of clinical synovitis, patients were asked to return to the outpatient clinic for 
clinical evaluation. 
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Ultrasound examination
At baseline, trained ultrasound examiners blinded for the clinical details applied 
ultrasound, following the ‘European League Against Rheumatism’ (EULAR) guidelines, 
concerning patient position and scanning planes.9 To minimise inter-variability 
ultrasound examiners followed a standardised scanning protocol regarding acquisition 
and scoring. The ultrasound machine used was the Esaote MyLab60 with a high-
frequency linear array probe (LA435, 10-18MHz). Twenty-six joints were evaluated using 
grayscale (GS) and power Doppler (PD) imaging. We scanned MTP2-5 (dorsal aspect), 
MCP2-5 and PIP2-5 (dorsal and palmar aspects), and wrist (radiocarpal and intercarpal 
joints). A single midline (longitudinal 12 o’clock position) scan perpendicularly to 
the bone surface was used as advised by the OMERACT ultrasound working group.10 
The following PD settings were used: colour gain was set at the disappearance of 
colour noise. The Pulse Repetition Frequency (PRF) was set as low as possible to have 
maximum sensitivity, but minimising noise, which resulted in a frequency of 750 Hz. 
We adjusted the size and position of the colour box to include the subcutaneous tissue 
to recognize artefacts caused by vessels above the joint.11 PD signals were measured 
only in joints with GS≥1. The total scanning time was ½ hour per patient per session. 
The treating rheumatologist and the research nurse were blinded for the results of the 
ultrasound examination at baseline.
Ultrasound evaluation
Image evaluation followed the recommendations of the Spanish society for 
Rheumatology, which is a modified version of the previously developed OMERACT 
definitions of sonographic pathology.12 Joints were graded according to a semi-
quantitative scoring system (0-3) for both GS and PD. For GS, all joints were graded 
as: 0 = no capsular distension, 1 = hypoechoic material only at the level of the joint 
margins; 2 = partial distension of the whole capsule which appears mostly concave 
or flat; 3 = complete distension of the whole capsule which appears mostly convex. 
Synovial vascularisation was measured using PD and graded as: 0 = absent; 1 = mild 
single vessel signal or isolated signal; 2 = moderate confluent vessels; 3 = marked vessel 
signals in more than half of the intra-articular area.13 
Ultrasound synovitis was defined as GS grade 2 or 3 and/or presence of PD (grade 1, 2 
or 3). 
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Outcome
One-year incident IA was defined as clinical soft tissue swelling. Observed soft tissue 
swelling needed to be confirmed as an arthritis by the treating rheumatologist whom 
was unaware of the ultrasound findings.  
Statistical analysis
If patients had no clinical evaluation for both their 6 and 12 months visits they were 
classified as lost to follow-up and not included in the analysis. 
Simple descriptives were used to describe baseline characteristics and the ultrasound 
findings. Depending on the distribution of the data we used the independent T-test 
or Wilcoxon-Mann-Whitney test to examine differences between cases and non-cases. 
Frequencies were compared using a Chi-square test. Sensitivity and specificity were 
used to assess the diagnostic value of ultrasound for the development of IA.
After consideration of the available literature14, 15 we identified the following variables 
as relevant in the association with emerging IA: demographic characteristics (age, 
gender), clinical characteristics (tender joint count, high positive auto-antibodies 
(ACPA, RF),  morning stiffness lasting ≥30 minutes), and ultrasound findings (presence 
of ultrasound synovitis, positive PD signal in at least one joint).14-16 These variables were 
tested for their association with IA using univariate logistic regression. For multivariate 
logistic regression, we used a backward stepwise model procedure to select the 
strongest predictors (p=0.157).17 The p-value of 0.157 is equal to Akaike’s Information 
Criterion for predictors with one regression coefficient and is recommended to use 
in stepwise selection of predictors.18 Missing values of independent variables were 
handled by multiple imputation using the STATA MICE routine (multiple imputation 
by chained equations; M=20).19 Analyses were done using STATA 14. 
Results
In total, 297 patients were recruited to participate. The flowchart [Figure 1] shows the 
distribution of patients during follow-up. At baseline, 196 patients met the inclusion 
criteria. One-hundred seventy-eight patients (91%) returned for their clinical 
evaluation at six months and 159 patients (81%) had their twelve months assessment. 
We could determine our primary outcome for 174 patients (89%). In total, 31 (16%) 
patients had developed IA within one year follow-up, of whom 15 had started DMARD 
therapy. Twenty-two patients had no definite diagnosis; 12 patients had mono-
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arthritis, 10 patients had poly-arthritis. Definite diagnosis after 12 months was given 
for nine patients (rheumatoid arthritis: n=4; psoriatic arthritis: n=4; spondyloarthritis: 
n=1). Baseline characteristics of IA patients and non-IA patients are shown in table 1. 
We found statistically significant difference in baseline characteristics between IA and 
non-IA for age (mean 50 vs 44 years; p=0.005). In addition, ULTRASOUND synovitis 
was found more often in IA than in non-IA (59% vs 32%; p=0.007) and PD signal was 
present in 31% of the IA patients vs 12% of the non-IA patients (p=0.012).
 
	
 
	
n	=	297		
n	=	196		
n	=	178		
n	=	159		
T0	
T12	
T6	
n	=	63,	exclusion	
n	=	38,	lost	to	follow-up	
n	=	18,	lost	to	follow-up	
n	=	19,	lost	to	follow-up	
Figure 1. Flowchart of SONAR study showing the distribution of patients during follow-up. 
Ultrasound findings
Ultrasound findings are described in more detail in table 2. In total, 72 arthralgia 
patients (37%) had ultrasound synovitis of whom 29 had a positive PD signal. Wrists 
(26%) and MTP joints (11%) were most commonly involved which was also observed 
if only PD was taken into consideration. Distribution of ultrasound synovitis over the 
different joint groups between patients who developed IA and who did not develop IA 
was comparable, except for the MTP joints which were more involved in the IA group.
Diagnostic value of ultrasound
Sensitivity and specificity of ultrasound synovitis in relation to the incidence of IA if one 
joint was positive on ultrasound were 59% and 68% respectively. Positive predictive 
value (PPV) was 26% and negative predictive value (NPV) was 74%. When we required 
two joints to be ultrasound positive to identify a IA case sensitivity decreased to 28% 
and specificity increased to 86% (PPV 27%; NPV 73%). For the presence of PD signal, 
sensitivity was 31% and specificity was 88% for one positive PD joint (PPV 33%; NPV 
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67%). When two joints were required, sensitivity decreased to 14% and specificity 
increased to 95% (PPV 38%; NPV 63%). If no joints were positive on ultrasound, the 
NPV was 89%. 
Table 1 Baseline characteristics (n=174)
IA patients (n=31) Non-IA patients (n=143) p-value*
Women, n (%) 25 (81) 119 (83) 0.731
Age, years, mean (sd) 50 (8) 44 (12) 0.005
BMI, mean (sd) 26.8 (4.4) 27.5 (5.2) 0.534
SJC44, median (IQR) 0 (0-0) 0 (0-0) - 
TJC44, median (IQR) 4 (2-9) 5 (3-8) 0.828
RF positive, n (%) 9 (31) 37 (27) 0.628
ACPA positive, n (%) 7 (24) 19 (14) 0.161
ESR, median (IQR) 10.5 (5-22) 10.5 (5-21) 0.824
Morning stiffness, minutes, median (IQR) 30 (30-60) 30 (15-60) 0.515
DAS28, mean (sd) 3.4 (1.1) 3.3 (1.0) 0.710
US synovitis†, n (%) 17 (59) 44 (32) 0.007
PD score >0, n (%) 9 (31) 17 (12) 0.012
IA: inflammatory arthritis; BMI: body mass index; SJC44: swollen joint count in 44 joints; TJC44: tender joint 
count in 44 joints; RF: rheumatoid factor; ACPA: anti-citrullinated protein antibody; DAS28: disease activity score 
in 28 joints; US: ultrasound; PD: power Doppler; IQR: interquartile range; sd: standard deviation; *Depending 
on the distribution of the data, we used the independent t test or the Wilcoxon-Mann-Whitney test, frequencies 
were compared using a Chi2 test, p-value≤0.05; †US synovitis: grayscale grade 2 or 3 and/or presence of PD (≥1)
Table 2 Distribution of ultrasound findings
US synovitis*, n (%) PD positive, n (%)
IA (n=31) Non-IA (n=143) IA (n=31) Non-IA (n=143)
US positive 17 (55) 45 (31) 9 (29) 17 (12)
MCP 3 (10) 9 (6) 1 (3) 3 (2)
PIP 3 (10) 1 (1) 2 (6) 0 (0)
wrists 8 (26) 35 (24) 4 (13) 15 (10)
MTP 9 (29) 11 (8) 4 (13) 2 (1)
US: ultrasound; PD: power Doppler; MCP: metacarpophalangeal joint; PIP: proximal interphalangeal joint; MTP: 
metatarsophalangeal joint; *US synovitis: grayscale grade 2 or 3 and/or presence of PD (≥1)
Association of independent variables with development of IA
To quantify the associations between baseline characteristics and incident IA at 
follow-up we performed univariate and multivariate logistic regression after multiple 
imputation (M=20). Results are presented in table 3. Age (OR 1.06: 95% CI 1.03-1.09), 
morning stiffness >30 minutes (OR 2.39: 95% CI 1.20-4.73) and positive ACPA (OR 2.08: 
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95% CI 1.07-4.07) were univariately associated with IA. Other clinical and demographic 
characteristics did not differentiate IA patients from non-IA patients. For the presence 
of ultrasound synovitis in at least one joint the OR was 3.03 (95% CI 1.69-5.41) and for 
the presence of PD signal in at least one joint the OR was 3.12 (95% CI 1.61-6.03). In 
the multivariate logistic regression analysis, age (OR 1.06: 95% CI 1.03-1.10), morning 
stiffness >30 minutes (OR 2.80: 95% CI 1.33-5.90), positive ACPA (OR 2.35: 95% CI 1.13-
4.87) and ultrasound synovitis (OR 2.65: 95% CI 1.44-4.88) remained associated with the 
development of arthritis during one year follow-up. If we replaced ultrasound synovitis 
by the presence of PD signal (OR 3.44: 95% CI 1.71-6.95), the OR for age and morning 
stiffness were similar, but positive ACPA was not associated with the development of 
arthritis. 
Discussion
Sixteen percent of early arthralgia patients developed IA after one year follow-up 
of whom 59% showed ultrasound synovitis at baseline. Age, morning stiffness >30 
minutes and positive PD signal were all significantly associated with the development 
of IA after one year in a multivariate model. Regarding the value of ultrasound in the 
diagnostic work up of early arthralgia patients at risk for IA, ultrasound did not perform 
well in ruling in IA (PPV 26%), but did perform well in ruling out IA in patients who did 
not have ultrasound synovitis (NPV 89%).
Up to now only few studies investigated subclinical synovitis in arthralgia patients 
by making use of imaging modalities. In an auto-antibody positive arthralgia cohort, 
patients with positive ultrasound had an increased risk for IA.14, 15 This was confirmed 
in our study although only 15% of the patients was ACPA positive and 24% was RF 
positive. In another study evaluating patients with very early hand symptoms, the 
presence of PD signal was associated with IA in addition to clinical features (e.g. 
swollen joints) and laboratory tests (e.g. serology, RF, ACPA).20 For MRI, results are not 
conclusive. Among a seropositive arthralgia population, changes on MRI indicative 
for inflammation of MCP and PIP joints were not associated with the development of 
arthritis at three year follow-up.21 In opposite, MRI findings in the most affected hand 
in patients with clinically suspect arthralgia showed that subclinical MRI inflammation 
preceded clinical arthritis with a few months. This was also found in a sub analysis in a 
seronegative arthralgia population.22, 23
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Table 3 Association between baseline characteristics and development of IA using univariate logistic regression 
analyses and multivariate logistic regression analysis after multiple imputation (n=174)
Univariate model Multivariate model
including US synovitis
Multivariate model
including presence of PD
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Demographics
Age, years 1.06 (1.03-1.09) <0.001 1.06 (1.03-1.10) <0.001 1.07 (1.04-1.10) <0.001
Sex 0.84 (0.42-1.70) 0.627
BMI 0.98 (0.92-1.04) 0.438
Clinical variables
Tender joints 1.01 (0.96-1.07) 0.676
DAS28 1.21 (0.92-1.58) 0.175
Morning stiffness* 2.39 (1.20-4.73) 0.013 2.80 (1.33-5.90) 0.007 3.34 (1.60-6.96) 0.001
RF positive 1.21 (0.65-2.23) 0.545
ACPA positive 2.08 (1.07-4.07) 0.032 2.35 (1.13-4.87) 0.021
ESR 1.00 (0.98-1.02) 0.850
Ultrasound
US positive 3.03 (1.69-5.41) <0.001 2.65 (1.44-4.88) 0.007
PD positive 3.12 (1.61-6.03) 0.001 3.44 (1.71-6.95) 0.001
IA: inflammatory arthritis defined as clinical soft tissue swelling; BMI: body mass index; RF: rheumatoid factor; 
ACPA: anti-citrullinated protein antibody; US: ultrasound; PD: power Doppler; OR: odds ratio; US synovitis: 
grayscale grade 2 or 3 and/or presence of PD (≥1); * morning stiffness >30 minutes
Our results should be interpreted in the light of the choices we made. As explained 
in the introduction we aimed for very early identification of  IA. For this study we 
restricted the population to patients with at least two painful joints and in addition 
two criteria related to inflammation to be more sure of the inflammatory component. 
These inclusion criteria may have driven the selection to a population at increased risk 
for poly-arthritis. We missed those patients who might be at risk for IA, but only had 
one painful (large) joint. However, our inclusion criteria are in line with other arthralgia 
cohorts and with the new EULAR guidelines regarding clinically suspect arthralgia.22, 24 
Other forms of selection may have occurred due to rheumatologists who recruited 
clinically suspected patients with possibly more severe symptoms.25 In addition, 38 
patients decided not to participate without giving specific reasons which could have 
introduced a bias to patients with more severe complaints. These patients did not 
differ in age and sex compared to the responders, but we do not know whether their 
clinical symptoms differed. Information bias could have occurred as patients were 
lost to follow-up (14%). This was anticipated at the start of the study so we included 
a telephone service if patients did not respond to their initial invitation for follow-up. 
If those patients did not wish to return they were asked a small set of questions to 
establish whether they were at risk to be a case of IA. We saw no differences in their 
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baseline characteristics compared to those returning to the clinic. We did not include 
these patients in the analysis. Other bias could have been introduced by not blinding 
the clinical examination and ultrasound examination as we only included arthralgia 
patients. This could have led unconsciously to less sensitive assessment of clinical and 
ultrasound synovitis. However, at baseline several patients were excluded because 
of clinical apparent arthritis confirmed by a trained research nurse. Another item to 
take into account is that ultrasound is still considered operator-dependent, therefore 
the ultrasound examiners scanned patients following the ultrasound study protocol 
as training prior to the start of the study. In addition, ultrasound examiners followed 
protocol regarding acquisition and scoring. Previous research regarding inter-reliability 
confirmed that a consensus scoring system combined with a standardised acquisition 
protocol provided good inter-reliability.26, 27 In our definition of ultrasound synovitis 
we combined GS abnormalities with PD signal. Studies showed that GS abnormalities 
also occur in non-arthritic individuals, and especially the discriminative value of GS 
score 1 is debatable.14, 28 Therefore, we used a threshold of 2 for grayscale ultrasound 
abnormalities. 
Conclusions
Sixteen percent of the arthralgia patients developed IA after one year follow-up of 
whom 59% showed ultrasound synovitis at baseline. Positive PD signal, morning 
stiffness and age were independently associated with the development of IA after one 
year. Given the high negative predictive value, ultrasound has added value to identify 
which patients will not develop into IA. Further research is recommended to determine 
confirm our results regarding the diagnostic value of the presence of PD ultrasound 
synovitis to predict the progression to IA in early arthralgia patients. 
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Abstract
Objective: Part of the psoriasis patients with musculoskeletal complaints will have 
inflammation of the entheses. Entheseal inflammation is difficult to assess by clinical 
examination only. Therefore, we aimed to determine the frequency of clinically 
relevant ultrasound inflammation at the most commonly assessed entheses (MASEI; 
Madrid Sonographic Enthesis Index) in primary care psoriasis patients with one or 
more tender entheses. 
Methods: Adult primary care psoriasis patients with musculoskeletal complaints 
(tender enthesis or arthritis at physical examination) had an ultrasound examination 
of seven entheses according to the MASEI. Clinically relevant ultrasound inflammation 
was defined as active inflammation on ultrasound in combination with at least one 
clinical feature at the same enthesis. Active ultrasound inflammation contained 
positive power Doppler signal or in case of the plantar aponeurosis increased thickness. 
Structural changes entailed calcifications, enthesophytes, increased thickness, 
hypoechogeneicity indicating irregular fiber structure and erosions. Clinically, an 
enthesis was scored positive by a tender enthesis at clinical examination, reported pain 
in the history or self-reported pain in the questionnaires. 
Results: Of 542 primary care psoriasis patient, 111 patients had tender entheses and/
or arthritis. These patients were both clinically and ultrasonographically evaluated. 
Active ultrasound inflammation accompanied with pain or tenderness at the enthesis 
was found in 36% of the patients (n=40). Most common were inflammation at the 
knee (n=11) and at the plantar aponeurosis (n=10). Structural changes were observed 
in 95% of the psoriasis patients independent of their clinical manifestation.
Conclusion: We found concurrent presence of ultrasound inflammatory changes and 
clinical symptoms in 36% of the primary care psoriasis patients who had tenderness at 
one or more entheseal sites. 
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Introduction
Enthesitis is an important domain in psoriatic arthritis (PsA). Since the introduction 
of the CASPAR classification criteria for PsA in 2006, psoriasis patients can classify as 
PsA with only enthesitis as inflammatory articular involvement.1 Increasing attention 
is paid to its assessment2, 3, but up to now no consensus has been achieved on its 
measurements in the diagnostic setting. In both the classification criteria for PsA and 
spondyloarthritis (SpA), enthesitis is included. The CASPAR criteria suggest that the 
doctor diagnoses enthesitis as he sees fit. The ASAS criteria for peripheral SpA include 
only the Achilles tendon and the plantar aponeurosis without being specific which 
clinical characteristics need to present.4 
Enthesitis is defined as inflammation at tendon, ligament, joint capsules or aponeurosis 
insertion sites to bone. Entheseal pain can be severe, disabling and continuous, and 
can last for several years.5, 6 The ethiopathogenesis is poorly understood and may 
relate to mechanical stress on top of the immune response.7 Clinical assessment of the 
entheses is difficult as inflammation is often not visible or palpable. In addition, it may 
be difficult to anatomically locate the enthesis if it lies deep within the surrounding 
tissue.8 The location of several entheseal sites overlaps with those of the tender points 
of fibromyalgia.9 Furthermore, the presence of a tender enthesis is not necessarily 
indicative for underlying inflammatory disease as it could be related to overuse, 
metabolic disease or ageing.10 These challenges could lead to clinically false-positive 
patients. 
To resolve the difficulties regarding clinical assessment of the entheses, inflammatory 
characteristics at the enthesis can be visualized by ultrasound.11 Especially the use of 
the power Doppler mode improves the assessment of inflammation at the entheses.12, 13 
New data about ultrasound enthesitis emerged in patients with psoriasis, PsA and 
healthy controls.14-16 So far, studies evaluated enthesitis in patients with psoriasis 
who were referred from the dermatologist.16-20 A significant higher prevalence of 
both grayscale (GS) and power Doppler (PD) ultrasound enthesopathy was found in 
patients with psoriasis than in controls (patients with dermatological diseases other 
than psoriasis).16-18 In patients with PsA the severity of ultrasound abnormalities was 
even higher than in patients with psoriasis.20 Ultrasound abnormalities at the entheses 
were present in both symptomatic (true-positive) and asymptomatic (false-positive or 
subclinical disease) psoriasis patients which suggests single application of ultrasound 
is not sufficient to detect clinically relevant entheseal inflammation.19, 21
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Little data is available on the presence of PsA in primary care psoriasis patients.22, 23 In 
several countries psoriasis patients are treated by their general practitioner and this 
might mean that cases of PsA are missed. In addition, these studies did not include 
ultrasound to assess inflammation at the entheses. In a large primary care based study 
the frequency of PsA in psoriasis patients was estimated to be 3.1% for arthritis and 
axial disease, increasing to 4.6% when enthesitis would be included.24
In this study we describe the frequency of ultrasound abnormalities at the entheses 
and its clinical information in primary care psoriasis patients who had at least one 
tender enthesis at clinical examination. We combined PD ultrasound and clinical 
information at the same enthesis to differentiate between active inflammation and 
other manifestations of enthesopathy.
Materials and methods
Patients
Adult patients with psoriasis (ICPC S91) were identified from 97 general practitioners 
(GPs) in the Rotterdam area. These patients were invited to participate in the SENSOR 
study. Details of this cross-sectional study can be found in Karreman et al.24 In brief, 
patients who reported regular episodes of pain in joints, entheses or the lower back 
were eligible and invited for clinical evaluation by a trained nurse. Patients were not 
recruited consecutively. Data collection included a detailed clinical examination 
(amongst others, swollen joint count, tender joint count, entheses evaluation), 
demographic characteristics and symptom history. 
Written informed consent was obtained from the participants. The study was approved 
by the medical ethic committee of Catharina Hospital, Eindhoven, the Netherlands.
Entheses evaluation
Clinical examination
Physical examination included the 66/68 joint count for PsA and entheseal assessment 
following the Leeds Enthesitis Index (LEI) and the Maastricht Ankylosing Spondylitis 
Enthesis Score (MASES).2, 3 Other assessments included measurement of psoriasis 
severity by the PASI and body mass index. If clinical examination indicated a painful 
enthesis on the LEI/MASES or indicated an arthritis, ultrasound examination of the 
entheses was performed. 
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Ultrasound examination
An independent ultrasound examiner blinded for the clinical details performed the 
ultrasound using Esoate MyLab60 (probe LA 435). The six entheses of the Madrid 
Sonographic Enthesis Index (MASEI)25 and the lateral epicondyle tendon insertion 
(elbow) were examined. Each tendon was examined in the longitudinal plane. Knee 
entheses were examined with the patient in supine position and the knee flexed at 
20°. The Achilles tendon and the plantar aponeurosis were examined with the patient 
in prone position and the feet hanging over the edge of the examination table in 
neutral position. To examine the lateral aspect of the elbow, the patient was positioned 
with the elbow flexed, forearm extended and palm down. To examine the olecranon, 
the patient was asked to raise the elbow and to keep the elbow flexed (90°) with the 
hand palm resting on the table. According to the MASEI scoring system the following 
elemental lesions of enthesitis were evaluated at each site: calcifications, bursitis, 
erosions, PD signal in bursa or enthesis full tendon (cortical bone profile, intratendon 
and paratendon on the enthesis insertion) and thickness and structure.25 Ultrasound 
abnormalities were divided into ‘active inflammation’ and ‘structural change’ 
parameters. Active inflammatory components on ultrasound included the presence 
of PD signal (<2mm of the bony cortex)15 or in case of the plantar aponeurosis an 
increased thickness (≥4.4mm).26 Structural changes included calcifications, erosions, 
structure, and increased thickness.
Self-reported pain at the entheses
Patients completed online self-reported questionnaires including the EARP27 and 
PEST28. From the EARP questionnaire we used the question regarding the Achilles 
tendon. From the PEST questionnaire we used those questions regarding pain of the 
heel, elbows, and knees. Patient history included questions about symptom history 
regarding previous episodes of entheseal inflammatory complaints, which were 
diagnosed by a GP.
Enthesitis definition
In this study we combined data from ultrasound and clinical examination, and 
patient-reported questionnaires to define active inflammation at the enthesis. We 
defined enthesitis as active inflammation on ultrasound (presence of PD signal and/
or increased thickness of the plantar aponeurosis) in combination with at least one 
clinical feature at the same enthesis: i) tender point LEI/MASES, ii) self-reported pain 
at the elbow, knee, Achilles tendon and heel from the EARP or PEST questionnaire, 
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iii) self-reported entheseal complaints (defined as previous episodes of entheseal 
inflammatory complaints, diagnosed by a GP).
Statistical analysis
To determine differences in baseline characteristics and ultrasound findings between 
patients suspected for enthesitis and patients suspected for arthritis we used descriptive 
statistics. Depending on the distribution of the data we used the independent T-test 
or Wilcoxon-Mann-Whitney test. Frequencies were compared using a Chi-square test. 
Analyses were done using STATA 12.0.
Results 
In total, 111 patients of the total study population with psoriasis (n=524) who reported 
regularly musculoskeletal complaints were evaluated by ultrasound. Of these patients, 
88 patients were referred for ultrasound because they had at least one tender enthesis 
on the LEI/MASES. The other 23 patients were referred for suspected arthritis and also 
underwent an evaluation of the entheses by ultrasound. Nine (8%) patients had a 
confirmed diagnosis of PsA by a rheumatologist. Patient characteristics are presented 
in Table 1. 
Table 1 Baseline characteristics of primary care psoriasis patients (n=111)
Suspected for enthesitis (n=88) Suspected for arthritis (n=23) p-value
Women (%) 57 39 0.130
Age, years (mean, sd) 54 (13) 54 (14) 0.936
LEI (median, IQR) 2 (1-4) 0 (0-1) <0.001
MASES (median, IQR) 2 (0-4) 0 (0-1) <0.001
MASEI (median, IQR) 7 (5-12) 10 (5-13) 0.302
Power Doppler positive, n (%) 0.626
- 1 enthesis 14 (16) 2 (9)
- 2 entheses 12 (14) 3 (13)
- 3 entheses 3 (3) 1 (4)
LEI = Leeds Enthesitis Index (range: 0-6); MASES = Maastricht Ankylosing Spondylitis Enthesis Score (range: 0-13); 
MASEI = Madrid Sonographic Enthesis Index (range: 0-136); sd = standard deviation; IQR = interquartile range
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Entheses evaluation
Clinical examination
The median number of tender entheses on the LEI was 2 (IQR: 0-3). The median number 
of tender entheses on the MASES was 1 (IQR: 0-3). Patients suspected for enthesitis 
had more tender entheses on both the LEI and the MASES (median (IQR): 4 (1-7)) than 
patients suspected for arthritis (median (IQR): 2 (0-4); p<0.0001). The most common 
tender entheses were found at the lateral epicondyle of the humerus (52%) and at the 
medial epicondyle of the femur (50%) [Table 3].
Ultrasound examination
In 106 (95%) patients (n=111) we detected one or more ultrasound abnormalities at the 
enthesis [Table 2]. There was no difference in ultrasound findings between patients 
suspected for enthesitis and patients suspected for arthritis. 
Table 2 Ultrasound abnormalities at the enthesis using the MASEI score (n=111) , n (%)
Insertion PD signal Structure Thickness Bursitis Erosion Calcification
Lateral epicondyle tendon (elbow) 21 (19) 19 (17) 51 (46) 35 (32) 47 (42)
Triceps tendon 0 25 (23) 18 (16) 9 (8) 26 (23)
Quadriceps tendon 13 (12) 12 (11) 53 (48) 3 (3) 66 (59)
Proximal patella tendon 2 (2) 4 (4) 29 (26) 2 (1) 15 (14)
Distal patella tendon 9 (8) 3 (3) 77 (69) 1 (1) 3 (3) 23 (21)
Achilles tendon 4 (4) 1 (1) 12 (11) 0 1 (1) 70 (63)
Plantar aponeurosis † 1 (1) 20 (18) 0 20 (18)
MASEI = Madrid Sonographic Enthesis Index (range: 0-136); PD = power Doppler; † = not detectable
In 50 (45%) patients we found ultrasound abnormalities indicating inflammatory 
disease at the enthesis [Table 3]. Thirty-five (32%) patients were PD positive on 
ultrasound of whom 5 (5%) also had a thickened plantar aponeurosis. Fifteen (14%) 
patients only had a thickened plantar aponeurosis. 
Positive PD signal was found most often at the lateral epicondyle of the humerus (21 
patients, 19%) and at the insertion of the quadriceps tendon at the superior pole of the 
patella (13 patients, 12%). In 19 (17%) patients we found positive PD signal at more than 
one enthesis. Of note, we did not find any indication of inflammatory disease at the 
triceps enthesis at the olecranon. 
Structural changes of the enthesis on ultrasound [Table 3] were very common. 
Increased thickness of the distal patella tendon at the tuberositas tibiae (69%), and 
calcifications at the enthesis of the quadriceps tendon (superior pole patella: 59%) and 
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at the enthesis of the Achilles tendon (63%) were found most often. Structural changes 
without indication of inflammatory disease were found in 56 (50%) patients. 
Self-reported pain at the entheses
In total, 105 patients (95%) reported pain at  a location relevant to the enthesis: the 
elbow, knee, Achilles tendon, or heel. Pain in the knee was most frequently reported 
(71%), followed by the heel (55%) and elbow (49%). Nineteen (17%) patients reported 
pain at the Achilles tendon insertion.
Patients fulfilling enthesitis definition
Patients who had clinical symptoms and PD at one of their enthesis or a thickened 
plantar aponeurosis were classified as having ultrasound confirmed inflammatory 
enthesitis. Of the 50 patients with ultrasound abnormalities indicating inflammatory 
disease, the ultrasound findings were confirmed by clinical information in 40 
patients (36%). These patients were classified as having active (ultrasound confirmed 
inflammatory) enthesitis. Twenty-eight patients had active enthesitis at one enthesis. 
These were found at the knee (n=11), at the insertion of the plantar aponeurosis (n=10), 
at the lateral epicondyle of the humerus (n=6) and at the Achilles tendon (n=1). Ten 
patients had active enthesitis at two entheses, and two patients had active enthesitis 
at three entheses. Thirty-two cases were referred because they had at least one tender 
enthesis on the LEI/MASES. The other eight cases were referred for suspected arthritis.
Table 3 Ultrasound and clinical findings per entheseal site (n=111), n (%)
Insertion US inflammatory US structural Tender point Self-reported 
Lateral epicondyle tendon (elbow) 21 (19) 62 (56) 58 (52) 54 (49)
Triceps tendon 0 49 (44) † 54 (49)
Quadriceps tendon 13 (12) 68 (61) 55 (50)* 79 (71)
Proximal patella tendon 2 (2) 37 (33)
Distal patella tendon 9 (8) 74 (67)
Achilles tendon 4 (4) 68 (61) 32 (29) 19 (17)
Plantar aponeurosis 20 (18) 16 (14) † 61 (55)
US = ultrasound; † = not included in LEI/MASES; * = medial epicondyle femur
Ten patients had inflammatory ultrasound abnormalities while they did not report 
clinical problems. We found a positive PD signal in five patients. The PD signal was 
found at the enthesis of the lateral epicondyle of the humerus (n=3), at the entheses 
of the knee (n=1), and in one patient both at the lateral epicondyle (humerus) and 
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the Achilles enthesis. The plantar aponeurosis was thickened in fi ve patients without 
clinical symptoms. 
Figure 1 shows the distribution of the ultrasound fi ndings, both structural changes and 
active inflammation combined with the clinical fi ndings at each entheseal site.
Five patients had a painful enthesis clinically without having any ultrasound 
abnormalities. These patients all had a painful knee, combined with a painful enthesis 
at the lateral epicondyle of the humerus (n=4), with a painful heel (n=2), or a tender 
Achilles enthesis (n=1). 
The other 56 patients had a painful enthesis with structural changes on ultrasound. 
Figure 1. Distribution of the ultrasound fi ndings, both structural changes (US structural) and active inflammation 
(US inflammatory), in combination with the clinical fi ndings ( - = negative; + = positive) at each entheseal site (US 
= ultrasound). 
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Discussion
In 36% of the primary care psoriasis patients who had tenderness at one or more 
entheseal sites (n=111) enthesitis was present, defined as concurrent presence of 
ultrasound inflammatory changes and clinical symptoms. Ultrasound assessment 
included five elemental lesions: the presence of calcifications, erosions, increased 
thickness, changes in fiber structure, and positive PD signal. We indicated the first 4 
lesions as ‘structural changes’ of the enthesis which were present in 95% of the patients, 
while we named positive PD signal the ‘inflammatory component’, present in 32% of 
the patients. One exception was made for the plantar aponeurosis as ultrasound was 
not able to elicit any PD signal in this area. Therefore, increased thickness was chosen 
to assess inflammatory changes at the enthesis of the plantar aponeurosis, which was 
present in 18% of the patients. In total, 45% of the patients (n=50) had ultrasound 
inflammatory changes. Combined with clinical information at the same enthesis this 
led to 36% of the patients (n=40) having enthesitis. In part of our study population (9%; 
n=10) we found ultrasound inflammatory components, but these were not confirmed 
by clinical information. This could be related to subclinical disease, which could be 
predictive for the development of PsA in patients with psoriasis.21, 29-31 
Considerable advances have been made in the use of ultrasound to evaluate entheses. 
Nevertheless, context of clinical information remains needed to differentiate between 
active inflammation and other manifestations of enthesopathy.10 By adding ultrasound 
to the clinical evaluation of entheses we were able to visualize the presence of active 
inflammatory involvement of the enthesis. This could help to differentiate patients with 
non-inflammatory entheseal pain from patients with entheseal involvement related to 
inflammation, helping physicians to make informed decisions about whom to treat 
with anti-inflammatory drugs. First-line treatment recommendations for enthesitis 
in PsA patients are NSAIDs. After insufficient response to NSAIDs, treatment can be 
switched to biological agents.32, 33 Since rheumatologists are quite reserved to prescribe 
biologic agents to treat enthesitis, ultrasound might give more certainty for detecting 
inflammatory disease at tender entheses. However, further research regarding the 
treatment of ultrasound confirmed enthesitis is needed. 
One of the difficulties we came across was the absence of general accepted definitions 
for both the clinical presentation as well as the ultrasound presentation of enthesitis. 
The OMERACT Ultrasound Task Force recently debated the latter, but they did not come 
to a definite conclusion what would be inflammatory.15 The main reason for this was the 
discussion on entheseal thickness. Part of the ultrasound examiners felt this to belong 
to inflammatory changes while other examiners attributed this to structural changes. 
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Both could be true. In the acute phase, increased thickness might be present due to 
inflammation as shown by McGonagle et al with soft tissue and bone edema at the plantar 
aponeurosis insertion on MRI appearances.34 However, thickening could also be the result 
of a disorganized repair process (scar tissue) in which no inflammation is present anymore. 
There are several strengths and weaknesses to discuss when interpreting the results of 
our study. At first, for practical reasons we choose to apply ultrasound, rather than MRI. 
Ultrasound was easy accessible, we could apply it to different locations at once and 
there were no safety issues. It has the disadvantage that it is reader dependable, which 
was solved by one examiner for all patients. However, ultrasound cannot depict bone 
edema which is also indicative for inflammatory changes like MRI does. MRI is capable 
of detecting soft tissue changes associated with surrounding soft tissue edema in the 
region adjacent to the enthesis.10 However, application of MRI would require long 
acquisition time to evaluate six entheses bilaterally. There have been recent advances in 
whole body MRI but issues need to be solved such as field of view, image resolution for 
small structures and body position.35 Secondly, patient position during the ultrasound 
examination of the knee entheses was not ideal. In our study maximum flexion of the 
knee was 20°, which could have influenced our PD signal at the entheseal level of the 
knee entheses. Previous studies found an severe decrease of PD signal when the knee 
was flexed at 30°.36 Flexion of the knee could increase intratendinous tension, which 
facilitates collapse of the microvessels. Thirdly, due to the aim of our initial study, which 
was to estimate the prevalence of PsA in primary care psoriasis patients, we did not 
include control patients. However, there is a substantial body of evidence that shows 
the usefulness of the MASEI score in differentiating patients with PsA/SpA from healthy 
controls20, 37, especially if using inflammatory changes (PD signal) rather than structural 
changes.21 This stresses our choice to use a positive PD signal at the enthesis as an 
indication for active ultrasound enthesitis. A strength of our study is that we included 
primary care patients with psoriasis with musculoskeletal complaints. Most studies 
evaluating enthesitis with ultrasound have included psoriasis patients in secondary 
care referred by the dermatologist.16 Our study population is a different population in 
which it would be beneficial to screen for PsA and to improve early diagnosis of PsA. 
In conclusion, enthesitis defined as concurrent presence of ultrasound inflammatory 
changes and clinical symptoms was present in 36% of the primary care psoriasis 
patients who had tenderness at one or more entheseal sites. Combining clinical data 
and ultrasound at the same enthesis reduced the frequency of entheseal lesions that 
should be evaluated by the rheumatologist compared to clinical exam only. Consensus 
needs to be reached to find a generally accepted definition for enthesitis which would 
be feasible in daily clinical work.  
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Abstract
Objective: Investigating the agreement of ultrasonographical findings at the MTP 
joints with physical examination in newly diagnosed RA patients who were treated to 
target.
Methods: In a multicenter cohort study, newly diagnosed RA patients were followed for 
one year. Symptom duration was <1 year and patients were treatment naïve. Patients 
underwent physical (SJC, TJC, squeeze test), laboratory and ultrasound examination 
(MTP2-5) at baseline, three months and one year follow-up. Ultrasound images 
were scored semi-quantitatively for grayscale (GS;0-3) and power Doppler (PD;0-3). 
Ultrasound synovitis was defined as GS≥2 and/or PD≥1. Kappa-statistic (κ), positive 
and negative percent agreement were calculated. 
Results: In total, 174 patients were included of whom 62% achieved DAS28 remission 
(DAS28≤2.6) at one year follow-up. At baseline, 63% of patients had ≥1 ultrasound 
positive MTP joint, which decreased to 25% at one year follow-up, irrespective of 
achieving remission or not. Positive percent agreement between physically swollen 
MTP joints and ultrasound was 16% at baseline (κ=0.02); 5% at one year follow-up 
(κ=0.01). The percentage negative agreement between physically non-swollen MTP 
joints and negative ultrasound was 86% at baseline. Agreement of the squeeze test 
and ultrasound at MTP joints ranged from 64% (κ=0.08) at baseline to 29% (κ=0.09) 
after one year follow-up.
Conclusion: In newly diagnosed RA patients, we saw a decrease in mean DAS 
score and number of ultrasound positive MTP joints. However, 25% of ultrasound 
synovitis remained irrespective of DAS. Agreement between ultrasound and physical 
examination at joint level was poor. 
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Introduction
In patients with rheumatoid arthritis (RA), metatarsophalangeal (MTP) joints are 
frequently affected early in the course of the disease.1 Up to 36% of RA patients has 
involvement of the foot joints prior to involvement of the hands.2 In diagnosing and 
monitoring RA, physical examination of the joints is important, but is characterised by 
poor reproducibility and accuracy.3 Especially physical examination of the feet is more 
difficult than that of other joints. For instance, other causes of pain and swelling of 
the feet such as osteoarthritis, polyneuropathy and oedema could confound accurate 
assessment of RA disease activity.4, 5
Nowadays, intensive treatment of early RA results in improved outcomes and treat-
to-target management strategies are recommended by international guidelines.6, 7 
The goal of the treat-to-target strategies is to achieve clinical remission, of which the 
assessment includes physical examination of the joints. In 2011, the American College of 
Rheumatology (ACR)/European League Against Rheumatism (EULAR) together with an 
Outcome Measures in Rheumatology (OMERACT) task force have redefined the definition 
of remission in RA.8 Both the Boolean-based definition and the SDAI-based definition are 
based on 28-joint counts. Theoretically, a patient could be classified as being in remission 
according to 28-joint counts, while having considerable disease activity in ankles and feet 
joints. Previous research regarding this issue shows conflicting results. Several studies 
agreed that remission assessing 28-joint counts is inferior to remission using the original 
DAS, which counts 44 joints including the assessment of the feet, and showed that up 
to 40% of patients in DAS28 remission had disease activity in the feet.9-12 On the other 
hand, it has been shown that DAS28 and SDAI may overrate disease activity and classify 
patients into higher disease activity states, compared with the DAS.13 However, other 
studies concluded that reduced joint counts are appropriate and valid to assess disease 
activity at group level in observational studies or in clinical trials.4, 14, 15
Previous research showed that ultrasonography could be a useful tool in clinical 
decision making since ultrasound detects synovitis more sensitively than physical 
examination.16, 17 Many RA patients with physically no swollen joints have synovitis at 
ultrasound, which appears to be predictive of worse outcomes.18-20
In this study we investigated the agreement of inflammation of the MTP joints as 
assessed by ultrasound and as assessed with physical examination in newly diagnosed 
RA patients who are treated to target. This way we can answer the question whether 
ultrasound may be added to physical examination in daily clinical practice for 
monitoring the feet.
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Patients and methods
Patients
This was a multicentre (7 centres in the Netherlands) study in which a cohort of 
consecutively recruited newly diagnosed RA patients (1987 ACR criteria)21 was 
prospectively followed for one year. At study entry, symptom duration was less than 1 
year and all patients were naïve for treatment with conventional synthetic DMARDs, 
biologicals and glucocorticoids. All patients were treated to target (low disease activity 
or remission) with regular visits. Patients had to be able to understand, speak and write 
in Dutch. Patients underwent physical (44 swollen joint count (SJC), 44 tender joint 
count (TJC)), laboratory (CRP, BSE, serology) and ultrasound examination at enrolment 
in the study (T0), at three months (T3) and at one year follow up (T12). Patients were 
categorised into three groups depending on their disease activity state: i) remission: 
DAS28≤2.6, ii) low disease activity (LDA): 2.6<DAS28≤3.2, and iii) high disease activity 
(HDA): DAS28>3.2. In addition, in four centres the squeeze test was performed, 
assessing pain at tangential compression of the metatarsophalangeal (MTP) joints22, 
scored as absent or present. 
Written informed consent was obtained from the participants according to the 
declaration of Helsinki. The study was approved by the local medical ethic committee 
of Erasmus MC, University Medical Centre Rotterdam, the Netherlands.
Ultrasound assessment
The ultrasonographers had nine trainings sessions prior to and during the study to 
optimise interpretation and acquisition reliability between them. For the ultrasound 
examination each centre used the same machine and transducer (Esaote MyLab60 
with linear array LA-435 probe 6-18MHz). MTP 2 to 5 joints were scanned bilaterally 
at the dorsal orientation. Patient and probe positioning were according to EULAR 
guidelines.23 Joints were graded according to a semi-quantitative scoring system (0-3) 
for both grayscale (GS) and power Doppler (PD). For GS, all joints were graded according 
to Szkudlarek et al., 0 = no synovial thickening, 1 = minimal synovial thickening, filling 
the angle between the periarticular bones, without bulging over the line linking the 
bone diaphyses of the periarticular bone regions; 2 = synovial thickening without 
extension over the bone diaphyses; 3 = synovial thickening over at least one of the 
bone diaphysis.24 Synovial vascularisation was measured using power Doppler. Power 
Doppler was graded according to Naredo et al., 0 = absent; 1 = mild, single vessel signal 
or isolated signal; 2 = moderate, confluent vessel signals in the intra-articular area; 3 = 
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marked, vessel signals in more than half of the intra-articular area.17 For power Doppler 
(PD) we used a colour gain setting at the disappearance of colour noise, frequency of 
10 MHz, a pulse repetition frequency of 750 Hz and wall filter at level 3 out of 5 (=max). 
We adjusted the size and position of the colour box to include the subcutaneous tissue 
to recognize artefacts caused by vessels above the joint. Based on data in the literature, 
we considered a joint to have ultrasound synovitis if it was scored with at least grade 2 
in the GS ultrasound domain or at least grade 1 in the PD ultrasound domain.25, 26 
Primary outcome
Ultrasound synovitis in MTP joints defined as GS≥2 and/or PD≥1. 
Analysis
We used descriptive statistics to present physical examination and ultrasound findings 
in the MTP joints. No statistical inferences were conducted in the study. At joint level 
we calculated the kappa statistic27, and positive and negative percent agreements 
(PPA/NPA)28 between physical examination (SJC, TJC and squeeze test) and ultrasound 
findings. All analyses were done using STATA14. 
Results
In total, 174 patients were included in the study. Baseline characteristics are shown in 
table 1. After three months 9 patients were lost to follow-up. At one year follow-up we 
had complete data for 157 patients. At one year follow-up, 62% of the patients achieved 
DAS28 remission and 18% had LDA. 
Ultrasound assessment
At baseline, 63% of the patients had at least one MTP joint with ultrasound synovitis 
(GS≥2 and/or PD≥1). The median number of MTP joints with ultrasound synovitis was 
1 (IQR: 0-4). At one year follow-up the median was 0 (IQR: 0-0). At one year follow-
up 25% of the patients showed ultrasound synovitis in at least one MTP joint. Figure 
1 shows the course of ultrasound positive and ultrasound negative MTP joints during 
follow-up. Twenty-three (13%) patients had at least one MTP joint ultrasound positive 
at all three visits, 42 (24%) patients had no ultrasound positive MTP joint at one year 
in the study. 
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Table 1 Patient characteristics and ultrasound findings at baseline and during the study
Baseline
 (n = 174)
at 3 months 
(n=165)
at 12 months
 (n = 157)
Age, mean (sd),  years 55 (14)
Women, n (%) 111 (64)
RF positive, n (%) 115 (66)
ACCP positive, n (%) 103 (60)
DAS28, mean (sd) 4.9 (1.3) 2.9 (1.3) 2.3 (1.2)
SJC28, median (IQR) 6 (3-11) 1 (0-4) 0 (0-1)
TJC28, median (IQR) 6 (2-10) 1 (0-4) 0 (0-2)
BSE, median (IQR) 27 (12-47) 10 (5-22) 8 (3-17)
DAS28 remission, n (%) 8 (5) 71 (43) 98 (62)
DAS28 LDA, n (%) 13 (7) 26 (16) 29 (18)
DAS28 HDA, n (%) 153 (88) 68 (41) 32 (20)
US MTP, median (IQR) 1 (0-4) 0 (0-2) 0 (0-0)
US MTP >0, n (%) 109 (63) 71 (43) 39 (25)
ACCP = anti-cyclic citrullinated peptide; SJC = swollen joint count in 28 joints; TJC = tender joint count in 28 joints; 
LDA = low disease activity (2.6<DAS28≤3.2); US = ultrasound; sd = standard deviation; IQR = interquartile range; 
US MTP = GS≥2 and/or PD≥1; GS = grayscale; PD = power Doppler
Clinical disease activity and ultrasound
At baseline, the majority (88%) of the early RA patients had HDA. During follow-up 
disease activity decreased. After 12 months, 20% of the patients had HDA and 62% of 
the patients achieved DAS28 remission. Figure 2 shows the distribution of ultrasound 
synovitis over the different disease activity categories (HDA; LDA and remission). The 
number of patients with at least one ultrasound positive MTP joint decreased over 
time from 63% on average overall to 25% in all three categories of disease activity at 
12 months. 
Physical assessment and ultrasound
At joint level, we had complete data of 1032 MTP joints of which 302 (29%) were 
swollen at physical examination and 149 (14%) had ultrasound synovitis at baseline. 
Table 2 shows the kappa statistic, PPA and NPA during follow-up. Overall, agreement 
was poor. PPA of SJC with ultrasound was 16% (n=47). Focussing on physically non-
swollen joints (n=730; 71%), NPA with ultrasound findings was 86% (n=628). During 
follow-up PPA between physically swollen joints and ultrasound decreased to 5%. NPA 
between physically non-swollen joints and ultrasound increased to 96%. 
In addition, we evaluated the agreement between physically tender joints and 
ultrasound findings at joint level for MTP joints. These results were comparable to 
those of physically swollen joints [data not shown]. 
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Figure 1. Course of ultrasound (US) fi ndings in time in patients. Ultrasound synovitis positive and ultrasound 
negative patients (MTP joints) at baseline (T0), three months (T3), and twelve months (T12). At 12 months, 39 
patients showed US synovitis (US+: GS≥2 and/or PD≥1) in the MTP joints and 118 patients showed no US synovitis. 
Figure 2. Distribution of early RA patients according to disease activity (DAS28) at baseline (T0), three months 
(T3), and twelve months (T12). The green bar depicts the percentage of patients who have at least one US positive 
MTP joint. (HDA = high disease activity; LDA = low disease activity; US = ultrasound)
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Squeeze test and ultrasound
We had data on bilateral compression pain of MTP joints of 71 patients at baseline. 
We found positive test results in 44 patients of the MTP joints. During the study, the 
number of patients with positive squeeze test decreased to 7 (12%) after 12 months. 
Focusing on the PPA between the squeeze test and the ultrasound findings, 64% of 
the patients with a positive squeeze test of the MTP joints had a positive ultrasound of 
the MTP joints at baseline. After 12 months follow-up, the PPA decreased to 29%. NPA 
increased from 70% at baseline to 89% after 12 months. 
Table 2 Agreement at joint level between US and physical examination of MTP joints
    SJC + SJC - 
T0 (n=1032) US + 47 102
  US - 255 628
  κ: 0.02 PPA: 15.6% NPA: 86.0%
       
    SJC + SJC - 
T3 (n=944) US + 5 57
  US - 81 801
  κ: -0.01 PPA: 5.8% NPA: 93.4%
       
    SJC + SJC - 
T12 (n=856) US + 1 33
  US - 18 804
  κ: 0.01 PPA: 5.3% NPA: 96.1%
US: ultrasound; + = positive; - = negative; MTP: metatarsophalangeal joint; SJC: swollen joint count; PPA: positive 
percent agreement (agreement on positive cases); NPA: negative percent agreement (agreement on negative 
cases)
Discussion
In this study we investigated the course of ultrasound inflammation and its agreement 
with physical examination of the MTP joints in newly diagnosed RA patients who 
were treated to target. At one year of follow-up, we saw a decrease both in mean DAS 
score and number of ultrasound positive MTP joints. Eighty percent of the patients 
achieved DAS28 remission (DAS28≤2.6) or LDA (2.6<DAS28≤3.2), while irrespective 
of patients’ clinical disease activity status, in 25% of the patients at least one MTP 
joint remained positive on ultrasound. Ultrasound and physical examination agreed 
poorly for individual joints. At baseline,  positive ultrasound findings agreed in 14-16% 
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with joints that were both physically swollen or tender. This decreased to 1-5% at one 
year. Conversely, we found high agreement between physically non-swollen or non-
tender MTP joints and a negative ultrasound. In 33 joints (4%) ultrasound synovitis 
was found in a physically non-swollen MTP joint at 12 months, which could indicate 
ongoing subclinical disease activity. This could lead to structural damage in the feet 
joints.29, 30 In addition, we evaluated the agreement between the squeeze test of the 
feet and ultrasound findings in a subpopulation. The agreement on positive cases 
ranged from 64% at baseline to 29% after one year follow-up. In a previous study it was 
shown that adding the squeeze test of MTP joints to the DAS28 improved disease state 
categorisation in patients with RA.22 
The discordance between physical examination and ultrasound results raises 
discussion to what extent adding ultrasound findings of the MTPs to physical exam 
results would lead to better patient care. Assessing MTP joints physically may be 
difficult in patients with high BMI, osteoarthritis and/or oedema.4, 5 Our results show 
that scanning patients’ feet at baseline is not effective as the number of ultrasound 
affected joints decreased over time comparable to the DAS. However, scanning the 
feet at turning points in the treatment may very well be effective. Persistent activity 
of  the feet joints might justify intensification of treatment, or in a situation of DAS28 
remission when treatment de-escalation would be an option, one could scan the feet 
to assess whether the feet are really in remission. 
Previous studies concluded that subclinical joint inflammation detected by ultrasound 
could account for joint destruction in RA patients in clinical remission.19, 20 Therefore, 
it would be recommended for future research to follow-up this study population to 
investigate whether we will find radiological progression, especially in the feet, in 
patients who have positive ultrasound findings of the MTP joints but do not show 
swelling at physical examination and vice versa (physically swollen, but negative 
ultrasound). 
Heterogeneity in treatment strategies between centres could be considered as a 
limitation. However, all patients were treated according to a treat-to-target protocol, 
which reflects daily clinical practice. Another issue is that ultrasound is operator-
dependent, therefore the ultrasound examiners attended training sessions to increase 
interobserver-reliability regarding acquisition and scoring. On joint level, interobserver 
reliability between the 7 ultrasonographers was 0.58 (ICC(A,1)) after four trainings 
sessions prior to the start of our study. Previous research regarding ultrasound 
interobserver-reliability confirmed that a consensus scoring system combined with a 
standardised acquisition protocol performed well.31-33
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In summary, we evaluated inflammation of the MTP joints, both physically and by 
ultrasound, to answer the question whether ultrasound may be added routinely 
to physical examination in daily clinical practice for monitoring the feet. From our 
results we conclude that ultrasound synovitis is still present in one or more MTP 
joints in a quarter of the patients regardless of the status (remission or not) of their 
disease activity. This might imply that ultrasound of the feet could help us at turning 
points in the treatment of RA patients. At joint level, ultrasound synovitis in the MTP 
joints correlated poorly with physical examination findings. The clinical implications 
at patient level in an era aiming for remission may be vast and need to be further 
investigated.
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Abstract
Objectives: Although rheumatoid arthritis (RA) patients achieve clinical remission, risk 
of flare still exists. Given the association between ultrasound synovitis and increased 
risk of flare, it is of clinical interest whether these patients report a different health 
status. Therefore, we evaluated the frequency of ultrasound remission in RA patients 
in clinical remission. In addition, we compared health status of RA patients in clinical 
remission with them who were also in ultrasound remission.  
Methods: In a prospective study we included 89 RA patients (aged>17 years) treated with 
a synthetic DMARD and a TNF-inhibitor who were in remission (DAS44≤2.4&SJC≤1). 
Demographic characteristics, swollen and tender joints, laboratory variables, 
ultrasound (MCP2-5;PIP2-5;wrists;MTP2-5) and patient reported outcomes (general 
health, functional ability, fatigue, depression and anxiety, pain, morning stiffness) were 
recorded at two consecutive visits (three months in-between). Ultrasound remission 
was defined as grayscale grade≤1 and power Doppler=0. 
Results: At visit 1, 39% of patients were in ultrasound remission. At visit 2, 32% of 
patients were in ultrasound remission. At visit 1, functional ability (Health Assessment 
Questionnaire (HAQ)) was scored lower by patients in ultrasound remission 
(p=0.029). At visit 2, HAQ scores were similar (p=0.928). At visit 2, Hospital Anxiety 
and Depression Scale (HADS) anxiety score and VAS pain were significantly higher 
in patients in ultrasound remission. Similar levels were found for the other patient 
reported outcomes. 
Conclusions: One-third of RA patients in clinical remission were in ultrasound 
remission. In our study population we could not find a clear association between 
health status of RA patients and being in ultrasound remission.
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Introduction
Due to the effectiveness of synthetic and biological disease modifying anti-rheumatic 
drugs (DMARDs), and tight-controlled treatment, many rheumatoid arthritis (RA) 
patients are able to reach a state of clinical remission.1 Although patients achieve 
clinical remission, studies reported that risk of flare still exists in these patients while 
DMARD treatment is continued.2, 3 This might indicate that underlying inflammation 
is still present. Such subclinical inflammation could be detected with ultrasound. 
Previous studies found ongoing active ultrasound synovitis in 48-73% of RA patients 
who were clinically in remission.3-7 Furthermore, previous research indicated that 
ultrasound synovitis (power Doppler (PD) positive) predicts short-term relapse in RA 
patients in clinical remission.3, 8, 9
Given the association between ultrasound synovitis and increased risk of flare, it is of 
clinical interest whether these patients with ultrasound synovitis report a different 
health status regarding pain, fatigue and general health. Subtle changes in health 
status may precede clinical flare.9, 10 This could be used by physicians to adapt their 
treatment different in these patients compared to patients who are both in clinical 
and ultrasound remission. However, the association between health status and clinical 
remission or ultrasound remission has not been investigated thoroughly. If a better 
health status is associated with ultrasound remission, regularly measuring the self-
reported health of RA patients would help to monitor patients at risk of flare. This 
relates to the aim of the Outcome Measures in Rheumatology (OMERACT) RA Flare 
Group, working on a validated outcome measure to identify flare including both the 
patient and the physician perspective.11, 12
In this study, we evaluated the frequency of ultrasound remission in RA patients 
who were in clinical sustained remission while they were continuing their synthetic 
and biological DMARD treatment. Our second objective was to compare the health 
status of RA patients in clinical remission with RA patients who were also in ultrasound 
remission. 
Patients and methods
Patients
We used consecutive RA patients (aged >17 years) who were included in the ongoing 
TARA (TApering strategies in Rheumatoid Arthritis) study. Patients were treated with 
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the combination of a synthetic DMARD (sDMARD) and a TNF-inhibitor  (TNFi) and 
were in remission defined as DAS44≤2.4 and SJC ≤1 (TARA remission). According to the 
Boolean remission definition we permitted one swollen joint.13 This study focusses on 
the first two visits (baseline and three months follow-up) of the TARA study. During these 
three months follow-up, patients continued their medication. The use of concomitant 
NSAIDs was allowed. Patients were asked to refrain from corticosteroids, but there 
were no restrictions on the use of intra-articular injections with glucocorticosteroids. 
At baseline (visit 1) demographic characteristics, medication use, swollen and tender 
joint count (44 joint count), laboratory variables (ESR, serology), ultrasound and 
patient reported outcomes were recorded for each patient. After three months (visit 2), 
if the patient was still in TARA remission, laboratory variables, swollen and tender joint 
count, ultrasound and patient reported outcomes were recorded again. 
Patients had to be able to understand, speak and write in Dutch. Written informed 
consent was obtained from the participants according to the declaration of Helsinki. 
The study was approved by the local medical ethic committee of Erasmus MC, 
University Medical Centre Rotterdam, the Netherlands.
Ultrasound examination
A trained ultrasound examiner blinded for the clinical details performed ultrasound 
following the ‘European League Against Rheumatism’ (EULAR) guidelines, concerning 
patient position and scanning planes.14 Twenty-six joints were evaluated with the 
Esaote Mylab60 (probe LA435) using grayscale (GS) and power Doppler (PD) imaging. 
We scanned MTP2-5 (dorsal aspect), MCP2-5 and PIP2-5 (dorsal and palmar aspects), 
and wrist (radiocarpal and intercarpal joints) bilaterally. A single midline (longitudinal 
12 o’clock position) scan perpendicularly to the bone surface was used as advised by the 
OMERACT ultrasound working group.15 The following PD settings were used: colour 
gain was set at the disappearance of colour noise. The Pulse Repetition Frequency (PRF) 
was set as low as possible to yield maximum sensitivity which resulted in a frequency of 
750 Hz. We adjusted the size and position of the colour box to include the subcutaneous 
tissue to recognize artefacts caused by superficial vessels.16 PD signals were measured 
only in joints with GS≥1. The total scanning time was ½ hour per patient per session. The 
treating rheumatologist was unaware of the results from the ultrasound examination.
Ultrasound evaluation
Image evaluation followed the recommendations of the Spanish society for 
Rheumatology. This is a modified version of the previously developed OMERACT 
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definitions of sonographic pathology.17 Joints were graded according to a semi-
quantitative scoring system (0-3) for both GS and PD. For GS, all joints were graded 
according to Szkudlarek et al., 0 = no synovial thickening, 1 = minimal synovial 
thickening, filling the angle between the periarticular bones, without bulging over 
the line linking the  bone diaphyses of the periarticular bone regions; 2 = synovial 
thickening without extension over the bone diaphyses; 3 = synovial thickening over at 
least one of the bone diaphysis.18
Synovial vascularisation was measured using power Doppler. Power Doppler was 
graded according to Naredo et al., 0 = absent; 1 = mild, single vessel signal or isolated 
signal; 2 = moderate, confluent vessel signals in the intra-articular area; 3 = marked, 
vessel signals in more than half of the intra-articular area.19
Ultrasound remission was defined as GS grade 0 or 1 and absence of PD. 
Health status
Patients completed questionnaires regarding their health status before each visit. General 
health and functional ability were assessed at baseline and after three months. Fatigue, 
morning stiffness, pain, depression and anxiety were evaluated after three months. 
General health. Physical and mental health was assessed by the Medical Outcomes 
Study Short Form 36 (SF-36) health survey. The SF-36 includes eight scales that assess 
pain, physical functioning, general health, fatigue/vitality, mental health, social 
functioning, and role limitations due to either physical or emotional problems. Two 
summary scores, the physical component summary (PCS) and mental component 
summary (MCS) were computed.20, 21 The scores range from 0–100, where a higher 
score indicates a better physical or mental health.
Functional ability. Functional ability was assessed by the Health Assessment 
Questionnaire (HAQ).22 The HAQ comprises 20 questions on eight dimensions of 
functional ability (e.g. dressing, arising, eating). The score ranges from 0–3, where 
higher scores indicate more disability.
Fatigue. Fatigue was measured by two questionnaires: the Fatigue Assessment Scale 
(FAS) and the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire 
(BRAF-MDQ). The FAS asks about fatigue on an average day and has two dimensions 
(physical and mental). Scores range from 10–50, with scores above 21 being regarded 
as fatigued and scores above 34 as severely fatigued.23 The BRAF-MDQ asks about how 
fatigue has affected the patient in the past seven days and has four dimensions (i.e. 
physical, living, cognition and emotion). Scores range from 0-70.24 For both the FAS 
and the BRAF, higher scores indicate higher levels of fatigue.
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Depression and anxiety. The Hospital Anxiety and Depression Scale (HADS) was used to 
assess anxiety and depression status. A HADS score ≥8 (range: 0-21) is indicative of the 
presence of symptoms of mild, moderate or severe depression or anxiety.25
Pain. Pain was measured by tender joint count and by the Visual Analogue Scale (VAS) 
for pain. Tender joint count was measured during physical examination and included 
44 joints. For the VAS pain patients were asked to self-assess the joint pain they have 
due to their arthritis. VAS pain ranges from 0-10 cm. The level of pain increases with 
higher scores. 
Morning stiffness. Patients were asked if they encountered morning stiffness, for how 
long the morning stiffness was present (in minutes) and they were asked to self-assess 
the severity of the morning stiffness by a score ranging from 0 to 10. The severity of 
morning stiffness increases with higher scores. 
Statistical analysis
Our primary outcome was ultrasound remission. Ultrasound remission was defined as 
GS grade ≤1 and absence of power Doppler signal. Simple descriptive techniques were 
used to describe the study sample. We analysed differences in health status between 
patients who were and who were not in ultrasound remission cross-sectionally for 
both baseline (visit 1) and after three months (visit 2). Since the data were not normally 
distributed we used the Wilcoxon-Mann-Whitney test. Frequencies were compared 
using a Chi-square test. Analyses were done using STATA 13.0, using a p-value ≤ 0.05 as 
the level of statistical significance.
Results
For this analysis we included 89 patients. Table 1 shows the baseline characteristics 
of all patients. According to the DAS44, 82% of the patients were in clinical remission 
(DAS44<1.6). Eighteen percent of the patients had low disease activity (LDA; 
1.6<DAS44≤2.4). After three months (visit 2) we had data of 71 patients. Seven patients 
had a flare (DAS44≥2.4 or ≥1 swollen joint) while continuing their combination 
treatment of synthetic and biological DMARDs. Of these seven patients, four patients 
had ultrasound synovitis at visit 1. At joint level, there was no concordance between the 
clinical findings (SJC) and ultrasound synovitis. Eleven patients were lost to follow-up 
at visit 2. 
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Ultrasound examination
In total, 39% of the patients in TARA remission were in ultrasound remission at 
visit 1. At visit 2 after three months 32% of the patients were in ultrasound remission. 
Eighteen percent of the patients were in ultrasound remission at both visits. In the 
patients who were not in ultrasound remission, ultrasound synovitis was found most 
often in the wrists (visit 1: 39%; visit 2: 45%) and in the MTP joints (visit 1: 27%; visit 2: 
30%). Ultrasound synovitis was found in 3% (visit 1) to 6% (visit 2) of the patients in 
the PIP joints. When we focussed on the absence of PD signal, the number of patients 
in ultrasound remission increased to 54% (visit 1) and 42% (visit 2). Table 2 shows the 
ultrasound findings for visit 1 and visit 2. 
Table 1: Baseline characteristics of patients in TARA remission - DAS44≤2.4 & SJC ≤1 (n=89)
Characteristic
Age, mean ±sd years 55 (12)
Women, n (%) 59 (66)
Time since diagnosis, mean ±sd years 5 (3.4)
DAS44, mean ±sd 1.1 (0.5)
DAS44 remission (DAS44<1.6) , n (%) 73 (82)
SJC = 1, n (%) 12 (14)
BSE, median (IQR) 8 (3-16)
RF positive, n (%) 45 (55)
ACCP positive, n (%) 56 (69)
DAS44 = disease activity score in 44 joints; SJC = swollen joint count; ACCP = anti-cyclic citrullinated peptide 
antibody; sd = standard deviation; IQR = interquartile range
Table 2: Ultrasound findings at baseline and at three months
  Visit 1 (n=89) Visit 2 (n=71)
GS, # positive joints, median (IQR) 0 (0-2) 0 (0-1)
PD, # positive joints, median (IQR) 0 (0-1) 1 (0-1)
US synovitis, %
MCP 12 10
PIP 6 3
Wrists 39 45
MTP 30 27
US remission, % 39 32
PD remission, % 54 42
GS = grayscale (GS≥2); PD = power Doppler; # = number; US = ultrasound; IQR = interquartile range; US synovitis = 
GS≥2 and/or presence of PD; US remission = GS≤1 and absence of PD; PD remission = absence of PD
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Health status and ultrasound remission
Table 3 shows the health status at baseline and at three months. No clear pattern 
emerged on health status between patients who were in ultrasound remission and 
who were not in ultrasound remission. At visit 1 functional ability (HAQ) was scored 
lower by patients who were in ultrasound remission than by patients who were not 
in remission (p=0.029), while general health (SF36) and TJC were similar. At visit 2 
similar levels in both ultrasound groups were observed for functional ability, general 
health, TJC, depressive symptoms and fatigue. In general we found low scores for 
HADS anxiety, HADS depression and for VAS pain. But the HADS anxiety score and 
VAS pain were significantly higher in patients who were in ultrasound remission than 
in patients who were not ultrasound remission at visit 2 (HADS anxiety: p<0.001; VAS 
pain: p=0.014).  
We conducted the same analysis on health status and the presence or absence PD 
signal. The results were not analogous with the results we found with ultrasound 
remission. At visit 1 SF36 physical scale was significantly lower in patients with the 
presence of PD signal (no PD ultrasound remission; p=0.015). At visit 2 we could not 
find any association between health status and the presence or absence of PD signal. 
Discussion
Thirty-nine percent of the RA patients in TARA remission were in ultrasound remission 
(GS grade ≤1 and absence of PD signal) at baseline. This indicates that the remaining 
two-third of the patients had ultrasound synovitis (GS grade 2 or 3 and/or PD grade 1, 
2 or 3) while they were in TARA remission and continued their synthetic and biological 
DMARDs. This is comparable with previous studies who found active ultrasound 
synovitis in 48-73% of RA patients who were clinically in remission.3-7, 26 After three 
months follow-up patients returned to the outpatient clinic, at this visit 32% of the 
RA patients were in ultrasound remission. Comparing the ultrasound results at both 
visits, 18% of the patients were in ultrasound remission at visit 1 and at visit 2. If we 
focussed on the absence of PD signal, 31% of the patients had no PD signal at both 
visits. According to the Boolean remission criteria for RA we allowed one clinically 
swollen joint. At joint level however, the ultrasound findings were not consistent with 
the clinically swollen joints.
In our study population we could not find a clear association between health status 
and being in ultrasound remission. Overall patients reported good health with low 
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scores for pain, functional disability, anxiety, depression and fatigue and higher scores 
for general health. These self-reported patient outcomes were expected, because all 
patients were in clinical remission or had LDA. A study of Sakellariou et al. showed 
that being in clinical remission was associated with low disability (low HAQ-score) and 
absence of PD signal.27 We found low HAQ-scores overall, but we did find positive PD 
signals in half of our population, while they were in clinical remission.  
In our definition of ultrasound synovitis we combined GS abnormalities with PD 
signal. GS abnormalities in RA patients could also be explained as hypertrophy of 
the synovium after inflammation.28 Other studies showed that GS abnormalities also 
occur in non-arthritic individuals, and especially the discriminative value of GS score 1 
is debatable.29, 30 In addition, it has been shown that the presence of PD signal increases 
the risk of flare.3, 8, 9 We found a positive PD signal in 46% (visit 1) to 58% (visit 2). These 
percentages are comparable with other studies evaluating the presence of PD signal in 
RA patients in clinical remission.3-7, 26 After analysis of health status and the presence 
or absence of PD signal the results were not analogous with the results we found with 
ultrasound remission. This indicates that using a different definition for ultrasound 
remission is not helpful to distinguish between patients by their health status. We 
choose to include 26 joints (MCP2-5, PIP2-5, wrists, MTP2-5), because these joints are 
most frequently involved in RA.31 Based on a review of Ten Cate et al. it also seemed that 
it is not necessary to include large joints in the ultrasound assessment.28
We found significant higher scores on the HADS anxiety score and VAS pain in patients 
who were in ultrasound remission than in patients who were not in ultrasound 
remission. Although the median score on both outcomes was low, these were still 
unexpected findings since one might expect an association in the opposite direction. 
It might be explained by the fact that patients who were not in ultrasound remission 
were less sensitive to pain or could cope better, or these results might be spurious 
findings. Another explanation could be related to a drop-out bias, since seven patients 
had a flare and 11 patients were lost to follow-up at visit 2. The majority (n=13) of these 
patients were not in ultrasound remission at visit 1, which might imply that they had 
worse health status. However, we do not have data for HADS anxiety and VAS pain at 
visit 1 which made it not possible to say whether this explanation holds. 
There are limitations to monitor patients only with self-reported health status. Previous 
studies showed that changes in self-reported health status were of limited value to 
predict disease activity in individual patients.32, 33 We know from previous research in 
RA patients in clinical remission that clinically swollen or tender joints and ultrasound 
synovitis can predict disease relapse. Our results indicate that ultrasound remission 
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does not distinguish between patients with different health status. Therefore, it 
might be desirable to combine physical examination, self-reported health status and 
ultrasound examination to optimise patient care. 
Our study has some limitations. At three months follow-up (visit 2) only 8% (n=7) of the 
patients in TARA remission had a flare, which was capture by DAS44≥2.4 or ≥1 swollen 
joint. This low flare rate might be explained by selection bias by the rheumatologists 
who included the patients. Rheumatologists could be tempted to only refer RA patients 
who achieved remission easily and who had less severe disease. 
In this study we included patients with a mean disease duration of five years. These 
patients were treated following a tight treatment protocol and with the availability 
of biologicals. Our study population possibly consisted of patients with less severe 
disease, because they had no longstanding disease and were in clinical remission on 
combination therapy of a synthetic and a biological DMARD. 
In conclusion, one-third of the RA patients in clinical remission were also in ultrasound 
remission. In our study population we could not find a clear association between health 
status of RA patients and being in ultrasound remission. We did find that patients in 
ultrasound remission experienced more pain and anxiety, however this in the opposite 
direction than expected. This might indicate that health status is not be a suitable tool 
to distinguish patients who have or have not underlying ultrasound synovitis while 
they are continuing their synthetic and biological DMARDs. We recommend that 
our results need to be confirmed in other cohorts with RA patients who are in clinical 
remission.
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Abstract
Objectives: Prognostic factors that may guide tapering decisions for DMARDs and 
TNFi on individual patient level are not available. Studies using ultrasound suggest 
that the presence of subclinical synovitis may elicit early disease relapse in remission. 
Our aim is to determine if ultrasound synovitis precedes disease relapse while tapering 
synthetic DMARD (sDMARD) or TNFi in patients with RA who achieved clinical 
remission on sDMARD and TNFi.
Methods: We included 125 RA patients (aged>17 years) treated with an sDMARD and a 
TNF-inhibitor who were in remission (DAS44≤2.4&SJC≤1). Demographic characteristics, 
swollen and tender joints, laboratory variables and ultrasound synovitis (MCP2-5;PIP2-
5;wrists;MTP2-5) were recorded at each visit (every three months) during one year 
follow-up. Patients were randomised to two tapering strategies: i) tapering sDMARD; 
ii) tapering TNFi. Disease relapse was defined as DAS44>2.4 or SJC>1. Ultrasound 
synovitis was defined as GS≤1 and/or PD≤0. 
Results: Ultrasound synovitis was found in 58% of RA patients in clinical remission. 
After one year follow-up 36% of RA patients had a disease relapse. In the multivariate 
Cox model increasing number of joints with ultrasound synovitis was not significantly 
associated with disease relapse (HR 1.21; 95%CI:0.97-1.51). Positive predictive value of 
ultrasound for having a disease relapse was 14%, negative predictive value was 92%. 
Conclusions: Monitoring RA patients who started tapering their medication every 
three months showed limited value for ultrasound to identify patients who will have 
a disease relapse. 
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Introduction
Effective tapering of medication in rheumatoid arthritis (RA) patients in early 
remission might help to reduce the costs of expensive TNF inhibitors (TNFi) without 
compromising on the health of our patients. One of the possible ways is to taper the 
TNFi early in the remission state. For the majority of patients, tapering is in line with the 
patient’s willingness to reduce their medication for their rheumatoid arthritis when 
signs and symptoms of joint inflammation disappeared. They would like to live without 
medication but are also worried about disease relapse when tapering medication.
Prognostic factors that may guide tapering decisions for classical disease modifying 
anti-rheumatic drugs (DMARDs) and TNFi on individual patient level are not available. 
Previous research suggested that failure of tapering of classical DMARDs is associated 
with anti-CCP positivity and a high mean DAS preceding the period of remission. None 
of the characteristics in the remission state itself were associated with tapering failure.1 
To improve successful tapering subclinical synovitis may play a role in maintaining 
the remission state. Studies using ultrasound suggest that the presence of subclinical 
synovitis may elicit early disease relapse in remission.2-5 This may be because the true 
underlying inflammation process is insufficiently suppressed, and a clinical detectable 
disease relapse easily provoked.2, 3, 6-9 
To improve individual tapering decisions in remission we need to know which risk 
factors for disease relapse play a role. One important factor is insufficient suppression 
of disease activity. Therefore, we monitored RA patients in clinical remission tapering 
their TNFi or synthetic DMARD (sDMARD) every three months during one year follow-
up with ultrasound. This information will help to optimise tapering strategies in future 
patients in remission. Our main aim is to determine if ultrasound synovitis precedes 
disease relapse while tapering sDMARD or TNFi in patients with RA who achieved 
clinical remission on sDMARD and TNFi.
Methods
Patients
We used consecutive RA patients (aged >17 years) who were included in the TARA 
(TApering strategies in Rheumatoid Arthritis) study. The TARA study is a multicentre 
randomised single-blind controlled trial. Patients were treated with the combination 
of a sDMARD and a TNFi and were in remission defined as DAS44≤2.4 and SJC ≤1 (TARA 
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remission) for two consecutive visits (three months). In line with the Boolean remission 
definition we permitted one swollen joint.10 Patients were excluded if they needed to 
taper or stop their medication due to other reasons such as the wish to get pregnant 
or a scheduled surgery. The use of concomitant NSAIDs was allowed. Patients were 
asked to refrain from corticosteroids, but there were no restrictions on the use of 
intra-articular injections with glucocorticosteroids. If patients were in TARA remission 
at the second visit, they were randomised to two tapering strategies: i) Tapering 
sDMARD and ii) Tapering TNFi, and followed for one year. Tapering was terminated 
if the DAS>2.4 or SJC>1 at one of the 3-month follow-ups. Depending on the DAS and 
the number of swollen joints at physical examination, patients were either switched 
to the last effective dosage in case of a flare (DAS>2.4 or SJC>1) or tapered down 
further when they were still in TARA remission (DAS44≤2.4 and SJC ≤1). In case of a 
flare, one intramuscular injection with glucocorticosteroids was allowed to be given 
as bridging therapy in addition to switching to the last effective dosage. Every three 
months patients returned to the outpatients clinic and demographic characteristics, 
medication use, swollen and tender joint count (44 joint count), laboratory variables 
(ESR, CRP, serology) and ultrasound examination were recorded.
Patients had to be able to understand, speak and write in Dutch. Written informed 
consent was obtained from the participants according to the declaration of Helsinki. 
The study was approved by the local medical ethic committee of Erasmus MC, 
University Medical Centre Rotterdam, the Netherlands.
Ultrasound examination
A trained ultrasound examiner blinded for the clinical details performed ultrasound 
following the ‘European League Against Rheumatism’ (EULAR) guidelines, concerning 
patient position and scanning planes.11 Twenty-six joints were evaluated with the 
Esaote Mylab60 (probe LA435) using grayscale (GS) and power Doppler (PD) imaging. 
We scanned MTP2-5 (dorsal aspect), MCP2-5 and PIP2-5 (dorsal and palmar aspects), 
and wrist (radiocarpal and intercarpal joints) bilaterally. A single midline (longitudinal 
12 o’clock position) scan perpendicularly to the bone surface was used as advised by the 
OMERACT ultrasound working group.12 The following PD settings were used: colour 
gain was set at the disappearance of colour noise. The Pulse Repetition Frequency (PRF) 
was set as low as possible to yield maximum sensitivity which resulted in a frequency of 
750 Hz. We adjusted the size and position of the colour box to include the subcutaneous 
tissue to recognise artefacts caused by superficial vessels.13 PD signals were measured 
only in joints with GS≥1. The total scanning time was ½ hour per patient per session. The 
treating rheumatologist was unaware of the results from the ultrasound examination.
47571 Myrthe van der Ven NIEUW.indd   90 09-12-17   09:48
Ultrasound monitoring while tapering medication in RA
91
7
Ultrasound evaluation
Image evaluation followed the recommendations of the Spanish society for 
Rheumatology. This is a modified version of the previously developed OMERACT 
definitions of sonographic pathology.14 Joints were graded according to a semi-
quantitative scoring system (0-3) for both GS and PD. For GS, all joints were graded 
according to Szkudlarek et al., 0 = no synovial thickening, 1 = minimal synovial 
thickening, filling the angle between the periarticular bones, without bulging over 
the line linking the tops bone diaphyses  of the periarticular bone regions; 2 = synovial 
thickening without extension over the bone diaphyses; 3 = synovial thickening over at 
least one of the bone diaphysis.15
Synovial vascularisation was measured using PD. PD was graded according to Naredo 
et al., 0 = absent; 1 = mild, single vessel signal or isolated signal; 2 = moderate, confluent 
vessel signals in less than half of the intra-articular area; 3 = marked, vessel signals in 
more than half of the intra-articular area.16
Outcomes
The primary and secondary outcomes were defined as follows:
Primary outcome: Disease relapse defined as DAS44>2.4 or SJC>1 during one year 
follow-up.
Secondary outcome: Presence of ultrasound synovitis defined as GS>1 and/or PD>0.
Analysis
Simple descriptive techniques were used to describe the study sample. 
Sensitivity and specificity were used to assess the prognostic value of ultrasound for 
having a disease relapse.
To estimate whether ultrasound is able to identify patients who will have a disease 
relapse while tapering their medication a Cox proportional regression model for 
time to event data was used. Estimates were corrected for potential confounding 
variables (age, gender, ACCP, time since diagnosis and DAS at time of ultrasound). 
For each event, DAS and number of joints with ultrasound synovitis recorded at the 
previous visit were included as time-varying covariates. The validity of the proportional 
hazard assumption of the variables in each model was determined using Schoenfeld’s 
residuals. The analysis was stratified for tapering strategy. Since this study is still 
ongoing, randomisation is still concealed. We performed a second analysis with the 
number of joints with power Doppler signal. 
All analyses were performed using intention-to-treat analysis and per-protocol 
analysis. Analyses were done using STATA 14.0.
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Results
We included 125 patients in this analysis who were in TARA remission at baseline and 
started tapering their medication. Baseline characteristics are shown in Table 1. Disease 
relapse was defined as DAS44>2.4 or SJC>1. After one-year follow-up 45 patients (36%) 
had a disease relapse. The mean time to flare was 8 months (sd: 3 months). Patients 
had a relapse because they had two or more swollen joints (23/45; 51%), because they 
had both a DAS44>2.4 and SJC>1 (14/45; 31%) or because they had a DAS44>2.4 (8/45; 
18%). Table 2 shows the number of patients who had a disease relapse and the number 
of patients who had ultrasound synovitis at each visit. At baseline 72 patients (58%) 
had ultrasound synovitis.
Table 1: Baseline characteristics of patients in TARA remission - DAS44≤2.4 & SJC ≤1 (n=125)
Characteristic
Age, mean (sd) years 56 (13)
Women, n (%) 78 (62)
Time since diagnosis, mean (sd) years 5.4 (3.3)
SJC44, median (IQR) 0 (0-0)
TJC44, median (IQR) 0 (0-1)
DAS44, mean (sd) 1.0 (0.5)
ESR, median (IQR) 9 (3-15)
CRP, median (IQR) 2 (1-6)
RF positive, n (%) 65 (52)
ACCP positive, n (%) 80 (64)
US synovitis, n (%) 72 (58)
DAS44 = disease activity score in 44 joints; SJC = swollen joint count; TJC = tender joint count; ACCP = anti-cyclic 
citrullinated peptide antibody; US = ultrasound; sd = standard deviation; IQR = interquartile range
Table 2: Distribution of disease relapse and US synovitis during follow-up, n (%)
T0 T3 T6 T9 T12
US synovitis 72/125 (58) 60/124 (48) 62/112 (55) 40/96 (42) -
Disease relapse 0 6/124 (5) 8/112 (7) 23/96 (24) 8/67 (12)
US synovitis at previous visit - 4/6 (67) 5/8 (63) 14/23 (61) 6/8 (75)
No disease relapse 0 118/124 (95) 104/112 (93) 73/93 (78) 59/67 (88)
No US synovitis at previous visit - 46/118 (39) 47/104 (45) 23/73 (32) 29/59 (49)
US = ultrasound
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Ultrasound findings 
At baseline, ultrasound synovitis was found in 27 patients (60%) who had a disease 
relapse during the subsequent year. PD signal was present at baseline in 25 patients 
(56%) who had a disease relapse. Table 3 shows the distribution of joints with GS 
synovitis and PD synovitis at baseline in the RA patients who had a disease relapse. 
Table 3. Ultrasound findings at baseline in RA patients who had a disease relapse (n = 45), n (%)
Joint group GS >1 PD >0
MCP 8 (18) 5 (11)
PIP 1 (2) 0 (0)
wrist 18 (40) 17 (38)
MTP 14 (31) 6 (13)
GS: grayscale; PD: power Doppler
Agreement ultrasound and disease relapse
At patient level, 29 (64%) patients showed ultrasound synovitis at the previous visit 
before they had a disease relapse [Table 2]. 
In 13 patients (29%) who had a disease relapse, at least one joint which was found 
clinically swollen, showed ultrasound synovitis at the previous visit. Most frequently, 
agreement was found in the wrist joints (7/13; 54%). Eight patients had a disease 
relapse occurring in their large joints (elbow or knee), which were not included in the 
ultrasound assessment. In 13 patients who had a disease relapse no ultrasound synovitis 
was detected in any joint at the previous visit. In 15 patients ultrasound synovitis was 
detected, but the ultrasound positive joints did not match the clinically swollen joints 
during disease relapse. 
Prognostic value of ultrasound
Given that patients returned to the outpatient clinic every three months, we had 368 
observations during follow-up at which we could determine the prognostic value 
of ultrasound. Sensitivity and specificity of ultrasound synovitis in relation to the 
incidence of disease relapse were 69% and 44% respectively. Positive predictive value 
(PPV) was 14% and negative predictive value (NPV) was 92%. For the presence of PD 
signal, sensitivity was 45% and specificity was 65% (PPV 14%; NPV 90%). 
Predictors for disease relapse
Increasing number of joints with ultrasound synovitis was not significantly associated 
with disease relapse within three months (HR 1.21; 95%CI: 0.97-1.51) in the multivariate 
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Cox model. In the model with PD signal, increasing number of positive joints with PD 
was significantly associated with disease relapse within three months (HR1.35; 95%CI: 
1.02-1.80). In both models DAS at time of ultrasound was significantly associated with 
disease relapse within three months. 
Table 4. Multivariate Cox model with US synovitis or PD synovitis for disease relapse, HR (95% CI)
Model US synovitis Model PD synovitis
Age 0.99 (0.97-1.02) 0.99 (0.97-1.02)
Gender 1.08 (0.53-2.17) 1.05 (0.53-2.11)
Time since diagnosis 1.02 (0.92-1.13) 1.03 (0.93-1.14)
ACCP 0.47 (0.24-0.91) 0.51 (0.27-0.97)
DAS (at time of US) 2.25 (1.21-4.19) 2.34 (1.25-4.41)
US synovitis 1.21 (0.97-1.51)
PD synovitis 1.35 (1.02-1.80)
US = ultrasound; PD = power Doppler; HR = hazard ratio; ACCP = anti-cyclic citrullinated peptide antibody; DAS 
= disease activity score
Discussion
Data from several ultrasound studies indicate that subclinical disease lingers in RA 
patients in clinical remission.17-19 We found ultrasound synovitis in 58% of RA patients 
in clinical remission, which is comparable with previous research.3, 20 During one year, 
an ultrasound assessment was done every three months in RA patients in clinical 
remission who tapered their medication. Increasing number of joints with a positive 
PD signal increased the risk for having a disease relapse within three months. However, 
at individual patient level ultrasound did not perform well in predicting disease 
relapse (post-test probability positive test 14%), but did perform well in ruling out 
disease relapse in patients who did not have ultrasound synovitis (post-test probability 
negative test 92%). These results were likely to occur due to the high number of patients 
who were ultrasound positive (about 50% at each time point) and the initial low level 
of disease flare (5%) at three months follow-up. In general, ultrasound identified two 
thirds of patients who had a disease relapse at a subsequent time point. 
Recent work by Lamers-Karnebeek et al. showed that baseline ultrasound was 
informative at group level (HR: 1.7; 95% CI: 1.1-2.5) for predicting disease relapse 
within one year in RA patients discontinuing TNFi, but was the first to show that at 
patient level ultrasound had little added value over easy available clinical variables.20 
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Although we tapered rather than stopped medication, our results indicate the same as 
Lamers-Karnebeek that there seems no direct value in scanning every patient in clinical 
remission to decide if tapering could be safely initiated. However, this is conflicting 
with results from previous studies. There are two observational studies and one clinical 
trial showing more positive results for ultrasound as predictor of disease relapse. The 
observational studies found strong associations of the presence of PD at baseline with 
disease relapse (OR: 29.9; 95%CI: 6.81-131.40)21 and high positive predictive value (89%) 
and negative predictive value (74%)22, suggesting that PD ultrasound contributes to 
improve selection which RA patients in sustained clinical remission could taper or 
discontinue their biologic therapy. Both studies included a relatively small and very 
heterogeneous RA population with respect to disease characteristics and biological 
treatment. A randomised controlled trial included RA patients in sustained remission 
and evaluated disease relapse during continuation, tapering or stopping DMARDs or 
biologic treatment.23 GS and PD scores at three months (GS OR: 4.51; PD OR: 4.62) were 
identified as predictors for disease relapse within 12 months in patients who tapered 
biologic treatment. In comparison with these studies, our study population visited 
the outpatient clinic every three months and if a patient had sustained remission 
(DAS44<2.4 & SJC<1) the next step in tapering was taken. At each treatment de-
escalation step an ultrasound assessment was done, while three of four studies used 
baseline ultrasound data only.20-22 In our study population, baseline ultrasound at the 
start of tapering did not contribute to identifying patients with a disease relapse at any 
time point during one year follow-up [data not shown]. With the notion that patients 
continued tapering at each visit when they had sustained clinical remission. 
Agreement between swollen joints and ultrasound assessment was found in 13/45 
patients who had a disease relapse during follow-up. Physical examination included 
44 joints following the DAS and the ultrasound protocol used included only 26 joints 
(MCP2-5, PIP2-5, wrists, MTP2-5). Therefore, inflammation in large joints could have 
been missed. However, the presence of PD signal in any joint was associated with 
having a disease relapse. Other studies had a more extensive ultrasound protocol 
including 40 to 42 joints21-23, but our results suggest that a reduced number of joints 
might be feasible as well. Since we found GS ultrasound synovitis in the PIP joint of 
one patient only, it could be considered to remove the PIP joints from the ultrasound 
protocol. 
Several other studies provide results on disease relapse frequency  when tapering or 
stopping drugs.20-24 We found during one year follow-up that 36% of RA patients had 
a disease relapse. This flare rate is slightly lower compared with results from other 
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studies. In other RA populations in clinical remission, 40% to 50% of the patients failed 
tapering or discontinuation of biologic therapy.20-24 This could be explained by the fact 
that definitions for clinical remission and for disease relapse were heterogeneous and 
different from the ones we used in the present study. 
In our study patients were randomised to two tapering strategies, either tapering the 
sDMARD or tapering the TNFi. Since this study is still ongoing, randomisation is still 
concealed. It might be that tapering strategy does not influence disease relapse, but it 
could be that ultrasound has more added value in one strategy compared to the other 
strategy. 
Our study results raises the debate whether we look at lingering disease or too many 
false positive findings. Previous histology data has shown that ultrasound findings 
show histological changes in the joint tissue, suggesting that our patients have 
lingering disease.25 However, disease flare was only reported in 4 of the initial 72 
ultrasound positive patients at 3 months. What does an ultrasound positive joint mean 
in the other 68 patients who stayed relapse free? Could we simply ignore ultrasound 
positive results and taper only those patients who are ultrasound negative? Given the 
high NPV, ultrasound might be useful to determine which patients could go to the next 
step in tapering their medication. This could help the rheumatologist in their decision 
making, especially in those patients in whom it was hard to reach remission and there 
is limited choice of other DMARDs to reintroduce remission after disease relapse.
We found ultrasound synovitis in 58% of RA patients in clinical remission. Subclinical 
inflammation can explain why some patients deteriorate in radiological damage.17, 19 
Follow-up of RA patients who had a disease relapse could be interesting to determine 
if radiological damage would occur. 
In conclusion, monitoring RA patients who started tapering their medication every 
three months showed limited value for ultrasound to identify patients who will have a 
disease relapse. 
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Abstract
Introduction: In many patients with rheumatoid arthritis (RA) subclinical disease 
activity can be detected with ultrasound, especially using power Doppler ultrasound. 
However, power Doppler ultrasound may be highly dependent on type of machine. 
This could create problems both in clinical trials and in daily clinical practice. To clarify 
how the power Doppler ultrasound signal differs between machines we created a 
microvessel flow phantom.
Methods: The flow phantom contained three microvessels (150, 1000, 2000 micron). 
A syringe pump was used to generate flows. Five ultrasound machines were used. 
Settings were optimised to assess the lowest detectable flow for each ultrasound 
machine.
Results: The minimal detectable flow velocities showed very large differences between 
the machines. Only two of the machines may be able to detect the very low flows in 
capillaries in inflamed joints. There was no clear relation with price. One of the lower-
end machines actually performed best in all three vessel sizes.
Conclusions: We created a flow phantom to test the sensitivity of ultrasound machines 
to very low flows in small vessels. The sensitivity of the power Doppler modalities 
of five different machines was very different. The differences found between the 
machines are probably caused by fundamental differences in processing of the power 
Doppler signal or internal settings inaccessible to users. Machines considered for 
power Doppler ultrasound assessment of RA patients should be tested using a flow 
phantom similar to ours. Within studies, only a single machine type should be used.
47571 Myrthe van der Ven NIEUW.indd   104 09-12-17   09:48
Power Doppler in a flow phantom
105
8
Introduction
Rheumatoid arthritis (RA) is a common disease with a prevalence of around 1% 
worldwide.1 It is in potential an invalidating disease2, but early diagnosis in the 
so called ‘window of opportunity’3, 4 and treating according to a ‘treat to target’5 
protocol can optimize the outcome for RA patients. Adding ultrasound to the 
diagnostic workup and monitoring of treatment may provide even better results. In 
rheumatological ultrasound both grayscale and power Doppler is used of which power 
Doppler seems to have the largest value. It has the potential to reclassify patients to 
a higher joint group according to the 2010 classifi cation criteria for RA increasing the 
risk for undifferentiated arthritis to be defi nite RA.6 Furthermore, presence of power 
Doppler ultrasound inflammation in joints that are not swollen at clinical examination 
has shown to be clinically relevant in patients in remission of RA, since it predicts 
occurrence of flare and erosive progression.7-10 Correct assessment of presence and 
absence of power Doppler signal indicating the presence of  inflammation is therefore 
vital in rheumatological ultrasound. 
However, it has been published that power Doppler ultrasound may be highly 
dependent of type of ultrasound machine used.11, 12 We observed this in our centre also 
[Figure 1].
Figure 1. Interphalangeal joint of the fi rst digit of the right hand with two different machines in the same patient. 
(A) Machine B: presence of positive power Doppler signal (arrow) within the region of synovial proliferation. (B) In 
the image made with machine A this signal is absent; vessel (arrowhead); Noise on cortical surface (*)
47571 Myrthe van der Ven NIEUW.indd   105 09-12-17   09:48
Chapter 8
106
If there are indeed large differences in the performance of power Doppler ultrasound 
per machine, the choice of the machine might be essential for a valid detection of 
inflammation. Using different machines within a multimachine study or during 
patient treatment could then have a detrimental impact on treatment decisions or 
study outcome.
To quantify the suspected differences in power Doppler sensitivity of different machines 
in an objective way, we decided to perform an in-vitro experiment. To compare the power 
Doppler function of different ultrasound machines one could use a flow phantom. This 
flow phantom should mimic the tissue that is scanned by power Doppler ultrasound in 
rheumatology, i.e. very small vessels and very low flows. To our knowledge, no studies 
have been conducted investigating the size of capillaries and the blood flow velocity 
in an inflamed joint, but there is data on capillaries in healthy subjects’ nail folds 
and capillaries in periulcerous regions. These capillaries have a diameter of around 
30 micron and the blood flow velocity can be as low as 0.5 mm/s.13, 14 Flow phantoms 
previously presented did not compare ultrasound machines15, used vessels that were 
considerably larger than capillaries, or assessed many capillaries close to each other at 
once, making it impossible to evaluate the flow velocity in the individual vessels.11, 12, 16, 17 
For these reasons, we created a new flow phantom with a very small, single vessel to 
obtain the lowest detectable flow velocity of five ultrasound machines. Two additional 
larger vessels were included in the phantom for comparison with literature.11, 12
Material and methods
Phantom
The flow phantom [Figure 2] consisted of an acrylic (PMMA) container filled with 
tissue mimicking material (TMM), according to a previously published recipe.18 In this 
TMM we placed three microvessels (150 micron (inner diameter) made of Polyethylene 
Terephtalate Glycol-modified (PETG; Paradigm Optics, Vancouver, WA, USA) and 2000 
and 1000 micron (inner diameter) made of silicone (Eriks bv, Alkmaar, NL). These two 
vessels were included to compare our phantom with already published studies.11, 12 
Initially we used vessels with diameters of 50 micron and 100 micron made of PETG as 
well but these blocked almost instantly. The blood mimicking fluid (BMF) was based 
on the recipe by Ramnarine.19. Briefly, 91.07% (w/w) demineralised water, 1.18% (w/w) 
dextran (average 150 kDa; D4876, Sigma-Aldrich, Zwijndrecht, the Netherlands), 
0.90% (w/w) ICI supersonic N surfactant, 5.03% (w/w) glycerol, and 1.82% w/w orgasol 
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particles (5 μm in diameter, Arkema) were mixed using a magnetic stirrer. The BMF 
was then filtered using a 40 micron sieve (352340, BD, Breda, the Netherlands) and 
degassed using a vacuum pump. Compared to the original recipe by Ramnarine, our 
BMF contained half the amount of dextran and glycerol, making our BMF less viscous 
which was necessary to prevent blockage of the vessels. A syringe pump (Harvard 
Apparatus Pump 11 Elite, Holliston, MA, USA) was used to generate flows. This pump 
can produce regular flows as low as 1.28 pl/min. For each vessel size, flow settings 
(ml/h) were calculated that corresponded to average flow velocities ranging from 40 
to 0.005 mm/s, using the following equation, where Q is flow (m3/second), Vavg is the 
average flow velocity (m/second) and R is the inner radius (m):
  Q= Vavg × πR
2    (1)
The actual volume flow through the vessels was tested by turning on the pump, 
completely filling the vessel until drops of BMF came out of the capillary. A complete 
number of drops were captured in a container while recording the time. This container 
was weighed before and after this experiment on a microbalance. With the relative 
density of the BMF we calculated the flow (transported volume per time).
 
Figure 2. The flow phantom with a fixated probe.
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Experiment
The lowest detectable flow for each machine/vessel diameter combination was defined 
as the flow that still resulted in a continuous power Doppler ultrasound signal [Figure 
3]. First the pump was set to a high flow, then gradually decreasing it in steps until a 
continuous power Doppler signal could just still be detected. The value of the lowest 
flow was recorded. Between each change of pump flow we waited 5 minutes for the 
system to reach stable flow velocities. For each lowest detectable flow per vessel we 
stored an image and recorded the machine settings used to acquire this image.
Figure 3. A continuous power Doppler ultrasound signal in a 1 mm vessel on Machine B.
Table 1. Machines tested in alphabetical order and probes used
Machine A Aloka α7 (probe UST-5411)
Machine B Esaote MyLab60 (probe LA 435)
Machine C Philips iU22 (probe L9-3)
Machine D Ultrasonix SonixTouch (probe L14-5/38)
Machine E Visualsonics Vevo2100 (probe MS200)
Ultrasound machines and settings
Five available ultrasound machines were tested [Table 1]. Machines A and B are used 
in our department of Rheumatology in daily clinical practice. Machine C a high-end 
machine for general imaging. Machines D and E are specialised research machines, the 
latter is a highly specialised machine for high frequency small animal imaging. Four 
machines operated at or around the most common frequency of 10 MHz (Machine 
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A, B, D and E), one (Machine C) below at a frequency between 3 and 9 MHz (actual 
frequency not displayed on this machine). Settings on all machines were optimised to 
detect lowest flows by adjusting pulse repetition frequency (PRF)/velocity range, wall 
filters, Doppler frequency and Doppler gain. In general this meant using for all vessels 
the lowest wall filter, the lowest velocity range or PRF and the highest suitable Doppler 
gain with respect to noise level. One experienced musculoskeletal ultrasonographer 
(DTC) performed all ultrasound exams. 
Results
We found that the pump was accurate enough for our purposes, especially when taking 
into account the very low flows used [Table 2]. The lowest detectable flow velocities in 
the different vessels are presented in table 3. These differed very much, by a factor of 
100 between machines. This was the case for all vessel sizes. In the smallest vessel (150 
micron), which most resembles the situation in an inflamed joint, two machines (D 
and E) could not detect a positive power Doppler signal at all at any flow velocity. For 
the others, the minimal detectable velocity ranged from 0.11 mm/s, (machine B), to 11.1 
mm/s. (machine A). The settings were optimised for the detection of lowest flow. For 
settings of PRF/velocity range, wall filter and Doppler frequency per machine for the 
smallest vessel see table 4.
Table 2. Measuring the reliability of the pump. 
Vessel size(micron)
Flow (ml/h)
2000 1000 150 150 150
Set flow 11.31 3.142 0.141 0.070 0.035
Measured flow 10.68 2.948 0.276 0.108 0.049
ml/h: millilitre per hour
Table 3. Lowest detected flow velocity (in mm/s) still resulting in a continuous positive power Doppler ultrasound signal
Flow velocity (mm/s)
Vessel size (micron)
Machine
2000 1000 150
A 4 2.22 11.1
B 0.005 0.06 0.11
C 1 0.56 1.68
D 1 0.56 N.D.
E 0.5 0.33 N.D.
mm/s: millimetre per second; N.D. = none detected
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Table 4. Settings for detection of lowest flow velocity in the 150 micron vessel
Machine PRF / Velocity range Wall filter Doppler frequency
A 1.3 cm/s Level 1 8 MHz
B 125 Hz Level 1 10 MHz
C 150 Hz 15 Hz R1 (Actual frequency not displayed on 
this machine)
D (no flow detected in this vessel) 200 Hz Level 1 10 MHz
E (no flow detected in this vessel) 1000Hz Low 12.5 MHz
Discussion
We showed that the sensitivity of the power Doppler modalities of five ultrasound 
machines (three  machines used in clinic and two used for research) was very different, 
using a microvessel flow phantom. The very large differences found between the 
machines are only partly explained by each machine’s Doppler frequency, lower limits 
of PRF and wall filter settings, but are most likely caused mainly by fundamental 
differences in processing of the power Doppler signal or internal settings inaccessible 
to users. There was no clear relation with price or technical sophistication of the 
machines: a lower-end machine (B) performed best for all three vessels, while mid-
range and high-end research machines (D,E) did not detect any flow in the smallest 
vessel, against expectations.
Only one machine of the five (B) could detect the low flow velocity in capillaries that 
are based on previous research are estimated to be between 0.5 and 1 mm/s. Machine C 
came close to this limit, which underlines our conclusion that the observed differences 
are mainly caused by differences in processing of the signal, since the probe that was 
available for machine C had a bandwidth of only 3 to 9 MHz. When a high frequency 
probe would have been used with this machine, it might also have been able to 
detect less than 1 mm/s in the smallest vessel. The other machines did not perform 
appropriately according to this limit. 
As mentioned above, flow phantoms have been published in literature before.11, 12, 15-17 
However, when comparing the power Doppler modalities of different ultrasound 
machines it is essential to use small, individual vessels. A positive power Doppler signal 
depends on the total detected Doppler signal power within the range gate (the colour 
Doppler “pixel size”, typically <1 mm). This power depends on the number of particles 
that have a velocity above a certain threshold. This threshold is determined by the wall 
filter, the PRF/velocity range. Whether a power Doppler signal is actually detected/
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displayed is also dependent on the noise level of the system and the system’s ability to 
suppress clutter and signal from stationary targets. If the vessel diameter is larger than 
the gate size, the velocity threshold will determine the lowest detectable velocity. This 
explains why the minimum velocities found for 1 mm and 2 mm vessels are similar. 
However, if the velocity is the same but the vessel is much smaller than the gate size, 
the number of moving particles will be lower and more stationary tissue will be inside 
the gate range. Then, the tissue suppression and noise level become more important 
and the minimal detectable velocity will be raised. This means that a phantom with a 
vessel that has a diameter that is too large11, 12 may use a flow velocity similar to that in 
vessels in an inflamed joint, but more particles are inside one pixel in the phantom-
situation (in vitro) compared to the situation in an inflamed joint (in vivo). This can 
possibly cause a positive power Doppler signal based on the large number of particles. 
In a flow phantom using a bundle of capillaries16, 17 one can never know for sure what 
the flow velocity in each vessel is. So the possibility remains that the flow is very high in 
a few capillaries, causing a positive power Doppler signal solely based on the high flow 
velocity of particles in these few capillaries.
A study comparing machines A and B (older versions than in our study) on an 1000 
micron flow phantom has been published in the past.12 These older versions of the 
machines were ranked regarding sensitivity the same as in our study. However, in our 
study the machine B detected a considerably lower flow compared to their study; 0.06 
mm/s in our study versus 1.3 mm/s in their study. Machine A detected a twofold lower 
flow in our study: 2.2 mm/s in our study versus 3.9 mm/s in their study. 
Another study tested an earlier, single-element version of machine E (Vevo 770), on a 
microvessel flow phantom with vessel dimensions similar to ours (160 micron).15 In this 
microvessel the Vevo 770 did detect flows as low as 0.5 mm/s. In our study machine 
E did not detect any flow in the smallest vessel (150 micron). A possible explanation 
for this higher sensitivity for low flows could be that the Vevo 770 uses a mechanically 
steered probe with a single element opposed to the array probe we used on machine E 
in our study. In general, the Doppler processing of a single-element system can be very 
different from an array system.
Some observations raised discussion within our research group. One of these 
discussions was about the very low flows detected by machine B in the 2000 micron 
vessel. To verify this finding the experiment was repeated several times by two 
observers (DTC and MvdV) which resulted in similar findings. When setting the flow 
slightly lower, the signal disappeared. Therefore, we think the measured flow is correct. 
A possible explanation for this low limit is that the PRF can be set to a very low level and 
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the wall filter cut-off frequency is probably also very low, in combination with a good 
clutter suppression. However, in in-vivo situations, normal tissue or probe motion will 
prevent detecting such extremely low flows. 
Another observation that raised discussion is the lower flow detected in the 1000 micron 
vessel as compared to the 2000 micron vessel. A reason for this could be that the flow 
velocity profile in the 1000 micron vessel is shaped differently, as compared to the 2000 
micron vessel, resulting in a larger difference between average flow and maximum 
flow. This may even have been reinforced by compression of the smaller vessel by the 
TMM. This means the average flow velocity is actually higher than estimated, since the 
calculation is quadratically dependent on the microvessel diameter. If the maximum 
velocity of the peak flow is slightly higher than the wall filter cut-off, this results in a 
positive power Doppler signal. This way the peak flow may be rather similar in the 
2000 micron and the 1000 micron vessel, but due to the shape of the flow profile this 
corresponds to a lower average flow velocity in the 1000 micron vessel. While the true 
value for the flow velocities may differ from the calculated values, this difference is the 
same for all machines, so the comparison between machines is still valid per vessel. 
A drawback of our study is that we have made assumptions on the capillary sizes 
and flow velocities in inflamed joints based on papers published on healthy subjects 
and periulcerous regions. This may not be entirely correct. Therefore, at present it is 
crucial to ascertain the flow velocities and capillary sizes in inflamed joints. With this 
information the minimal flows that rheumatological ultrasound machines need to be 
able to detect will be known. 
Nonetheless, for a reliable and reproducible detection of very low flows in inflamed joints, 
the choice of the ultrasound machine and its settings seems very important. Caution should 
be exercised when conducting a multi-machine trial or when making treatment decisions 
based on power Doppler ultrasound. Our flow phantom could be used to decide which 
ultrasound machine to use both in clinical practice and in clinical trials. 
Conclusions
We created a flow phantom to test the sensitivity of ultrasound machines to very low flows 
in small vessels. We found that the sensitivity of the power Doppler modalities was very 
different between five ultrasound machines. Based on the results of our study it would 
be advisable to standardise and validate ultrasound machines both for rheumatological 
clinical practice and for clinical trials. Our phantom could be used for this purpose.
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Abstract
Early recognition of joint inflammation will increase treatment efficacy in rheumatic 
arthritis (RA). Yet, conventional power Doppler (PD) ultrasound might not be 
sufficiently sensitive to detect minor inflammation. We investigated the sensitivity 
of high-frame rate Doppler, combined with Singular Value Decomposition technique 
to suppress tissue signals, for microvascular flow in a flow phantom setup and in a 
proof-of-principle study in healthy controls and in RA patients with different disease 
activities.  
In the flow phantom, minimal detectable flow velocity was a factor three lower with 
high-frame rate PD than with conventional PD ultrasound. In the proof-of-principle 
study we detected a positive PD signal in all volunteers, diseased or healthy, with 
high-frame rate PD ultrasound. We saw a gradual increase of PD signal in RA patients 
depending on disease activity. In conclusion, high-frame rate Doppler is more sensitive 
to detect vascularisation than conventional PD ultrasound. 
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Introduction
Rheumatoid arthritis (RA) is an inflammatory joint disease with a prevalence of 
1% worldwide.1 RA leads to destruction of joints, severe disability and increased 
cardiovascular mortality.2 Obligatory for the current diagnosis of RA is inflammatory 
arthritis of at least one joint.3 Arthritis is assessed by manual palpation of swelling in 
joints. Treatment of RA is directed at suppressing inflammation and establishing a state 
of remission according to a treat-to-target protocol.4, 5 Remission is regarded as the 
ultimate therapeutic goal for RA patients to prevent further joint damage and disability 
and to maintain function and quality of life. Therefore, it is important to ensure that the 
methods of assessing disease activity are accurate to diagnose and monitor RA. Current 
clinical measures rely on composite scores based on physical examination (swollen and 
tender joints) and laboratory assessments.6, 7 These measures have the disadvantage of 
not directly measuring inflammation and may be subject to confounding influences 
and subjectivity. In addition, reports suggest a disparity between clinical status and 
outcome, with evidence of radiographic or cytoscopic progression despite apparent 
clinical remission.8-10 This indicates ongoing subclinical inflammation. Data from 
several ultrasound studies indicate that subclinical disease lingers in joints which 
lack clinical signs of arthritis.11-13 Presence of subclinical disease may explain why some 
patients still develop bone erosions or have a relapse of their disease, while clinically 
the disease is in remission.11, 13-16
A review from Ten Cate et al.17 revealed that ultrasound imaging has added value in the 
diagnosis of RA and monitoring RA patients who are in remission, especially the use of 
the power Doppler (PD) mode. In conventional ultrasound, any PD signal in the joint 
indicates elevated vascularisation, which is an important sign of active inflammation. 
Conventional PD modes are able to detect flow velocities down to 0.05 mm/s in a flow 
phantom experiment in which the background tissue is motionless, although there is 
a large variability between ultrasound machines in the sensitivity to detect low flows.18 
In actual clinical application, the settings used in these phantom experiments produce 
flash artefacts -caused by unavoidable minor motion- which fully cover the blood 
signal. To be able to detect low flow velocities in actual clinical application there is a 
need for a sensitive PD ultrasound modality which reduces such flash artefacts. 
The past decade has shown that high-frame rate ultrasound has improved sensitivity 
to blood flow.19, 20 With high-frame rate ultrasound, the entire field of view is imaged 
with a single transmission, enabled by advances in the electronic hardware of the 
ultrasound machines. The high-frame rate ensures high temporal correlation between 
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frames, which facilitates a good separation between relatively slow tissue motion, 
and blood flow.20, 21 This has led to improved sensitivity of blood flow imaging in e.g. 
rheumatology20, 21, brain vascular imaging22, 23, and carotid flow velocity estimation24-26. 
The high temporal correlation between frames also allows for using spatial correlation 
to further discriminate blood flow in small localized vessels from global motion of soft 
tissue and bone, generally enabled with Singular Value Decomposition (SVD).27, 28
We applied the combination of high-frame rate Doppler ultrasound imaging and 
SVD fi ltering, which is expected to be more sensitive to low flow velocities than the 
conventional method27, for perfusion imaging of fi nger joints. It is our premise that 
such a more sensitive technique can provide accurate detection of active inflammatory 
joint tissue in RA, enabling earlier diagnosis of RA and better treatment monitoring. 
Of note, an early diagnosis of RA assumes that the patient is frequently seen by a 
rheumatologist. This is the case, since the persons have inflammatory joint complaints, 
albeit without clinically apparent swollen joints -and so, according to clinical decision 
diagrams, do not get the diagnosis RA at that point. In such case, sensitive PD 
ultrasound would be able to improve diagnosis accuracy.
In this study, our fi rst aim was to test in a flow phantom if the high-frame rate Doppler 
ultrasound technique is more sensitive in detecting low flows than a conventional 
clinical ultrasound machine. Our second aim was to perform a proof-of-principle study 
in RA patients with various disease activities to evaluate whether we are able to detect 
higher levels of vascularisation in affected joints with the new technique than with the 
conventional method. The proof-of-principle study was complemented with healthy 
volunteers to evaluate to what level healthy joints show vascularisation. 
A        B
Figure 1. (A.) Flow phantom before actual fi lling the cavity with tissue mimicking material; (B.) Experimental 
phantom setup; BMF: blood mimicking fluid.
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Methods
Flow phantom
The flow phantom [Figure 1] consisted of an acrylic (polymethyl methacrylate) 
container filled with tissue mimicking material, according to a previously published 
recipe.29 In this tissue mimicking material we placed a 0.7 mm (inner diameter) 
microvessel made of silicone (Eriks bv, Alkmaar, the Netherlands). Evaluation of the 
vessels was at a depth of 8-10  mm, which would be the largest depth of possible 
vessels in the metacarpophalangeal (MCP) joint that we study. A blood-mimicking 
fluid (BMF) was prepared based on the recipe by Ramnarine et al.30 The BMF contained 
91% (w/w) demineralised water, 1% (w/w) dextran (average 150 kDa, D4876; Sigma-
Aldrich, Zwijndrecht, the Netherlands), 1% (w/w) ICI supersonic N surfactant, 5% (w/w) 
glycerol, and 2% w/w Orgasol particles (5 μm in diameter; Arkema B.V., Rotterdam, The 
Netherlands). The BMF was mixed using a magnetic stirrer, filtered using a 40 μm sieve 
(352340; BD, Breda, the Netherlands) and degassed using a vacuum pump. Compared 
with the original recipe by Ramnarine and colleagues, our BMF contained half the 
amount of dextran and glycerol – this made our BMF less viscous, which was necessary 
to prevent blockage of the vessels. A syringe pump (Hugo Sachs Elektronik, March-
Hugstetten, Germany) was used to generate flows. Flow settings were calculated 
that corresponded to average flow velocities ranging from 26 to 0.13 mm/s, using the 
following equation, where Q is flow (m3/second), Vavg is the average flow velocity (m/
second) and R is the inner radius (m):
 Q= Vavg × πR
2    (1)
By assuming a parabolic flow profile, the peak velocity is twice the average velocity in a 
circular tube.31 Reported velocities are peak velocities. 
Study population
Ten healthy controls and 14 RA patients were included in this proof-of-principle 
study. To be able to interpret ultrasound results we included RA patients with a broad 
spectrum of disease activity: i) RA patients in clinical remission (no clinically swollen or 
tender joints); ii) RA patients who were well controlled (low to medium disease activity, 
but with clinically swollen and/or tender joints); and iii) RA patients with a clinical flare 
(high disease activity with clinically swollen and/or tender joints). Disease activity 
was measured by physical examination of swollen and tender joints, and disease 
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activity score (DAS) in 28 joints was calculated.6 A clinically swollen joint needed to 
be confirmed by the patient’s treating rheumatologist. Written informed consent was 
obtained from the participants according to the declaration of Helsinki. The study was 
approved by the local medical ethics committee of Erasmus MC, University Medical 
Centre Rotterdam, the Netherlands (MEC-2015-179).
Ultrasound equipment and machine settings 
Conventional ultrasound machine
The conventional ultrasound machine was an Esaote MyLab60 which is used in daily 
clinical practice, equipped with a high-frequency linear array probe (LA435, 10-18MHz). 
In both the phantom and clinical studies, the probe was mounted on a 4-degree-of-
freedom mounting arm with a hydrostatic brake (442110/290 mm, NOGA, Israel) to 
reduce probe motion caused by the sonographer. To reduce the motion of the hand 
of the participant, the hand was positioned in a custom plate with pins to spread the 
fingers [Figure 2]. Participants were sitting on a chair, and were asked to hold breath 
(after breathing out) during the measurement to reduce residual motion as much 
as possible. The PD gain was set at the disappearance level of colour noise in the 
PD images. The Pulse Repetition Frequency (PRF) was set as low as possible to have 
maximum sensitivity for low flow, which was 125 Hz in the phantom study, and 750 Hz 
in the clinical pilot study. Further settings are shown in Table 1. 
We adjusted the size and position of the colour box to include the subcutaneous tissue 
to recognise artefacts caused by vessels above the joint.32
Figure 2. Experimental set-up for the proof-of-principle study with the probe-mounting arms and the custom 
plate with pins to spread and fixate the fingers. Left machine: Esaote MyLab 60; right machine: Verasonics 
Vantage-256 on a custom trolley.
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Table 1. Conventional ultrasound (Esaote MyLab60) settings for the phantom study and for the proof-of-principle 
study
Phantom study Proof-of-principle study
Doppler frequency (MHz) 10 10
Pulse repetition frequency (Hz) 125 750
Wall filter Level 1 Level 3
Power Doppler persistence Level 4 Level 4
Image depth (cm) 3.0 2.5
Research ultrasound machine
The research system was a Vantage-256 (Verasonics, Kirkland, WA USA) with a high-
frequency probe (L40-8/12, Ultrasonix, Richmond BC, Canada) with a customized 
adapter to the Verasonics system. The specifications of this probe are equal to the 
Verasonics L22-14v probe. The system was programmed in high-frame rate mode, 
i.e. plane wave transmissions, and capturing and saving the full channel data.21 One 
B-mode image and one Doppler ensemble were recorded per dataset. The Doppler 
ensemble consisted of 122 frames in In-Phase Quadrature (IQ) format. Each Doppler 
frame was composed by coherent summation of the images reconstructed from 11 
angled plane wave transmit/receive events, transmitting over an angular range of -10 
to +10 degree. The image reconstruction was performed by the internal Verasonics 
reconstruction algorithm. The ultrasound pulse was a 1-cycle tone burst at 12.5 MHz 
for the B-mode, and a 4-cycle tone burst at 12.5 MHz for the Doppler data. The PRF was 
set to 1375 pulses per second, leading to a rate of 125 frames per second in the Doppler 
ensemble. This led to the recording time of approximately 1 sec, i.e. one Doppler image 
per second. Given a general heart rate of one beat per second, this recording time 
implies that the PD signal is obtained over one complete heart cycle, and no diastolic 
or systolic difference will be observed, unlike regular PD which has image rates of a few 
per second. 
The performance of the high-frame rate imaging was tested in a flow phantom. In 
this experiment we used a Doppler frame rate of 500 Hz and 62 frames, leading to a 
recording time of 124 ms. Such a Doppler ensemble recording time is closer to that 
of the image rate in the clinical scanner. This measurement served as initial test to 
show the higher sensitivity to low flow velocities of the high-frame rate imaging in a 
controlled environment.
To investigate the influence of wall filters, we tested both a conventional wall filter 
with static high-pass filtering characteristics, and a recent approach of Singular Value 
Decomposition (SVD) following the procedure of Demené et al.27 In the phantom 
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study, the conventional wall filter (Verasonics built-in filter ‘WeakFlowVLow’) had -6dB 
and -20 dB cut-off frequencies of 12 Hz and 6 Hz, respectively, which results in a cut-
off velocity of 0.4 - 0.8 mm/s. In the volunteers study, we used a 6th order zero-phase 
Butterworth filter with -6dB cut-off frequency of 37.5  Hz, which results in a cut-off 
velocity of 2.4 mm/s. Lower cut-off frequencies led to severe flash artefacts. The SVD 
filtering is a statistical approach in which high-amplitude tissue signals with large 
spatial coherency are separated from the low-amplitude local blood signals, and 
then removed. Moreover, electronic noise is separated and subsequently removed 
by the filter, since noise has low amplitude and very low spatial coherency. The lower 
separation threshold (for tissue suppression) was manually set to visually suppress 
tissue signals and quasi-static signals from the bone structure, while maintaining the 
blood signal in the PD image.27 The higher separation threshold (for noise suppression) 
was manually set to suppress the noise signal in the deeper regions of the image, 
where no ultrasound echo would be expected from since that region is located inside 
bone. This led to SVD cut-off values of 18 and 32 respectively (of a set of 122 frames). 
The power Doppler signal is then normalized to the maximum Doppler power value 
in the image. In the images we overlay the Doppler power to the B-mode images; if 
the Doppler power in any pixel is larger than 12% of the maximum Doppler power in 
the image, then the pixel gets its Doppler power value, otherwise the pixel gets the 
B-mode grayscale value. Note that this procedure may be different from conventional 
power Doppler, in which the grayscale value determines the local power Doppler 
sensitivity in the image (so called colour priority) which enhances larger vessels in 
the power Doppler images that appear black on the grayscale images. Such power 
Doppler enhancement by colour priority is not meaningful when the vessel diameters 
are smaller than the image resolution, which is generally the case in scanning the fine 
vasculature in the hand. 
Imaging protocols
Phantom study
In the flow phantom the lowest detectable flow for each machine and vessel was 
defined as the flow that still resulted in a continuous PD signal. First the pump was 
set to a high flow, and then decreased gradually until the PD signal disappeared. The 
value of the lowest flow was recorded, an image for each lowest detectable flow was 
stored, and we recorded the machine settings used to acquire this image. Between 
each change in pump flow we waited five minutes to reach stable flow velocities. 
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Proof-of-principle study
In the volunteer study, we used the experimental set-up in Figure 2 to position the 
probe and the hand of the patient. For the clinical proof-of-principle study, patient 
and probe positioning was according to EULAR guidelines.33 In healthy controls, 
MCP2 (second metacarpophalangeal joint; dorsal aspect) was ultrasonographically 
evaluated in extended position. In RA patients two MCP joints were examined. In RA 
patients in clinical remission bilateral MCP2 joints were examined. In RA patients who 
had controlled disease, a clinically swollen joint (MCP2 or MCP3) was examined. In this 
group a clinically non-swollen joint (MCP2 or MCP3) was also examined to be used as 
an in-patient reference joint. In RA patients with a clinical flare two clinically swollen 
joints (MCP2 or MCP3) were examined. In all cases, each joint was evaluated three 
times by PD; the maximum score of three was the final score. 
Ultrasound evaluation
The comparison of images by different modalities (conventional and high-frame rate) 
was evaluated semi-quantitatively, and the presence or absence of PD signal on each 
imaging modality was recorded. Synovial vascularisation was measured using PD. PD 
was graded as: 0=absent; 1=mild single vessel signal or isolated signal; 2=moderate 
confluent vessels; 3=marked vessel signals in more than half of the intra-articular 
area.34
The PD images acquired with high-frame rate ultrasound were scored by four raters 
independently. Raters were blinded to all clinical information. For each image the 
median of the PD scores was taken. To optimise inter-rater reliability, the raters 
followed a standardised protocol which stated to ignore any residual signal elicited at 
bone surface and to ignore flash artefacts. 
Statistical analysis
Simple descriptives were used to describe baseline characteristics and the ultrasound 
findings. According to general convention of median values, if there is an even number 
of items in the data set, then the median is taken as the average of the two middle 
numbers after sorting. We calculated the kappa statistic35 to determine the inter-rater 
reliability for scoring PD images acquired with high-frame rate imaging. 
We analysed differences in PD scores between the conventional ultrasound method 
and high-frame rate imaging. Since the data were not normally distributed we used the 
Wilcoxon-Mann-Whitney test. Analyses were done using STATA 14.0, using a p-value ≤ 
0.05 as the level of statistical significance.
47571 Myrthe van der Ven NIEUW.indd   123 09-12-17   09:48
Chapter 9
124
RESULTS
Phantom study
Figure 3 shows the PD images obtained at the lowest detected velocities in the flow 
phantom. The high-frame rate ultrasound machine detected a minimal flow velocity of 
0.5 mm/s with the conventional wall fi lter, and 0.26 mm/s with the SVD-based wall fi lter. 
The conventional ultrasound machine detected a minimal flow velocity of 0.8 mm/s. 
Since the phantom and probe both had a very low residual motion, the PRF and wall fi lter 
in the conventional ultrasound machine could be set extremely low, compared to regular 
clinical settings. In the current exam, the PRF was 125 Hz and the wall fi lter was set to 1, 
which is the lowest setting. In regular clinical ultrasound, the minimal PRF to avoid flash 
artefacts is 750 Hz, and wall fi lter 3. This implies that the lowest detectable flow velocity 
with the conventional ultrasound machine in clinical conditions is at least a factor of six 
higher (because of the factor of six increase in the PRF), which is 4.8 mm/s. 
A
B C
Figure 3. PD images obtained in the 700 µm vessel at the lowest detected velocity with the respective machines 
and wall fi ltering; (A.) Conventional PD ultrasound, lowest wall fi lter, and Vpeak  = 0.8 mm/s ; (B.) High-frame rate 
Doppler, conventional wall fi lter, and Vpeak = 0.5 mm/s; (C.) High-frame rate Doppler, tissue fi lter based on Singular 
Value Decomposition (SVD), and Vpeak = 0.26 mm/s. (PD = power Doppler).
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Proof-of-principle study
We included ten healthy controls (mean age (range): 32 (22-59) years) and 14 RA patients 
(58 (31-70) years), of whom three patients were in clinical remission, nine patients 
were well controlled, and two patients had a clinical flare. Baseline characteristics are 
presented in Table 2. 
Example images are presented in Figure 4. The left images show the screen shot of the 
conventional PD ultrasound, while the right images are the high-frame rate Doppler 
ultrasound.
Images are taken from a healthy control [Figure 4A & 4F] and RA patients in different 
disease states [Figure 4B-4E & 4G-4K]. The bone edges are identified by the bright 
inclined structures in the images at depths between 2–5  mm. The joint is presented 
by the V-shape of the bone, and the synovium of healthy joints is located at the top 
of the area bounded by the V-shape. In healthy joints, the synovium is very thin and 
thus not visible in ultrasound images; however, it may contain a minor amount of 
blood vessels since the synovial fluid (inside the synovium) is fed from the synovium. 
In case of rheumatoid arthritis, the synovium is thick and highly perfused because of 
inflammation of the surrounding area. In that case, PD ultrasound should be able to 
measure significant blood signal.
Figure 4 illustrates these effects. The high-frame rate Doppler images show more PD 
signal with increasing disease severity, whereas the conventional Doppler only shows 
a PD signal for the swollen joint and with clinical flare. Moreover, the high-frame rate 
Doppler images also show a significant signal at the bone surfaces, where the cartilage 
is located. We presume that this is a PD artefact, caused by minor motion of the bone 
in combination with very large amplitude of the reflection signal. When scoring the PD 
signal, we neglected this signal at the location of the cartilage / bone surface.
Figure 4 also shows that the conventional imaging system has a high-quality grey 
scale image, presumably caused by an interleaved ultrasound sequence to generate 
a grey scale image and the Doppler image quasi-simultaneously. In our current 
implementation of the high-frame rate sequence, we did not optimise for the grey 
scale image quality; we used a quick angular plane wave compounding technique to 
produce the grey scale image, at a quality which is sufficient to align the transducer in 
real time, and sufficient to interpret the anatomic landmarks. In further clinical studies 
this grey scale acquisition sequence can be further optimised to reach regular clinical 
quality, in order to also score the disease state based on the grey scale images.
With reference to Table 2, conventional PD ultrasound in healthy controls and in 
RA patients in clinical remission showed no PD signal in MCP2 joints, and either no 
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or minimum signal in the non-swollen joints of RA patients. In the swollen joints of 
controlled RA patients and RA patients with a clinical flare, median PD score was 1 
(IQR: 0-2). 
With high-frame rate PD ultrasound median PD score was 2 (IQR: 2-2) in healthy 
controls, 1.5 (IQR: 1-2) in RA patients in remission, 2 in controlled RA patients in 
both non-swollen (IQR: 2-2) and swollen MCP joints (IQR: 1.5-2), and 2 (IQR: 2-3) in 
RA patients with a flare [Table 2]. PD scores with high-frame rate ultrasound were 
significantly different (p<0.001) from PD scores with conventional ultrasound.
Table 2. Baseline characteristics, and ultrasonographic findings
Controls 
(n=10)
RA – remission 
(n = 3)
RA – controlled 
 (n = 9)
RA – flare 
(n= 2)
Age, mean (range) 32 (22-59) 53 (48-59) 59 (31-70) 56-67
Female, % 60 100 78 100
DAS28, mean (range) 2.8 (2.7-3.0) 3.1 (1.3-4.2) 4.3-5.7
SJC, median (range) 0 (0-0) 5 (3-6) 1-11
TJC, median (range) 0 (0-0) 2 (0-3) 7-16
non-swollen MCP swollen MCP
Conventional US
PD score, median (IQR) 0 (0-0) 0 (0-0) 0 (0-1) 1 (0-2) 1 (0-2)
High frame rate US
PD score, median (IQR) 2 (2-2) 1.5 (1-2) 2 (2-2) 2 (1.5-2) 2 (2-3)
DAS28: disease activity score in 28 joints; SJC: swollen joint count; TJC; tender joint count; MCP: 
metacarpophalangeal joint; US: ultrasound; PD: power Doppler; IQR: interquartile range
If any PD signal was detected with conventional ultrasound, this was also detected with 
high-frame rate ultrasound and scored the same PD grade or higher. If no PD signal 
was detected with conventional ultrasound, high-frame rate ultrasound showed either 
no or mild PD signal detection. Moreover, the largest difference between conventional 
and high-frame rate ultrasound is observed in the controls, and in the non-swollen 
joints in the controlled-RA patient group. Apparently, the high-frame rate ultrasound 
detects increased microvasculature in the joint, compared to the control group. This 
increased microvasculature is detected neither by the physical examination, nor by the 
conventional power Doppler technique.
PD images acquired with high-frame rate ultrasound were scored by four observers 
independently. The kappa statistic for inter-rater reliability was κ=0.55, which means 
the agreement between the four observers was moderate.35
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A F
B G
C H
D I
E K
Figure 4. MCP joints of healthy controls and RA patients were scanned with conventional PD ultrasound (A.-E.) 
and high-frame rate Doppler imaging (F.-K.). Images (A. & F.) healthy control; (B. & G.) RA in remission; (C. & H.) 
RA controlled (non-swollen MCP); (D. & I.) RA controlled (swollen MCP); (E. & K.) RA flare. The dashed yellow box 
in A-E depicts the region of interest in F-K with the metacarpal bone (left hand side) and the proximal phalanx. 
(MCP = metacarpophalangeal; RA = rheumatoid arthritis)
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To investigate the potential grading power of high-frame rate Doppler, we plotted the 
distribution of PD scores (range 0-3) in all subjects for each different disease state in 
Figure 5. Note that, for each subject, all three measurements per examined joint were 
scored, and the median value was taken for the data shown in Figure 5. In all cases at 
least one out of the three recordings showed a PD score 1. In correspondence with the 
median values shown in Table 2, this plot shows a gradual shift of PD score from healthy 
controls to flaring joints, implying that the high-frame rate Doppler can indeed stage 
the vascularisation. On the other hand, we observe no difference in vascularisation 
between the swollen and non-swollen joints with controlled disease.
Discussion
Summary
This study investigated the sensitivity of high-frame rate PD ultrasound for use in 
rheumatology practice. In a flow phantom, we could detect lower velocities with 
the high-frame rate ultrasound machine (0.26 mm/s) than with the conventional 
ultrasound machine (0.8 mm/s) in a 0.7 mm vessel with the clinically unrealistic but 
optimal settings to detect low flow velocities with the clinical scanner. In the proof-
of-principle study we detected a positive PD signal in all volunteers, diseased or 
healthy, with high-frame rate PD ultrasound. This was opposite to the measurements 
with conventional PD ultrasound, where no PD signal was observed in the healthy 
volunteers and in RA patients in clinical remission. In controlled RA patients we found 
higher PD scores in both clinically swollen MCP joints and in non-swollen MCP joints 
with high-frame rate PD. In RA patients with a clinical flare, PD scores were higher 
as well with high-frame rate Doppler than with conventional PD ultrasound. For all 
groups, PD scores were significantly higher for high-frame rate ultrasound compared 
to conventional ultrasound. Therefore, high-frame rate PD ultrasound is a more 
sensitive tool to detect vascularisation than conventional PD ultrasound.
Clinical implications
There are several clinical implications of the findings. Firstly, in healthy controls 
conventional ultrasound could not detect any PD signal, but with high-frame rate 
imaging we found at least median grade 1 PD signal in all controls. These PD signals 
might refer to normal vascularisation of the synovium, which consists of low velocities 
not detectable by conventional imaging methods. This finding is consistent with 
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previous research with high-frame rate Doppler imaging in healthy volunteers by 
Maresca et al.21, although in that study the perfusion was increased by use of a warm 
water bath in which the hand was held. PD signals in healthy subjects in normal clinical 
circumstances were not included in the conventional grading system.34 Hence, a new 
grading system which includes PD signals in healthy controls is needed. Such grading 
system could be based on estimating the vessel density21, although such method needs 
careful consideration of the used thresholds. A new grading system could also improve 
interobserver agreement, which is important when a new method is introduced into 
clinical practice. In our study, the agreement was moderate, which could be explained 
by the semi-quantitative scoring scale which could introduce subjectivity regarding 
interpretation especially between grade 1 and grade 2 power Doppler. Anyhow, a study 
with larger population is needed to fi ne-tune the grading of signals on a scale ranging 
from healthy, through (early) inflammation, to full flare.
Overall, high-frame rate PD ultrasound was more sensitive to detect vascularisation, 
but with some loss of discrimination between healthy controls and RA patients. Further 
research with high-frame rate PD ultrasound to improve discrimination might lead to 
more knowledge regarding the physiology of inflammation, especially the relation 
between symptoms, clinical swelling, vascularisation and inflammation.8, 10
Secondly, in the clinical experiment we clamped the transducers and mildly fi xated 
the probe to reduce motion from both the ultrasound examiner and the participant. 
Figure 5. The distribution of PD scores (range 0-3) for healthy controls and the  RA patient groups for both 
conventional PD and high-frame rate PD. More active RA coincides with increasing PD score. (conv = conventional; 
HFR = high-frame rate; PD = power Doppler; sw = swollen)
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The mechanical arm in which the probe is held may complicate the dissemination. To 
assess its need, we performed an additional test in which we compare the high-frame 
rate PD images recorded with the mechanical arm, with those of manual scanning by 
an expert (MvdV). Figures 6 (A,B) shows two recordings made with the mechanical 
arm, and Figures 6 (C,D) show manual scanning. There, the bone reflections lead to 
residual Doppler signals, because of a much higher relative motion of bone, and no 
vasculature detection in the synovium. We quantified a peak-to-peak axial motion of 
6 μm per recording when scanning with the mechanical arm, and 20 μm with manual 
scanning (mean of 10 recordings each). The different appearances in Figure 6 indicate 
the need for mechanical stabilization. In the future, the rather large mechanical arm 
may be replaced by e.g. a dedicated wearable rheumatology probe which is very gently 
clipped onto the finger of interest. 
A B
C D
Figure 6. Variability of power Doppler signals when the probe was held in the hydrostatic arm (A, B)  and when 
manually held (C, D).
We used the mechanical arm also for our in-vivo measurements with conventional 
ultrasound to obtain comparable results. In the reported results, we used the same 
settings (PFR 750 Hz, wall filter 3) as in daily clinical practice, leading to presumed 
equal sensitivity to flow as in daily routine. Yet, with this clamping and hand fixation, 
we also tested more optimal settings to detect low-flow PD signal (PRF 370 Hz, wall 
filter 2) without the risk of flash artefacts. Scoring of those images did not lead to other 
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results than shown in the main study. Therefore, we only showed the results with the 
regular clinical settings. 
Furthermore, the fact that any exam should give a minor PD signal is highly beneficial 
for the confidence of the sonographer in the measurement. If no signal is detected, 
then this is a sign of failure of the measurement, such as malfunctioning (caused by, 
e.g., broken crystals in the probe), wrong settings, or poor acoustic contact between 
the probe and skin. This is unlike the conventional method, where ‘no PD signal’ 
always is interpreted as ‘no or very minor vascularisation’. The conventional ultrasound 
machine (Esaote MyLab60) is used in daily clinical practice. Although the machine can 
be considered as mid-range equipment, we selected this machine for comparison as it 
performed best in detecting low flows in an earlier phantom study.18 We realise that the 
use of a more recent high-end clinical ultrasound machine might have led to a different 
result in the comparison. Yet, in a preliminary test with the ultrafast Doppler mode on 
a Supersonic Imagine Aixplorer with SL15-4 probe, no vascularisation was observed in 
the metacarpophalangeal joints of a healthy volunteer. As both the Aixplorer ultrafast 
Doppler and the proposed high-frame rate ultrasound technique presumably have 
similar data acquisition schemes, the difference in sensitivity may be sought in either 
the choice of probe (the currently used probe has a more shallow elevation focus than 
the used probe of the Aixplorer) or the use of the SVD scheme to cancel tissue signals, 
thus allowing for more sensitive settings. 
Methodology
As there is no gold standard for imaging the microvasculature in finger joints in RA 
patients, we first investigated the technique with the flow phantom, establishing 
actual detection of very slow flows. Second,  to investigate whether the Doppler signal 
is ‘real’ in-vivo, we repeated the measurement ten times at the same location of the 
MCP joint of one healthy volunteer. It appeared that the same vessels always appeared, 
and no other appeared, except for isolated pixels at the level of the bone reflection. 
See Figures 6 (A, B) for two example images. The pixel difference would certainly not 
change the scoring of such image. The use of SVD to suppress tissue signals has been 
introduced before in high-frame rate Doppler27, 28, and similar to Demené et al. we have 
optimised the choice of the singular values which are supposed to contain blood flow 
information. By visual inspection of the resulting PD images, we found that most blood 
flow information was contained in the SVD singular values 5 to 32 (of 122 maximum). 
Yet, minimal bone motion also led to a PD signal in the lower values (range 5 to 15, 
roughly). In such case, minimal motion of a large scattering object such as the hard 
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boundary of bone produces similar PD signal as blood flow, which is characterised 
by a large motion of a low scattering object. Therefore we analysed the PD frames 
obtained with singular values 18 to 32. Different sets of SVD components, in which the 
pixel colouring threshold and colour priority was also manually varied, showed minor 
difference in appearance in terms of noise and bone signal. Yet, this did not lead to a 
different staging, since the observer in this series (MvdV) was used to interpret bone 
signal and noise as artefacts. Any automated analysis algorithms that may be used to 
stage the vascularisation should be devised to perform this discrimination based on 
the anatomical landmarks present in the grayscale images and PD data. 
Retrospectively, we also processed the high-frame rate raw data with a conventional 
wall filter with relatively low cut-off frequency (37.5 Hz, corresponding to 2.4 mm/s 
flow velocity). This resulted in very large signal from bone, and no detection of blood 
flow in cases where filtering with SVD resulted in minor but persistent detection. Lower 
cut-off values resulted in large flash artefacts and bone signals. This result is consistent 
with that provided by Demené et al. on the comparison between SVD and conventional 
wall filtering.27 The SVD filtering technique removes the tissue motion that is spatially 
coherent in the images, independent of the typical Doppler frequency of that motion. 
Since spatial coherency has no influence on the conventional wall filtering, the bone 
signal is not sufficiently suppressed by that wall filter. 
In conventional applications the Doppler power is scaled by the local B-mode intensity 
(so-called colour priority). Although this suppresses the spurious Doppler signal 
from bone, it may also enhance Doppler signal from hypo-echoic regions in the joint 
such as those shown in Figure 4E, thus resulting in a blooming effect and perhaps 
overestimating tissue motion. We therefore did not apply the scaling of the Doppler 
power by the B-mode intensity in the final data analysis.
Since we are processing the data in ‘power Doppler’ mode in which, basically, any signal 
variation (after tissue removal) is integrated and imaged, there is no intrinsic limitation 
of maximum detectable blood flow. Therefore, 125 Hz will not limit the maximum 
detectable flow velocities. Note that this is opposite to colour Doppler or pulsed wave 
Doppler, in which aliasing (caused by too low PRF) affects the sign and magnitude of 
flow velocity estimation dramatically.
Our relatively quick implementation of the complementary grayscale images led 
to a poor grayscale resolution compared to conventional ultrasound imaging. This 
shortcoming can be solved in the future by increasing the number of angles of plane 
waves for reconstructing the grayscale image, or even by using conventional line 
scanning, without dramatic increase of the overall recording time. 
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With the ability of treating rheumatic disease with more precision than we ever could, 
the questions is raised whether physical examination reached its maximum to identify 
joint inflammation in its earliest phases. And we know that physical examination is of 
limited value in detecting inflamed entheses unless the inflammation is visible as for 
example enthesitis of the Achilles tendon.
Over the last years ultrasound has become an important tool in the assessment of 
rheumatic diseases, as it accurately detects many essential lesions including joint 
effusion, synovial hypertrophy, enthesopathy, bursitis and bone erosions. Especially 
the power Doppler mode is of clinical interest, since presence of power Doppler signal 
indicates elevated vascularisation, which is an important sign of active inflammation. 
In this general discussion, the two aims of this thesis will be discussed separately. The 
first part will focus on our results regarding the added value of ultrasound in clinical 
decision making in rheumatology. In the second part I will elaborate on technological 
developments in ultrasound machines which could increase the sensitivity of power 
Doppler ultrasound. 
Ultrasound in clinical practice
Disease onset – inflammatory arthritis
Many of the first outpatient clinic visits in rheumatology are taken by patients who 
initially only present with arthralgia. Most of them will have benign symptoms 
unrelated to inflammatory arthritis (IA). However, a small part will develop IA over 
time. If left unobserved we miss the opportunity to treat them in  very early stages 
of disease. Previous studies in ACPA and/or RF positive patients who were still in the 
arthralgia phase showed that 35% will develop IA and in seronegative patients 12% 
developed IA over one year.1 Until now it has been fairly difficult to identify those 
arthralgia patients who will develop IA at first consultation to see whom would benefit 
from close observation by a rheumatologist. 
In our cohort of early arthralgia patients the presence of power Doppler signal had 
the strongest association with the development of IA within a year. This suggests that 
power Doppler ultrasound could be of diagnostic value to predict progression to IA. 
Ultrasound could be of specific use in the seronegative arthralgia patients, as they have 
few prognostic factors. Additionally, our findings endorse the use of ultrasound to rule 
out development of IA. If no joints were ultrasound positive, the negative predictive 
value was 89% (positive predictive value of ultrasound was 26%). It can be debated 
47571 Myrthe van der Ven NIEUW.indd   139 09-12-17   09:48
Chapter 10
140
whether ultrasound has added value in clinical practice in these patients, since they 
are also negative at physical examination. Since ultrasound is a time-consuming 
tool, routine assessment of early inflammatory arthralgia patients would not be 
recommended. 
Our findings correspond well with previous research. Auto-antibody positive arthralgia 
patients with a positive ultrasound had an increased risk for developing IA.2, 3 In 
patients with very early hand symptoms, the presence of power Doppler signal was 
associated with developing IA.4 These studies do not mention a negative predictive 
value or discuss the use of ultrasound to rule out development of IA, therefore further 
research regarding the added value of ultrasound to rule out development of IA is 
recommended. 
To identify which arthralgia patients progress to IA, power Doppler ultrasound could 
be useful, but our findings need to be validated. Besides ultrasound, other imaging 
modalities (e.g. MRI) or biomarkers might help us to predict development of IA in 
arthralgia patients. If an arthralgia patient is clinically (and ultrasonographically) 
suspect for developing arthritis, the question arises whether and when to start 
treatment. Intervention trials are needed to evaluate the efficacy of DMARD treatment 
in these patients. It has been shown that early treatment of RA is beneficial and 
improved outcomes (e.g. mortality rates) can still be seen after 20 years5, so these 
results encourage to strive for even earlier detection and treatment. For now, it is 
recommended to follow-up early inflammatory arthralgia patients who are suspect for 
developing arthritis by clinical expertise. It has been observed that these patients do 
not consider themselves as patients, so it would not be harmful with respect to their 
perception of symptoms or identity.6 Including ultrasound assessments in the follow-
up of these patients might increase the identification of patients who develop IA.  
Disease onset – enthesitis
With the introduction of the CASPAR (Classification criteria for psoriatic arthritis) 
criteria for psoriatic arthritis (PsA), psoriasis patients can classify as PsA with only 
enthesitis as inflammatory involvement.7 Up to now no consensus has been achieved on 
its measurements in the diagnostic setting and entheseal inflammation is difficult to 
assess by clinical examination only.8-10 Clinical examination  by assessing tender points 
at entheseal sites tend to overestimate entheseal inflammation.11 With ultrasound 
we were more specific in detecting enthesitis, since we were able to visualise active 
inflammatory involvement at the enthesis. By combining ultrasound with clinical 
data we reduced the number of patients with enthesitis who should be evaluated 
47571 Myrthe van der Ven NIEUW.indd   140 09-12-17   09:48
Discussion
141
10
in screening psoriasis patients by a rheumatologist. This could help to differentiate 
patients with non-inflammatory entheseal pain from patients with entheseal 
involvement related to inflammation, helping physicians to make informed decisions 
about whether the entheseal tenderness might be related to PsA and in whom to start 
anti-inflammatory treatment. 
One of the difficulties we came across was the absence of general accepted definitions 
for both the clinical presentation as well as the ultrasound presentation of enthesitis. 
The first steps towards agreement on ultrasound definitions and elementary lesions 
were taken by the OMERACT Ultrasound Task Force on enthesitis.12 However, consensus 
still needs to be reached on what exactly is defined as inflammatory components since 
they did not reach consensus on entheseal thickness. Besides that it would help if a 
generally accepted definition for enthesitis would be available for daily clinical work. 
In addition, the mismatch between clinical and ultrasound findings especially needs 
further investigation. Some of our patients showed explicit signs of ultrasound and did 
not experience any pain or stiffness. 
We showed that entheseal abnormalities detected by ultrasound are very common in 
psoriasis patients (95% had structural ultrasound abnormalities), but it is debatable if 
ultrasound needs to added to routine clinical practice to identify enthesitis in psoriasis 
patients since it time-consuming. However, Wervers et al. showed in an early PsA cohort 
that health-related quality of life across both physical and mental scales was lower in 
patients with tender entheses compared to those patients with no tender enthesis.13 
These results emphasise that the entheses are important in the assessment of PsA.
Whether ultrasound is the right method to detect enthesitis, needs further 
investigation since ultrasound abnormalities are also frequently found in healthy 
controls.14 Ultrasound features (e.g. altered signal, erosions, cysts) which are regarded 
specific for enthesitis are also seen in posttraumatic, degenerated entheses or could be 
related to mechanical stress. Poggenborg et al. confirmed this statement by assessing 
entheses of patients with PsA and of healthy controls with whole body MRI and found 
no statistically significant difference.15 The drawback of whole body MRI is the thicker 
image layers compared with conventional MRI causing low readability for distal 
peripheral joints. With MRI it is possible to detect bone marrow oedema, but this could 
also be found in the healing phase of trauma.16 This emphasises that proper evaluation 
of lifestyle, history of trauma and body weight are needed to differentiate between 
truly enthesitis and microtrauma-enthesopathy. 
To conclude, I would not endorse to introduce ultrasound as a screening tool for 
enthesitis in psoriasis patients. Ultrasound might have added value in patients who 
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clinically present themselves with inflammatory entheseal complaints to confirm 
diagnosis of enthesitis.  
Monitoring – rheumatoid arthritis
Feet involvement
The goal of treat-to-target strategies is to achieve clinical remission. For accurate 
assessment of inflammation in RA patients, physical examination is important but 
difficult to perform in the feet. Although the first disease activity score (DAS) contains 
the feet, quickly after its introduction simplified disease activity scores were introduced 
(DAS28, SDAI/CDAI), excluding the feet. Due to less joints, these scores made it easier 
to be applied in clinical practice but in the era of achieving disease remission may 
not suffice as the feet may still show signs of inflammation while other joints are in 
remission. 
Two definitions of remission were redefined in 2011, both based on 28-joint counts.17 
Several studies showed that these reduced 28-joints count overestimates the original 
DAS remission. This discrepancy can be explained by inflammation in joints not 
captured by  the DAS28, mainly by residual inflammation in ankles and feet.18, 19 For 
monitoring disease activity in RA patients it is recommended to perform a full joint 
assessment, including the feet. However, physical examination of the feet to identify 
synovitis is more difficult than that of other joints.20, 21 Ultrasound could be a useful tool 
to monitor inflammation of the feet. 
In newly diagnosed RA patients we found that 29% of all MTP joints were swollen at 
physical examination and 14% had ultrasound synovitis at baseline. The agreement at 
joint level was poor between physical examination and ultrasonographic evaluation 
(κ=0.02). Positive percent agreement between physically swollen MTP joints and 
positive ultrasound was low (<16%). Negative percent agreement (non-swollen MTP 
joint at physical examination and no ultrasound synovitis) was high (>85%). This 
indicates there is a role for ultrasound in monitoring inflammation in the feet in RA 
patients in clinical remission to assess whether the feet are really in remission and 
treatment could be tapered. 
Quality of life
Due to treat-to-target strategies, many RA patients are able to reach a state of clinical 
remission.22 Patient-reported outcomes are becoming more important in monitoring 
RA patients, but the association between health status and (ultrasound) remission has 
not been investigated thoroughly.23-26 We found that one-third of RA patients in clinical 
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remission were also in ultrasound remission. This is slightly lower, but still comparable 
with other studies which found ongoing ultrasound synovitis in 48-73% of RA patients 
who were in clinical remission.27-31 
The presence of ultrasound synovitis may indicate that patients still experience 
problems in their daily live even when they are in clinical remission. Therefore, we 
compared RA patients in clinical remission with and without ultrasound synovitis. 
In general, all patients in clinical remission reported good health, with low scores for 
pain, functional disability, anxiety, depression and fatigue and higher scores for general 
health. There were small differences between the two groups, although in opposite 
direction of what we had expected. We found that patients in ultrasound remission 
experienced more pain (VAS pain, range 0-10; 3 vs 1) and anxiety (HADS anxiety, range 
0-21; 5 vs 3). We could not find a clear association between health status and being in 
ultrasound remission. Our results implicate that ultrasound does not add extra clinical 
information that may identify lingering subclinical disease. 
Tapering
Previous research has shown that ultrasound, especially the presence of power Doppler 
signal, can be used as a predictor of disease relapse in RA patients in clinical remission 
who tapered or discontinued their medication.32-34 Our results in a relatively large group 
of RA patients in clinical remission showed less promising results and indicate that 
there is limited value in scanning every patient every three months to identify patients 
who will have a disease relapse. This was also found by Lamers-Karnebeek et al. in RA 
patients who discontinued TNFi.35 Baseline ultrasound was informative at group level 
for predicting disease relapse, but at patient level ultrasound had little added value 
over easy available clinical variables. 
We found a high negative predictive value, which is more interesting since that 
makes it possible to identify which patients could go to the next step in tapering their 
medication.  
Several studies showed that ultrasound synovitis predicts short-term relapse and 
erosions, but do we need to treat-to-target (T2T) with ultrasound monitoring and aim 
for ultrasound remission? Whether the incorporation of ultrasound in a T2T strategy 
would improve clinical and imaging outcomes has been investigated by Dale et al. 
Patients were randomised either to a DAS28-driven T2T strategy or to a ultrasound-
driven T2T strategy. Ultrasound-driven T2T therapy led to more intensive treatment 
and more patients achieved DAS44 remission after 18 months, but ultrasound-driven 
47571 Myrthe van der Ven NIEUW.indd   143 09-12-17   09:48
Chapter 10
144
T2T therapy was not associated with better clinical or imaging outcomes compared 
with DAS-driven T2T therapy.36 These results were also found in the ARCTIC  trial.37 Their 
results support our opinion that an ultrasound assessment should not be introduced 
as a regular imaging tool in routine clinical practice. There is a role for ultrasound in 
monitoring RA patients and is especially informative in treatment decision making 
when clinical disease activity status is not apparent. However, added value of routine 
use of ultrasound as part of a T2T strategy is not yet demonstrated. 
Experimental technical research 
Power Doppler and its variation
The importance of accurate monitoring of inflammation in rheumatic diseases has 
contributed to the increasing interest in ultrasound.38 Especially power Doppler seems 
to have a lot of potential. The presence of power Doppler signal in RA patients in clinical 
remission predicts disease relapse at group level and radiographic progression.26, 29, 39-41 
However, besides being operator-dependent, power Doppler ultrasound is dependent 
of type of ultrasound machine used.42, 43 The performance of the power Doppler 
modality of several ultrasound machines was compared by a flow phantom. We found 
large differences in sensitivity of the power Doppler modality between the machines. 
Since power Doppler signal is regarded very valuable in detection of (subclinical) 
inflammation, correct assessment of presence or absence of power Doppler signal 
is important in clinical decision making in rheumatology. This study also showed 
that not every ultrasound machine was capable to detect low flow velocities which 
could indicate subclinical inflammation. Our results regarding different sensitivities 
to low flows emphasize the significance of testing the power Doppler modality of 
ultrasound machines. In clinical practice it could lead to a patient being identified as 
having ultrasound inflammation and possible escalation of medication assessed by 
one machine, whereas the same patient could be identified as being in ultrasound 
remission by another machine and possible tapering of medication. Therefore, we 
recommend to pay extra attention to the sensitivity of the power Doppler modality 
when purchasing an ultrasound machine.
Improvement of power Doppler signal detection
To provide more accurate detection of active inflammation we studied a more sensitive 
ultrasound technique. We compared conventional ultrasound with high-frame rate 
47571 Myrthe van der Ven NIEUW.indd   144 09-12-17   09:48
Discussion
145
10
Doppler ultrasound in the same flow phantom and detected lower flow velocities 
with high-frame rate Doppler. With high-frame rate Doppler we found power Doppler 
signal in MCP2 joints of all healthy controls. These power Doppler signals are likely 
to represent normal vascularisation of the synovium. This of course can be seen as an 
advantage but also as a disadvantage. As an advantage in the sense that we are able to 
detect physiological flows, as a disadvantage in the sense that it makes discrimination 
between healthy and diseased more difficult. 
To make use of high-frame rate ultrasound a new grading system is needed. This should 
take into account that power Doppler signals are also seen in healthy controls and 
needs to fine-tune grading of power Doppler signals on a scale ranging from healthy, 
through (early) inflammation, to full flare. A new grading system could be based on 
objective estimation of the vessel density as proposed by Maresca et al.44 It would be 
recommended to incorporate grayscale findings in this grading system, which could 
be helpful to differentiate between healthy and diseased. Another option would be an 
adaptation of the semi-quantitative power Doppler grading system of Naredo et al.45 
by adding extra grade(s) around power Doppler score 2, since power Doppler score 2 
was mostly detected in healthy controls.46 
Overall, high-frame rate Doppler was more sensitive in detecting vascularisation, but 
with some loss of discrimination between healthy controls and RA patients. Therefore, 
further research with high-frame rate Doppler ultrasound is needed to improve 
discrimination and to increase our knowledge of the physiology of inflammation, 
especially the relation between symptoms, clinical swelling, vascularisation and 
inflammation.47, 48 
Questions arise when searching for a more sensitive imaging technique are: How 
sensitive for low flows is technically possible? And is it still clinically relevant? From a 
technological perspective, it is of interest to investigate which flow velocities are still 
detectable in vivo. From a clinical perspective, the rheumatologist wants a feasible 
valid method to determine for each individual patient if treatment alteration is 
needed. Remission is the ultimate therapeutic goal for RA patients to prevent (further) 
joint damage and disability and to maintain function and quality of life. With more a 
more sensitive imaging technique to detect relapsing disease at an earlier time point 
treatment intensification could be initiated. Therefore, it is very important to be able 
to distinguish healthy tissue from and inflamed joint or tendon. In addition, with the 
use of a more sensitive imaging method, it could be possible to identify patients in 
the preclinical phase of RA before clinically detectable arthritis develops. The persons 
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who will progress to develop arthritis need to be identified with high accuracy and risk 
stratification needs to be developed and investigated in preventive trials. 
Further imaging possibilities in rheumatology
The research presented in this thesis showed added value in decision making 
of ultrasound assessment to clinical practice in certain situations, but does not 
demonstrate added value of routine use of ultrasound. However, in the research 
domain you want to have valid imaging methods and ideally an automated objective 
scoring system. Technological developments in ultrasound machines are promising, 
like the implementation of high-frame rate Doppler ultrasound. Other developments 
in ultrasound are 3D ultrasound and shear wave imaging, which both provide overcome 
the largest disadvantage of conventional ultrasound which is operator-dependency. 
3D Ultrasound
3D ultrasound showed good to excellent agreement with conventional 2D 
ultrasound.49, 50 Advantages of 3D ultrasound over conventional ultrasound is the 
reduction of the operator dependence in assessing synovitis, because of the automatic 
image acquisition and shortening of the examination time.49-51 The evaluation of the 
acquired images can be done after the ultrasound assessment, with or without the 
presence of the patient. This feature is also interesting for clinical trials or observational 
studies, since assessors can be blinded for evaluation of the acquired ultrasound 
images. A pilot study by Naredo et al. suggests that 3D ultrasound can be responsive 
and repeatable in multicentre cohort studies.51 
Shear wave ultrasound52
Sonoelastographic techniques provide extra information to conventional ultrasound 
related to tissue properties. Shear wave elastography is being increasingly used in 
the evaluation of musculoskeletal tissues and complements diagnosis obtained at 
grayscale ultrasound and power Doppler ultrasound. In rheumatology, shear wave 
imaging could be used especially in the assessment of tendons and ligaments. Shear 
waves propagate faster healthy tendons than in those which are tendinopathic, and 
faster in contracted tendons than in those which are relaxed. In case of tendinopathy, 
shear wave velocity is lower than in normal tendons.  The basic physics of shear wave 
imaging is explained in Figure 1. Shear wave elastography is considered to be more 
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operator independent and reproducible, since there is no need for manual compression 
of the tissue.
Figure 1. Basic physics of shear-wave elastography. In step 1, shear waves are generated using acoustic radiation 
force; they propagate perpendicularly to the primary ultrasound wave at a lower velocity. In step 2, fast plane wave 
excitation is used to track displacement and velocity as shear waves propagate, and tissue displacement is 
calculated using a speckle tracking algorithm. In step 3, tissue displacements are used to calculate shear-wave 
velocity (cs) and shear modulus (G). [Adapted from Taljanovic et al.
52]
New insights
- The absence of ultrasound synovitis is of diagnostic value in clinically suspect 
arthralgia patients to rule out development to inflammatory arthritis.
- Adding ultrasound of the entheses to clinical information reduced the number 
of primary care psoriasis patients with enthesitis who should be evaluated by a 
rheumatologist. 
- In monitoring disease activity in RA patients ultrasound confi rms that a patient 
has no ongoing inflammation and is therefore of diagnostic value to identify RA 
patients who can taper their medication. 
- High-frame rate Doppler imaging is more sensitive than conventional power 
Doppler in detecting vascularisation in RA patients and healthy controls.
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Implications for clinical practice
Overall, clinical examination of joints is adequate in most situations and therefore I 
would not recommend to add a routine ultrasound assessment to clinical examination 
in daily practice. However, we found 3 subsamples of patients who would benefit from 
the addition of ultrasound to clinical examination. The absence of ultrasound rules 
out development of arthralgia to arthritis and the absence of ultrasound rules out 
disease relapse in RA patients in clinical remission who are tapering their medication. 
Evaluating the entheses by ultrasound in psoriasis patients may provide information 
about the presence of entheseal inflammation. I would recommend to use ultrasound 
as a tool in case of doubt to ensure if there is ongoing inflammation or not. 
The results from this thesis highlight the importance of conducting clinical trials to 
evaluate the added value of new imaging technologies or new treatment strategies 
including imaging before wide adaption in clinical practice. 
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Summary
The importance of early diagnosis and accurate monitoring of inflammation in 
rheumatic diseases has contributed to the increasing interest in ultrasound. Since 
ultrasound is more sensitive than physical examination in the detection of synovitis, it is 
increasingly used in daily clinical practice. Yet, the position of ultrasound regarding the 
already existing diagnostic and monitoring tools needs to be established. Therefore, 
the aims of this thesis were: 
 1.  to evaluate the added value of ultrasound in clinical decision making in:
  a. Patients with arthralgia
  b. Patients with psoriasis
  c. Monitoring rheumatoid arthritis patients
 2.  to increase sensitivity of power Doppler ultrasound for MCP joints.
The introduction, chapter 1, starts with a short background in ultrasound physics. This 
is followed by current perspectives of ultrasound in early recognition, diagnosis and 
monitoring in rheumatology and the challenges which are faced. 
With the introduction of the 2010 ACR/EULAR classification criteria for rheumatoid 
arthritis (RA) we are able to classify patients as having RA at an earlier stage (≥6/10 
points). The developers of the 2010 criteria suggest that there is a scope for using other 
cut points for different purposes. In chapter 2 we evaluated which cut point of the 2010 
criteria would enable us to identify more early RA patients among early inflammatory 
arthritis (IA) patients at first consultation. Early arthritis patients with at least one 
joint with clinical synovitis and symptoms less than one year were included. After one 
year follow-up they were classified as case or non-case (i.e. methotrexate initiation). 
Diagnostic performance of the 2010 criteria was determined. By lowering the cut point 
of the 2010 criteria from 6 to 5 points, we were able to identify 15% more RA patients at 
a cost of 8% more false-positive patients. This could be used as a simple tool to initiate 
early treatment in RA patients. 
This thesis is divided in two parts; ultrasound in clinical practice and experimental 
technical research. 
Part one – Ultrasound in clinical practice
Since physical examination reached its maximum to identify synovitis, the first part of 
this thesis focussed on the added value of ultrasound in daily clinical practice. Chapter 
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3 and chapter 4 focus on the diagnostic value of ultrasound. Chapters 5, 6 and 7 focus 
on the value of ultrasound in monitoring of RA patients. 
Previous research showed that 15% of arthralgia patients who present themselves 
without clinical signs of inflammation at baseline will develop IA within one year. Up 
to now it has been fairly difficult to identify those arthralgia patients who develop 
IA. In chapter 3 we aimed to identify arthralgia patients developing IA within a year 
using ultrasound to detect synovitis at first consultation. We included 196 arthralgia 
patients without clinical synovitis of whom 37% had ultrasound synovitis at baseline. 
We observed that 16% of the arthralgia patients developed IA within a year. Ultrasound 
did perform well in ruling out IA in arthralgia patients who did not have ultrasound 
synovitis. Factors associated with the development of IA were age, morning stiffness 
>30 minutes and the presence of power Doppler signal. The presence of power Doppler 
had the strongest association. Our findings suggest power Doppler ultrasound could 
be of diagnostic value to predict progression to IA in early arthralgia patients, but this 
needs further evaluation. 
The diagnostic performance of ultrasound to detect enthesitis in primary care psoriasis 
patients is studied in chapter 4. Part of the psoriasis patients who have musculoskeletal 
complaints will have inflammation of the entheses. Entheseal inflammation is 
difficult to assess by clinical examination only. Therefore, we combined data from 
ultrasound, clinical examination and patient-reported questionnaires to define active 
inflammation at the enthesis. Active ultrasound inflammation contained positive 
power Doppler signal at the enthesis or in case of the plantar fascia increased thickness. 
Clinically, an enthesis was scored positive by a tender enthesis at clinical examination, 
reported pain in the history or self-reported pain in the questionnaires. In 36% of the 
primary care psoriasis patients who had tenderness at one or more entheseal sites 
(n=111) enthesitis was present. By adding ultrasound to the clinical evaluation of 
entheses we were able to visualise the presence of active inflammatory involvement of 
the enthesis. This reduced the frequency of entheseal lesions that should be evaluated 
by the rheumatologist compared to clinical exam only. 
In RA patients the metatarsophalangeal (MTP) joints are frequently affected early in 
the course of the disease. Physical examination of the feet is more difficult than that 
of other joints. To enhance knowledge about the value of monitoring the feet in RA 
patients, we investigated the agreement of ultrasound findings at the MTP joints 
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with physical examination in newly diagnosed RA patients (n=174) who were treated 
to target in chapter 5. At baseline, 63% of the patients had at least one ultrasound 
positive MTP joint. After one year follow-up 62% reached DAS28 remission of whom a 
quarter still had at least one ultrasound positive MTP joint. At joint level, the presence 
of ultrasound synovitis in the MTP joints correlated poorly with physical examination. 
Conversely, we found high agreement between physically non-swollen or non-tender 
MTP joints and a negative ultrasound. The clinical implications of monitoring the 
feet at patient level in an era aiming for remission may be vast and need to be further 
investigated. 
In chapter 6, we evaluated the frequency of ultrasound remission in RA patients who 
were in clinical sustained remission. Our second objective was to compare the health 
status of RA patients in clinical remission with RA patients who were also in ultrasound 
remission. Given the association between ultrasound synovitis and increased risk of 
flare, it is of clinical interest whether these patients with ultrasound synovitis report a 
different health status regarding pain, fatigue and general health. This could be used 
by physicians to adapt their treatment different in these patients compared to patients 
who are both in clinical and ultrasound remission. Eighty-nine RA patients in clinical 
remission were examined by ultrasound and patient reported outcomes were recorded. 
One-third of the RA patients in clinical remission were in ultrasound remission. We 
could not find a clear association between the health status of RA patients and being in 
ultrasound remission. We did find that patients in ultrasound remission experienced 
more pain and anxiety, but this was in the direction opposite to what was expected. We 
recommend that our results need to be confirmed in other cohorts with RA patients 
who are in clinical remission.
To improve individual tapering decision in RA patients who are in clinical remission we 
need to know which risk factors for disease relapse play a role. In chapter 7, we monitored 
RA patients every three months with ultrasound to determine if ultrasound synovitis 
preceded disease relapse. We included 125 RA patients in clinical remission who 
started tapering their medication (synthetic DMARD or TNF inhibitor). After one year 
follow-up 36% of the patients had had a disease relapse of whom 60% had ultrasound 
synovitis at baseline. In our study population, increasing number of joints with 
ultrasound synovitis was not significantly associated with disease relapse. Increasing 
number of joints with a positive power Doppler signal did significantly increase the risk 
for having a disease relapse within three months. Monitoring RA patients who started 
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tapering their medication every three months by ultrasound showed limited value for 
ultrasound to identify patients who will have a disease relapse. Given the high NPV, 
ultrasound might have added value to identify which patients could go to the next step 
in tapering their medication. This could be of special importance in monitoring disease 
activity in those patients in whom it was hard to achieve remission and who might 
have lost their therapeutic response after re-initiation of biologic treatment.
Part two – Experimental technical research
The second part of this thesis focussed on experimental technical research, since 
technological developments in ultrasound machines could also improve early 
detection of inflammation. 
It has been shown that power Doppler ultrasound is highly dependent of the type of 
ultrasound machine used. The performance of the power Doppler modality of five 
ultrasound machines was compared by a flow phantom and described in chapter 8. 
Power Doppler settings were optimised to determine the lowest detectable flow for 
each ultrasound machine. The sensitivity of the power Doppler modalities of the five 
machines was very different. Only two of the machines were able to detect very low 
flows in the flow phantom. The differences found between the machines could be 
caused by fundamental differences in processing of the power Doppler signal or by 
internal settings inaccessible to users. In conclusion, the choice of ultrasound machine 
and its settings seems very important. Caution should be taken when conducting a 
multi-machine trial or when making treatment decisions based on power Doppler 
ultrasound.
Developments in high frame rate imaging are very promising, since this technique 
allows detection of slow flow in very small vessels. High frame rate Doppler ultrasound 
imaging is more sensitive to low flow than conventional ultrasound. Therefore, it 
might provide accurate detection of active inflammation in joints of RA patients. This 
could enable earlier diagnosis of RA and better treatment monitoring. In chapter 9 the 
sensitivity of high frame rate Doppler for microvascular flow in a flow phantom was 
investigated and a proof-of-principle study in healthy controls and RA patients with 
different disease activities was executed. In the flow phantom, minimal detectable 
flow velocity was a factor three lower with high frame rate power Doppler than with 
conventional power Doppler ultrasound. In the proof-of-principle study a positive 
power Doppler signal was detected in all volunteers, diseased or healthy, with high 
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frame rate power Doppler ultrasound. This was opposite to the measurements with 
conventional power Doppler ultrasound, where no power Doppler signal was observed 
in the healthy volunteers and in RA patients in clinical remission. With high frame 
rate power Doppler ultrasound a gradual increase of power Doppler signal in RA 
patients was seen depending on disease activity. For all groups, power Doppler scores 
were significantly different between high frame rate ultrasound and conventional 
ultrasound. Further research with high frame rate power Doppler ultrasound to 
improve discrimination between healthy controls and RA patients and might lead to 
more knowledge regarding the physiology of inflammation.
In chapter 10 our results are summarised and discussed considering methodological 
issues and current literature. This thesis ends with the clinical applicability of our 
results and recommendations for future research. 
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In de reumatologie zijn vroege diagnosestelling en accurate monitoring van 
ziekteactiviteit belangrijk. Dit heeft er mede voor gezorgd dat de interesse in echografie 
is toegenomen. Aangezien is aangetoond dat echografie sensitiever is in het detecteren 
van synovitis dan lichamelijk onderzoek, wordt het ook steeds meer in de klinische 
praktijk toegepast. Echter is de plaats van echografie in verhouding tot de bestaande 
diagnostiek en monitoring nog niet geheel duidelijk. Daarom zijn de doelstellingen 
van dit proefschrift als volgt:
 1.  Bepalen wat de toegevoegde waarde is van echografie in de klinische 
besluitvorming bij:
  a. Patiënten met artralgie
  b. Patiënten met psoriasis
  c. Monitoren van patiënten met reumatoïde artritis (RA)
 2.  Verbeteren van de sensitiviteit van power Doppler echografie van de MCP 
gewrichten. 
Hoofdstuk 1 geeft in het kort een introductie van de achterliggende natuurkunde 
van de gebruikte technologie. Daarna volgt de huidige plaats van echografie in 
vroegherkenning, diagnosestelling en monitoring in de reumatologie en welke vragen 
er momenteel nog liggen. 
In 2010 zijn nieuwe classificatiecriteria voor RA opgesteld door de Europese en 
Amerikaanse reumatologie verenigingen, waardoor het mogelijk is om patiënten al 
op een eerder moment te classificeren als RA patiënt (≥6/10 punten). De auteurs van 
de 2010 criteria hebben aangegeven dat andere afkappunten gebruikt kunnen worden 
voor andere doeleinden. In hoofdstuk 2 hebben we onderzocht welk afkappunt van de 
2010 criteria ons in staat zou stellen om tijdens een eerste poliklinisch bezoek meer RA 
patiënten te identificeren binnen een studiepopulatie van vroege inflammatoire artritis 
(IA) patiënten. Voor deze studie hebben we vroege artritis patiënten geïncludeerd. Zij 
hadden minimaal één klinisch gezwollen gewricht en korter dan één jaar klachten. 
Patiënten werden gedurende een jaar gevolgd, waarna werd vastgesteld of ze met 
methotrexaat waren gestart (case) of niet (non-case) binnen dit jaar. De diagnostische 
waarde van de 2010 criteria hebben we daarna vastgesteld. Bij het verlagen van het 
afkappunt van de 2010 criteria van 6 naar 5 punten, konden we 15% meer RA patiënten 
identificeren ten koste van 8% meer vals-positieve patiënten. Dit toont aan dat 
47571 Myrthe van der Ven NIEUW.indd   161 09-12-17   09:48
Addendum
162
verlaging van het afkappunt gebruikt kan worden als een simpele methode om in een 
vroeg stadium medicatie te kunnen starten in RA patiënten. 
Het proefschrift is hierna verdeeld in twee delen; echografie in de klinische praktijk en 
experimenteel technisch onderzoek. 
Deel 1 – Echografie in de klinische praktijk
Lichamelijk onderzoek heeft zijn grenzen bereikt met betrekking tot het ontdekken 
van synovitis, daarom richt het eerste deel van dit proefschrift zich op de toegevoegde 
waarde van echografie in de dagelijkse klinische praktijk. Hoofdstukken 3 en 4 
behandelen de diagnostische waarde van echografie. In hoofdstukken 5, 6 en 7 hebben 
we de waarde van echografie in de monitoring van RA patiënten onderzocht. 
Eerder onderzoek heeft aangetoond dat van patiënten met artralgie zonder klinische 
symptomen van ontsteking bij het eerste bezoek aan de reumatoloog, toch 15% 
IA ontwikkelt binnen een jaar. Het is echter nog steeds lastig deze patiënten te 
identificeren. Het doel van hoofdstuk 3 was om artralgie patiënten te identificeren 
die binnen één jaar follow-up IA ontwikkelen door middel van het detecteren van 
synovitis met echografie tijdens het eerste bezoek. Honderd zes-en-negentig artralgie 
patiënten zonder klinische synovitis werden geïncludeerd van wie 37% op het eerste 
bezoek echografische synovitis had. Binnen één jaar follow-up ontwikkelde 16% van de 
artralgie patiënten IA. De negatief voorspellende waarde van echografie was hoog, met 
andere woorden, als een patiënt geen echografische synovitis had, was de kans klein 
dat hij IA zou ontwikkelen. Factoren die geassocieerd waren met het ontwikkelen van IA 
waren leeftijd, ochtendstijfheid >30 minuten en de aanwezigheid van power Doppler 
signaal. De aanwezigheid van power Doppler signaal had de sterkste associatie. Deze 
resultaten geven aan dat power Doppler van diagnostische waarde zou kunnen zijn in 
vroege artralgie patiënten om de ontwikkeling van IA te voorspellen, maar dit moet 
worden vastgesteld in verder onderzoek. 
De diagnostische waarde van echografie in het detecteren van enthesitis in eerstelijns 
psoriasis patiënten wordt beschreven in hoofdstuk 4. Een deel van psoriasis 
patiënten met musculoskeletale klachten heeft een ontsteking van de entheses 
(peesaanhechtingen). Ontsteking van de enthesis is moeilijk vast te stellen met 
lichamelijk onderzoek. Daarom hebben wij de informatie verkregen uit de anamnese 
en vragenlijsten met echografie en lichamelijk onderzoek gecombineerd om zo een 
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actieve ontsteking van de enthesis vast te kunnen stellen. Actieve echografische 
ontsteking was gedefinieerd als de aanwezigheid van power Doppler signaal bij de 
enthesis of in het geval van de fascia plantaris een verdikking van de enthesis. Klinisch 
werd een ontsteking vastgesteld door drukpijn op de enthesis, door gerapporteerde 
pijn van de enthesis in de voorgeschiedenis of door pijn aangegeven in de vragenlijsten. 
Door deze data te combineren had 36% van de eerstelijns psoriasis patiënten (n=111) 
die aangaven pijn te hebben aan één of meer entheses, ontsteking van minimaal 
één enthesis. Door echografie toe te voegen aan de het lichamelijk onderzoek en de 
anamnese konden we de aanwezigheid van een actieve ontsteking van de enthesis 
visualiseren. Door de combinatie van klinische gegevens neemt het aantal patiënten 
met mogelijke enthesitis die door de reumatoloog moet worden gezien af. 
De metatarsophalangeale (MTP) gewrichten zijn vaak aangedaan in pas 
gediagnosticeerde RA patiënten. Lichamelijk onderzoek van de voeten is lastiger 
dan dat van andere gewrichten. In hoofdstuk 5 hebben we de overeenstemming 
van echografische bevindingen van de MTP gewrichten vergeleken met lichamelijk 
onderzoek in pas gediagnosticeerde RA patiënten (n=174). Patiënten werden gedurende 
één jaar gevolgd en treat-to-target behandeld. Tijdens het eerste bezoek had 63% van 
de patiënten minimaal één positief MTP gewricht op echo. Na één jaar follow-up was 
62% van de patiënten in remissie volgens de DAS28, een kwart van deze patiënten 
had nog minimaal één positief MTP gewricht op echo. Op gewrichtsniveau was de 
correlatie tussen aanwezigheid van echografische synovitis in een MTP gewricht en 
een klinisch gezwollen gewricht slecht. Aan de andere kant vonden we wel hoge mate 
van overeenkomst tussen klinisch niet gezwollen of niet pijnlijke gewrichten en een 
negatieve echo. De klinische waarde van het monitoren van de voeten op patiëntniveau 
waarbij remissie het behandelingsdoel is, moet nog verder onderzocht worden. 
In hoofdstuk 6 hebben we geëvalueerd hoeveel RA patiënten in klinische remissie ook 
echografisch in remissie waren. In deze patiëntenpopulatie hebben we bepaald of 
er verschil in gezondheidsstatus bestond tussen RA patiënten die alleen in klinische 
remissie waren en RA patiënten die ook in echografische remissie waren. Aangezien is 
aangetoond dat er een associatie bestaat tussen echografische synovitis en verhoogd 
risico op flare, is het vanuit klinisch oogpunt interessant om te weten of patiënten 
met echografische synovitis anders naar hun gezondheid kijken met betrekking tot 
pijn, vermoeidheid en hun algemene gezondheid. Hierdoor zouden reumatologen 
de behandeling in RA patiënten met echografische synovitis kunnen veranderen ten 
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opzichte van RA patiënten die in klinische en echografische remissie zijn. Bij 89 RA 
patiënten in klinische remissie is een echo gemaakt van de polsen en de kleine hand- en 
voetgewrichten. Deze patiënten hebben daarnaast meerdere vragenlijsten ingevuld. 
Eén-derde van de patiënten in klinische remissie waren ook in echografische remissie. 
We hebben geen duidelijke associatie gevonden tussen de gezondheidsstatus van 
RA patiënten in klinische remissie en het wel of niet in echografische remissie zijn. 
Patiënten in echografische remissie rapporteerden meer pijn en angst, maar dit was de 
tegengestelde richting van wat verwacht was. Als aanbeveling moeten onze resultaten 
bevestigd worden in andere cohorten met RA patiënten in klinische remissie. 
Om op patiëntniveau te kunnen bepalen of een RA patiënt in klinische remissie zijn 
medicatie af kan bouwen is het belangrijk om te weten welke risicofactoren een rol 
kunnen spelen bij het krijgen van een flare (toename van de ziekteactiviteit). In 
hoofdstuk 7 hebben we RA patiënten die medicatie (conventionele DMARD of TNF 
inhibitor) aan het afbouwen waren iedere drie maanden gemonitord met echografie 
om te bepalen of de aanwezigheid van echografische synovitis vooraf gaat aan een 
flare. Honderd vijf-en-twintig RA patiënten zijn geïncludeerd die gestart zijn met 
afbouwen van de medicatie. Binnen één jaar follow-up had 36% van de patiënten 
een flare meegemaakt, van hen had 60% op baseline echografische synovitis. In onze 
studiepopulatie was het aantal gewrichten dat op echo positief was niet significant 
geassocieerd met het ontstaan van een flare. Het aantal positieve power Doppler 
gewrichten was significant geassocieerd met het ontstaan van een flare binnen drie 
maanden, maar deze associatie was zwak. Het iedere drie maanden monitoren van 
RA patiënten met echografie die starten met afbouwen van medicatie heeft weinig 
toegevoegde waarde om een flare te voorspellen. Echter was negatief voorspellende 
waarde wel hoog, wat kan betekenen dat het mogelijk zou zijn om met echografie 
patiënten te identificeren die hun medicatie verder kunnen afbouwen. Dit kan met 
name van belang zijn in de behandeling van RA patiënten bij wie het lastig was om 
remissie te bereiken en voor wie nog maar een gelimiteerde keuze van andere DMARDs 
bestaat om opnieuw remissie te bereiken in geval van een flare. 
Deel 2 – Experimenteel technisch onderzoek
Het tweede deel van dit proefschrift richt zich op experimenteel technisch onderzoek, 
aangezien technologische ontwikkelingen in echomachines vroege detectie van 
ontstekingen kunnen verbeteren. 
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Het is aangetoond dat het wel of niet zien van signaal zeer afhankelijk is van de 
echomachine die wordt gebruikt. De prestaties van de power Doppler modaliteit van 
vijf echomachines zijn onderzocht met behulp van een flow fantoom en de resultaten 
zijn beschreven in hoofdstuk 8. De power Doppler instellingen van iedere machine 
waren zo ingesteld om de laagst detecteerbare snelheid te kunnen bepalen. De power 
Doppler sensitiviteit van de vijf machines verschilde onderling veel. Slechts twee 
van de machines waren in staat om zeer lage snelheden te detecteren in het flow 
fantoom. Het verschil tussen de machines kan deels verklaard worden door verschillen 
van signaalanalyse van het power Doppler signaal of door instellingen die niet te 
veranderen zijn door de gebruiker. Concluderend kan gezegd worden dat de keuze van 
een echomachine en de daarbij behorende power Doppler instellingen zeer belangrijk 
is. Hier moet men zeker op bedacht zijn in het geval van een multi-machine trial of 
bij het aanpassen van behandeling gebaseerd op de aan- of afwezigheid van power 
Doppler signaal. 
De ontwikkelingen in high frame rate echografie zijn veelbelovend, aangezien deze 
techniek het mogelijk maakt om zeer lage snelheden in kleine vaten te detecteren. 
High frame rate Doppler echografie is namelijk sensitiever voor lage snelheden 
dan conventionele power Doppler echografie. Hierdoor is accurate detectie van 
gewrichtsontstekingen in RA patiënten denkbaar. Met deze nieuwe methode zou het 
mogelijk zijn eerder de diagnose RA te stellen en behandeling beter te monitoren. 
In hoofdstuk 9 is de sensitiviteit van high frame rate Doppler voor microvasculaire 
flow in een flow fantoom onderzocht. Daarnaast werd een proof-of-principle studie 
uitgevoerd in gezonde vrijwilligers en in RA patiënten met verschillende mate van 
ziekteactiviteit. In het flow fantoom was de minimaal detecteerbare flowsnelheid 
een factor drie lager met high frame rate Doppler vergeleken met conventionele 
power Doppler echografie. In de proof-of-principle studie werd met high frame rate 
Doppler een positief power Doppler signaal in alle deelnemers gedetecteerd, gezond 
en ziek. Dit was tegenovergesteld aan de resultaten met conventionele power Doppler 
echografie, waarmee geen power Doppler signaal werd gedetecteerd in gezonde 
vrijwilligers en in RA patiënten in klinische remissie. Met high frame rate Doppler werd 
een geleidelijke toename in power Doppler signaal gezien in RA patiënten gerelateerd 
aan hun ziekteactiviteit. Voor gezonden en patiënten was er een significant verschil 
in power Doppler score tussen high frame rate Doppler echografie en conventionele 
power Doppler echografie. Verder onderzoek naar high frame rate Doppler echografie 
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is nodig om discriminatie tussen gezond en afwijkend te verbeteren en om meer kennis 
te vergaren over ontstekingsfysiologie in gewrichten van RA patiënten. 
In hoofdstuk 10 zijn onze resultaten samengevat en worden deze bediscussieerd aan 
de hand van methodologische kwesties en huidige stand van zaken. Dit proefschrift 
eindigt met de klinische relevantie van onze resultaten en aanbevelingen voor verder 
onderzoek. 
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